Influenza A Virus Vaccines and Inhibitors

ABSTRACT

The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. Ser. No. 13/907,472, filed on May 31, 2013, which is a divisional patent application of U.S. Ser. No. 12/706,804, filed on Feb. 17, 2010, now U.S. Pat. No. 8,455,621, which is a divisional of U.S. patent application Ser. No. 11/566,216, filed on Dec. 2, 2006, now U.S. Pat. No. 7,709,190, which claims priority to U.S. Provisional Application Ser. No. 60/741,764, filed Dec. 2, 2005 and Ser. No. 60/852,361 filed Oct. 16, 2006. All of the foregoing applications are hereby incorporated by reference in their entirety.

STATEMENT OF FEDERALLY FUNDED RESEARCH

This invention was made with U.S. Government support under Contract Nos. AI-11772 awarded by the NIH. The government has certain rights in this invention.

TECHNICAL FIELD OF THE INVENTION

The present invention relates in general to the field of anti-viral assays and molecules, and more particularly, to compositions and methods for developing, isolating and characterizing novel Influenza A virus inhibitors and vaccines.

INCORPORATION-BY-REFERENCE OF MATERIALS FILED ON COMPACT DISC

The present application includes a TABLE filed electronically via EFS-Web that includes a file named NS1A_F2F3. The table was last modified Dec. 1, 2006 at 4:49 PM and includes 252,952 bytes.

TABLES The patent application contains table(s) that have been included at the end of the specification.

BACKGROUND OF THE INVENTION

Without limiting the scope of the invention, its background is described in connection with Influenza virus.

Influenza A and B viruses cause a highly contagious respiratory disease in humans resulting in approximately 36,000 deaths in the United States annually (Wright and Webster, 2001; Prevention, 2005). These annual epidemics also have a large economic impact, and cause more than 100,000 hospitalizations per year in the United States alone. Influenza A viruses, which infect a wide number of avian and mammalian species, are responsible for the periodic widespread epidemics, or pandemics, that have caused high mortality rates (Wright and Webster, 2001). The most devastating pandemic occurred in 1918, which caused an estimated 20 to 40 million deaths worldwide (Reid et al., 2001). Less devastating pandemics occurred in 1957 and 1968. Influenza B virus infections comprise about 20% of the yearly cases, but influenza B virus, which appears to infect only humans, does not cause pandemics (Wright and Webster, 2001).

Influenza A and B viruses contain negative-stranded RNA genomes, which are in the form of eight RNA segments (Lamb and Krug, 2001). Most, but not all, of the corresponding genome RNA segments of influenza A and B viruses encode proteins of similar functions. Here we will focus on influenza A virus. The three largest genome segments encode the three subunits of the polymerase, PB1, PB2 and PA. The segment encoding PB1 also encodes a small nonstructural protein, PB1-F2, which has apoptotic functions. The middle-sized segments encode the hemagglutinin (HA), the nucleocapsid protein (NP) and the neuraminidase (NA). HA, the major surface protein of the virus, binds to sialic acid-containing receptors on host cells, and is the protein against which neutralizing antibodies are produced. NP protein molecules are bound at regular intervals along the entire length of each of the genomic RNAs to form ribonucleoproteins (RNPs), and also have essential functions in viral RNA replication. The NA viral surface protein removes sialic acid from glycoproteins. One of its major functions is to remove sialic acid during virus budding from the cell surface and from the HA and NA of the newly assembled virions, thereby obviating aggregation of the budding virions on the cell surface. The seventh genomic RNA segment encodes two proteins, M1 (matrix protein) and M2. The M1 protein underlies the viral lipid membrane, and is thought to interact with the genomic RNPs and with the inner (cytoplasmic) tails of the surface proteins, e.g., HA and NA. The M2 protein is an ion channel protein that is essential for the uncoating of the virus. The smallest segment encodes two proteins, NS1A and NS2. The NS2 protein mediates the export of newly synthesized viral RNPs from the nucleus to the cytoplasm. The NS1A protein is a multi-functional protein not that is not incorporated into virion particles (hence the designation “non structural”), and is discussed below.

The primary means for controlling influenza virus epidemics has been vaccination directed primarily against HA (Wright and Webster, 2001). However, the antigenic structure of the HA of influenza A virus can undergo two types of change (Wright and Webster, 2001). Antigenic drift results from the selection of mutant viruses that evade antibodies directed against the major antigenic type of the HA circulating in the human population. Mutant viruses are readily generated because the viral RNA polymerase has no proof-reading function. Because of antigenic drift, the vaccine has to be reformulated each year. Antigenic shift in HA results from reassortment of genomic RNA segments between human and avian influenza A virus strains, resulting in a new (potentially pandemic) virus encoding a novel avian-type HA that is immunologically distinct. The human population has little or no immunological protection against such a new virus. The viruses containing the H2 and H3 HA subtypes that caused pandemics in 1957 and 1968, respectively, resulted from the reassortment of avian and human genomic RNA segments (Wright and Webster, 2001). The HA of influenza B viruses undergoes antigenic drift, but not antigenic shift, because influenza B viruses do not have non-human hosts.

Pandemic influenza A viruses can also apparently arise by a different mechanism. It has been postulated that the 1918 H1 pandemic strain derived all eight genomic RNAs from an avian virus, and that this virus then underwent multiple mutations in the process of adapting to mammalian cells (Reid et al., 2004; Taubenberger et al., 2005). H5N1 viruses, which have already spread from Asia to Europe and Africa, appear to be undergoing this route for acquiring pandemic capability (Horimoto and Kawaoka, 2005; Noah and Krug, 2005). These viruses, which have been directly transmitted from chickens to humans, contain only avian genes, and are highly pathogenic in humans. The human mortality rate has been high, approximately 55% (WHO, 2006). H5N1 viruses have not yet acquired the ability for efficient transmission from humans to humans. Recent studies indicate that efficient human transmission will require more than the acquisition of the ability of HA to bind to human sialic acid receptors in the upper respiratory tract of mammalian organisms (Maines et al., 2006). However, at least one H5N1 gene, the PB2 gene, has already undergone adaptation to mammalian cells (Hatta et al., 2001). The vast majority of pathogenic H5N1 viruses have acquired a lysine at position 627 in the PB2 protein, in place of the glutamic acid that is found at this position in avian viruses. The presence of lysine at this position apparently enhances virus replication in mammalian cells, but the mechanism of enhancement has not been established (Crescenzo-Chaigne et al., 2002; Shinya et al., 2004).

Effective control of a H5N1 pandemic will require the use of antiviral drugs because it is not likely that sufficient amounts of an effective vaccine will be available, particularly in the early phase of a fast-spreading pandemic (Ferguson et al., 2005; Longini et al., 2005; Ferguson et al., 2006; Germann et al., 2006). Antivirals can be stockpiled, and if appropriately used, should limit the spread of pandemic influenza virus. The strategies that have been proposed for the use of antivirals to stem a H5N1 pandemic would also be expected to lead to more effective use of antivirals during annual influenza epidemics. Currently, there are two classes of antiviral drugs. One class, amantadine/rimantidine, is directed against the M2 ion channel of influenza A viruses (Pinto et al., 1992; Wang et al., 1993; Chizhmakov et al., 1996). Virus mutants resistant to this class of drugs rapidly emerge (Cox and Subbarao, 1999; Suzuki et al., 2003), and many of the human isolates of H5N1 viruses are already resistant to these drugs (Puthavathana et al., 2005). The other class of drugs is directed at NA, and is effective against both influenza A and B viruses (von Itzstein et al., 1993; Woods et al., 1993; Ryan et al., 1994; Gubareva et al., 1995; Kim et al., 1997; Mendel et al., 1998). However, H5N1 viruses that are partially, or completely, resistant to the NA inhibitor oseltamivir have been reported (de Jong et al., 2005; Le et al., 2005). The emergence of H5N1 viruses to these two classes of antiviral drugs highlights the need for additional antiviral drugs against influenza virus.

SUMMARY OF THE INVENTION

The present invention includes the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site, or “binding epitope”, on the surface of the influenza A non-structural protein 1 (NS1). When referring to influenza A, the protein is referred to herein as NS1A. The NS1 protein of influenza A virus will be designated as the NS1A protein to distinguish it from the NS1 protein encoded by influenza B virus, which will be designated as the NS1B protein. Several fragments of the NS1A protein were identified, from various influenza strains, that provide high-level expression and solubility in E. coli expression systems. The present invention also includes expression systems and protocols for producing large quantities of the previously identified F2F3 fragment of human CPSF30, which binds to the NS1A effector domain (Twu et al., 2006). These fragments of the NS1A protein and of CPSF30 provide high quality NMR spectra, suitable for lead compound optimization. Combining these reagents and information, we have designed a gel filtration assay suitable for characterizing complex formation between NS1A and CPSF30 (or fragments thereof), as well as a fluorescence polarization (FP) assay of NS1A-CPSF30 interactions that is suitable for high throughput screening for lead compounds to develop antiviral drugs. Using these reagents, complexes of the tetrameric complex between the NS1A effector domain and F2F3 were also generated. We have also developed a process for crystallizing this complex. These crystals were used to determine the 3D structure of the NS1A effector domain: F2F3 complex, and to definitively identify for the first time all the NS1A amino acids that comprise a portion of the CPSF30 binding epitope in the NS1A protein. These reagents and structural data, together with specific site-directed mutagenesis data, have allowed us to define a structure-based process for high-throughput screening of inhibitors and lead optimization that will allow development of influenza A antiviral drugs. Also disclosed is a process using these reagents and structural data to develop attenuated strains of influenza A suitable for use as animal (e.g. avian) or human vaccines.

Using the present invention it is possible for antiviral drug(s) to be directed at a viral target that differs from that of currently available influenza antivirals. Novel approaches are important because influenza A viruses, including avian influenza virus, are developing resistance to existing antiviral drugs. The present invention also describes a process for developing vaccines using structural information that has not been previously disclosed. A vaccine using live attenuated strains of influenza A virus is expected to provide better protection than a vaccine using inactivated virus. The present invention may also be used to develop, isolate and characterize antiviral drugs and live attenuated virus vaccine for both seasonal and pandemic influenza virus infections.

More particularly, the present invention includes a complex of the F2F3 fragment of CPSF30 with the portion of the NS 1A protein of influenza A virus comprising amino acid residues 85 to 215 (NS1A (85-215)). The complex can be used in a method of identifying an inhibitor of influenza A virus by preparing a reaction system comprising at least a portion of NS1A of an influenza A virus, the F2F3 fragment of CPSF30, and a candidate compound; and detecting binding between the at least a portion of NS1A and F2F3, wherein reduced binding in the presence of the candidate drug relative to the control is indicative of activity of the compound against influenza virus. Examples of the NS1A fragments are listed in Table 2, and may also include the full length NS1A, and mutations thereof. The skilled artisan will recognize that the NS1A protein fragment may be prepared from other strains of influenza A viruses, e.g., human influenza A virus, a bovine influenza A virus, an equine influenza A virus, a porcine influenza A virus, an avian influenza A virus, an avian H5N1 viral strain.

For use with the present invention, the CPSF30 may be, e.g., a full length CPSF30, F3 zinc-finger doman, an F2F3-F2F3 tandem duplex, an F1F2F3 fragment, a soluble fragment of CPSF30, combinations and mutants thereof. Detection of the binding may be by, e.g., a high throughput screening assay, X-ray crystallography, nuclear magnetic resonance, analytical gel filtration, and combinations thereof. Other methods of detecting the interaction of the NS1A and CPSF30 (or portions thereof) may be, e.g., fluorescence resonance energy transfer, fluorescence polarization, immunofluorescence, chemiluminescence, radioimmunoassays, enzyme linked immunosorbent assays, mass spectrometry, and combinations thereof. For example, fluorescence polarization may use either a fluorescent labeled CPSF30, variant or fragment thereof or a fluorescent labeled NS1A protein, variant or fragments thereof.

The present invention also includes a process for using 3D (three-dimensional) information of the CPSF30 binding epitope on the influenza A virus NS1A protein for identifying inhibitors of an influenza A virus by obtaining concurrently the coordinates for the molecular position of at least a portion of an influenza NS1A protein and at least a portion of a CPSF30 protein and designing a molecule that will fit between the influenza NS1A protein and the CPSF30 protein based on the coordinates. The portion of the NS1A protein and the portion of the CPSF30 protein will generally be selected to provide high quality NMR spectra, e.g., the NS1A (85-215) fragment and the F2F3 fragment may be selected to form a tetrameric complex.

In another example, the NS1A (85-215) fragment and the F2F3 fragment may form a tetrameric complex that is crystallized. Other examples may use an NS1A (85-215) fragment and the F2F3 fragment form a tetrameric complex that is crystallized and is used to determine the 3D structure of the NS1A (85-215):F2F3 complex using X-ray crystallography. The method may also include the step of identifying the NS1A amino acids that constitute the CPSF30 binding portion of the NS1A protein.

Yet another embodiment is a method of designing an inhibitor compound of an influenza A virus based on computational methods, wherein the inhibitor that binds at least one residue within the set of residues corresponds to the structure, using the crystal structure and its coordinates. The design method may be facilitated by using NMR spectra of samples of NS1A protein fragments, NMR spectra of samples of NS1A(85-215) or equivalent constructs thereof. The method may further include the step of optimizing the design of the molecule that fits between the NS1A (85-215) protein and the CPSF30 protein using X-ray crystallography, and synthetic chemistry. The method of designing an inhibitor compound may also include the step of optimizing the design of the molecule that fits between the NS1A(85-215) protein and the CPSF30 protein using X-ray crystallography, NMR, synthetic chemistry and combinations thereof. Another embodiment of method of designing an inhibitor compound may also include, optionally or in combination one or more of the following: modifying the F2F3 structure of CPSF30, or any substructure, based on its conformation bound to NS1A to rationally design one or more small molecule inhibitors; modifying the F2F3 structure of CPSF30, or any substructure, to rationally design one or more small molecule inhibitors based on its conformation bound to NS1A of the F2F3 aromatic rings, the sidechain of residue Lys101, or combinations thereof; modifying the F2F3 structure of CPSF30, or any substructure, to rationally design one or more small molecule inhibitors by virtual screening; using the three-dimensional structure of the NS1A binding pocket to select one or more small molecule inhibitors or using the three-dimensional structure of the NS1A binding pocket to select one or more small molecule inhibitors by virtual screening. Any fragments of, full length, and strains of NS1A, and fragments of, full length, and strains of CPSF30 and combinations thereof may be used in conjunction with the method of designing an inhibitor compound.

Another embodiment of the present invention includes a process for engineering a live attenuated influenza A virus vaccine by mutation of specific residues in the CPSF30-binding epitope of the NS1A protein based on the 3D structure of the complex formed between NS1A (85-215) and F2F3, a tetramer interface and combinations thereof. Specific examples of residues at the tetramer interface site include, e.g., F103, L105, M106 and equivalents thereof. Specific examples of residues at the CPSF30-binding epitope include, e.g., M106, K110, 1117, 1119, Q121, D125, V180, G183, G184, W187 and equivalents thereof. The process may further include mutating the double-strand RNA binding epitope.

Another embodiment of the present invention includes an attenuated influenza A virus vaccine that includes one or more of eight viral RNA segments, wherein a viral RNA segment eight has a first mutation that causes a substitution of a first amino acid corresponding to an amino acid of SEQ. ID. NO. 1 at a position F103, L105, M106, K110, 1117, 1119, Q121, D125, L144, V180, G183, G184, or W187; wherein the first mutation decreases the CPSF30 binding ability of the NS1A protein. In one embodiment, at least a second mutation anywhere in the NS1A protein. The vaccine may also include at least second mutation causes a substitution of at least a second amino acid corresponding to an amino acid of SEQ ID NO.: 1 at a position F103, L105, M106, K110, 1117, 1119, Q121, D125, L144, V180, G183, G184, W187 and equivalents thereof. Alternatively, the vaccine may also include at least second mutation with a substitution of at least a second amino acid corresponding to an amino acid of SEQ ID NO.: 1 at a position T5, P31, D34, R35, R38, K41, G45, R46, and T49 at a dsRNA binding epitope and equivalents thereof. Alternatively, the vaccine may also include at least second mutation with at least second mutation causes a substitution of at least a second and third amino acid corresponding to an amino acid of SEQ. ID. NO. 1 at a position T5, P31, D34, R35, R38, K41, G45, R46, and T49 at a dsRNA binding epitope and/or F103, L105, M106, K110, 1117, 1119, Q121, D125, L144, V180, G183, G184, W187 and equivalents thereof. The influenza virus is a may be a cold-adapted influenza virus and will generally be selected to elicit an immune response. Non-limiting examples of influenza virus that may be used to make the attenuated vaccine may be is selected from, e.g., a human influenza A virus, a bovine influenza A virus, an equine influenza A virus, a porcine influenza A virus, an avian influenza A virus, an avian H5N1 viral strain.

The present invention also includes a pharmaceutical composition having a live attenuated influenza A virus vaccine by mutation of specific residues in the CPSF30-binding epitope of the NS 1A protein based on the 3D structure of the complex formed between NS1A (85-215) and F2F3, a tetramer interaction site and combinations thereof and a pharmaceutically acceptable carrier or diluent. The vaccine may be used in a method of prophylaxis of a disease condition caused by the influenza virus by administering to a subject in need thereof a therapeutically effective amount of a live attenuated influenza A virus vaccine by mutation of specific residues in the CPSF30-binding epitope of the NS1A protein based on the 3D structure of the complex formed between NS1A (85-215) and F2F3, a tetramer interaction site, the dsRNA binding epitope and combinations thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the features and advantages of the present invention, reference is now made to the detailed description of the invention along with the accompanying figures and in which:

FIGS. 1A and 1B are graphs that show the effects on the growth of a recombinant influenza A virus resulting from mutations in its of mutations on NS1A protein that relate to the ability of the NS1A to bind to CPSF30;

FIG. 2 shows NMR spectra of certain NS1A effector domains, demonstrating that such data can be used for structure-function analysis, inhibitor discovery and optimization, and in validating the effects of mutations on the structure of the effector domain;

FIG. 3 shows the results from analytical gel filtrations assays of NS1A (85-215):F3F3 binding;

FIG. 4A shows the X-ray crystal structure of a tetrameric NS1A effector domain and F2F3;

FIG. 4B shows the X-ray crystal structure for the Met106 residue in the core of the tetrameric NS1A (85-215):F2F3 complex;

FIG. 5 shows the X-ray crystal structure for the F2F3 binding epitope on the surface of the NS1A effector domain;

FIG. 6 is a comparison of 3D structures for Udorn and PR8 NS1A effector domains; and

FIG. 7 shows the 3D structure and dimeric beta-sheet interface of the PR8 effector domain, which does not bind F2F3.

DETAILED DESCRIPTION OF THE INVENTION

While the making and using of various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed herein are merely illustrative of specific ways to make and use the invention and do not delimit the scope of the invention.

To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as “a”, “an” and “the” are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.

One of the best clues to a protein's function is its structure. The present invention takes advantage of structure-based bioinformatics platforms in “functional genomics.” The structure-function data obtained from various structural determination may be used the isolation of novel biopharmaceuticals and/or drug targets from gene sequence information with greater efficiency. One way to identify the biochemical and medical function of a gene product is to determine its three-dimensional structure. Although there are numerous examples in which the primary (i.e., linear) structure of a protein has provided key clues to its biochemical function, three dimensional (3D) structure determination is considered to be more definitive at establishing biochemical function and mechanisms underlying these functions.

Protein structure. It is a generally accepted principle of biology that a protein's primary sequence is the main determinant of its tertiary structure. Anfinsen, Science 181:223-230 (1973); Anfinsen and Scheraga, Adv. Prot. Chem. 29:205-300 (1975); and Baldwin, Ann. Rev. Biochem. 44:453-475 (1975). For over a decade, researchers have been studying the theoretical and practical aspects of the folding of recombinant proteins.

Generally, proteins are composed of one or more autonomously-folding units known as domains. Kim, et al., Ann. Rev Biochem. 59:631-660 (1990); Nilsson, et al., Ann. Rev. Microbiol. 45:607-635 (1991). Multi-domain proteins in higher organisms are encoded by genes containing multiple exons and combinatorial shuffling of exons during evolution has produced novel proteins with different domain arrangements having different associated functions. Multi-domain protein may increase the ability of higher organisms to respond to environmental challenges because, via recombinational events, because the genomes may readily add, subtract, or rearrange discrete functionalities within a given protein. Patthy, Cell 41:657-663 (1985); Patthy, Curr. Opin. Struct. Bio. 4:383-392 (1994); and Long, et al., Science 92:12495-12499 (1995).

Interpretation of a protein structure. Several methods have been used to elucidate the 3D structure of a given protein molecule, e.g., X-ray crystallography and Nuclear Magnetic Resonance (NMR).

X-ray crystallography. X-ray crystallography is a technique that directly images molecules. A crystal of the molecule to be visualized is exposed to a collimated beam of monochromatic X-rays and the consequent diffraction pattern is recorded on a photographic film or by a radiation counter. The intensities of the diffraction maxima are then used to construct mathematically the three-dimensional image of the crystal structure. X-rays interact almost exclusively with the electrons in the matter and not the nuclei. The spacing of atoms in a crystal lattice can be determined by measuring the angle and intensities at which a beam of X-rays of a given wave length is diffracted by the electron shells surrounding the atoms. Operationally, there are several steps in X-ray structural analysis. The amount of information obtained depends on the degree of structural order in the sample. Blundell et al. provide an advanced treatment of the principles of protein X-ray crystallography. Blundell, et al., Protein Crystallography, Academic Press (1976), herein incorporated by reference. Likewise, Wyckoff et al. provide a series of articles on the theory and practice of X-ray crystallography. Wyckoff, et al. (Eds.), Methods Enzymol. 114: 330-386 (1985), relevant portions herein incorporated by reference. Important techniques for X-ray crystallography include methods for determining diffraction data phases by a multiple anomalous dispersion (MAD) method (described, for example, in Hendrickson, 1991), particularly using biosynthethic enrichment with seleno-methione (SeMet), and a molecular replacement method (described, for example, in Rossmann, M. G. The molecular replacement method. Acta Cryst. A46, 73-82 (1990).

Nuclear Magnetic Resonance (NMR). A general approach for the analysis of NMR resonance assignments was first outlined by Wuthrich, Wagner and co-workers. Wuthrich, “NMR of proteins and nucleic acids” Wiley, New York, New York (1986); Wuthrich, Science 243:45-50 (1989); Billeter, et al., J. Mol Biol. 155:321-346 (1982), relevant portions of each incorporated herein by reference. For a general review of protein determination in solution by nuclear magnetic resonance spectroscopy, see Wuthrich, Science 243:45-50 (1989); Billeter et al., J. Mol. Biol. 155:321-346 (1982). More recent improvements using multidimensional and triple resonance NMR methods (described, for example, in J. Cavanagh, W. Fairbrother, A. Palmer, and N. Skelton, Protein NMR Specroscopy, Principles and Practice, 2ed Ed, Academic Press, N.Y., 2006, incorporated herein), familiar to someone trained in the art, are elaborations of these basic principles.

As used herein, the terms “CPSF30 binding epitope” or “CPSF binding site” refer to that portion of the NS1 protein of influenza that interacts with one or more zinc fingers of the CPSF30 protein.

As used herein, the terms “NS1A-binding epitope” or “NS1A binding site” refer to that portion of the CPSF30 protein that interacts with the NS1 protein of influenza A.

As used herein, the term “tetramer interface” refers to those portions of the NS1A protein and the CSPF30 protein that interact NS1A:CPSF30 complex, which can be a dimer or tetramer.

As used herein, the terms “double-strand RNA binding site” or “doubled-stranded RNA binding epitope” refer to that portion of the NS1A protein that interacts with double-stranded RNA, e.g., for suppressing host innate immune response. Greater structural details regarding the double-strand RNA binding site is taught by the present co-inventors in PCT/US2003/036,292, “Process for Designing Inhibitors of Influenza Virus Non-Structural Protein 1,” relevant portions incorporated herein by reference and U.S. Provisional Patent Application Ser. No. 60/737,742, “Novel Compositions and Vaccines Against Influenza and Influenza B Infections,” and PTC Patent Application Filed Nov. 17, 2006 “Novel Compositions and Vaccines Against Influenza and Influenza B Infections,” relevant portions and tables incorporated herein by reference.

As used herein, the term “epitope” refers to a portion of a protein that is capable of interacting with the same or another protein and that can be define by atoms in amino acids in a linear sequence, by atoms in amino acids that are located throughout the protein (or subunits thereof) and that come together in three dimensions to form an interactive structure. The skilled artisan will recognize that an epitope may be a structure such as a “zinc finger,” a portion of a molecular surface between two or more polypeptides that are capable of interacting, and/or a “binding pocket” or “enzymatic pocket” that lead to a function or interaction of the protein.

As used herein, the following nomenclature is used to define the zinc finger domains of the CPSF30 protein that interact NS1A, namely, “F1”, “F2” and “F3” when referring to individual zinc fingers, “F1F2”, “F2F3” when referring to a pair of zinc fingers and “F1F2F3” when referring to the three zinc fingers.

As used herein, the term “rationally design” refers to a series of steps for designing, e.g., initial small molecule inhibitors that may be further refined through medicinal chemistry and/or the selection of inhibitors that can be further modified chemically and that fit the molecular characteristics of a molecule that will meet the design criteria for modifying the interactions between or the activity of NS1A and CPSF30 based fully and/or at least in part on the three dimensional (3D) coordinates described herein.

As used herein, the term “virtual screening” refers to in silico design, using computer software to screen for possible binding ligands from a library of virtual molecules, allowing the characterization and refinement of small molecule inhibitors that will meet the design criteria for modifying the interactions between or the activity of NS1A and CPSF30 based fully and/or at least in part on the three dimensional (3D) coordinates described herein.

As used herein, the term “corresponding positions” refers to amino acids at that are generally in the same spatial location in the three-dimensional structures of homologous protein structures. In one example, a corresponding position is determined by 3D structure alignment using standard techniques known to a person skilled in the art, such as the PRISM program, described by Yang and Hong Yang, A.-S. and Honig, B. (2000) An Integrated Approach to the Analysis of Sequence and Structure. I. Protein Structural Alignment and a Quantitative Measure for Protein Structural Distance. J. Mol. Biol. 301: 665-678; Yang, A.-S. and Honig, B. (2000) An Integrated Approach to the Analysis of Sequence and Structure. III. A Comparative Study of Sequence Conservation in Protein Structural Families Using Multiple Structural Alignments, or the VISTAL program, described by Kolodny, R. and Honig, B. (2006) VISTAL—A New 2D Visualization Tool of Protein 3D Structural Alignments. Bioinformatics 22:2166-2167 (e.g., using the default settings for either), relevant portions incorporated herein by reference. The alignment may include the introduction of gaps in the sequences to be aligned. In the absence of 3D structures for protein pairs, corresponding positions may be identified (until such time that the requisite 3D structures are available) by sequence-based alignment using stardard techniques known to a person skilled in the art, such as a Needleman-Wunsch dynamic programming algorithm (described in Needleman, S. B. and Wunsch, C. D., J Mol Biol. 48: 443-453 (1970), a Gapped BLAST/PSI-BLAST algorithm (described in Altschul, et al Nucl. Acid. Res. 25: 3389-3402 (1997), or a CLUSTAL W/X multiple sequence alignment algoithm (described in Thompson, J. D., Higgins, D. G. and Gibson, T. J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucl. Acid. Res. 22:4673-80 (1994).)(e.g., using the default settings for either relevant portions incorporated herein by reference. Corresponding position alignment(s) may also include the introduction of gaps in the sequences to be aligned.

Further examples of “corresponding positions are taught by the present co-inventors in PCT/US2003/036,292, “Process for Designing Inhibitors of Influenza Virus Non-Structural Protein 1,” relevant portions incorporated herein by reference and U.S. Provisional Patent Application Ser. No. 60/737,742, “Novel Compositions and Vaccines Against Influenza and Influenza B Infections”, and PTC Patent Application Filed Nov. 17, 2006 “Novel Compositions and Vaccines Against Influenza and Influenza B Infections,” relevant portions and tables incorporated herein by reference.

Non-limiting examples of numerous influenza A strains may be used with the present invention including those strains that are readily available or will become available as they emerge in human populations. Examples of influenza A strains for use and analysis with the present invention may include A/Memphis/8/88, A/Chile/1/83, A/Kiev/59/79, A/Udorn/307/72, A/NT/60/68, A/Korea/426/68, A/Great Lakes/0389/65, A/Ann Arbor/6/60, A/Leningrad/13/57, A/Singapore/1/57, A/PR/8/34, A/Vietnam/1203/04, A/HK/483/97, A/South Carolina/1/181918 (the 1918 pandemic virus H1N1 strain), and A/WSN/33. The sequences of these strains are available from GenBank, CDC and viral stock may be available from the American Type Culture Collection, Rockville, Md. or are otherwise publicly available.

As used herein, the term “variant” gene or protein refers to a gene or protein that differs from the wild type gene or protein by way of nucleotide or amino acid substitution(s), addition(s), deletion(s), and combinations thereof. Depending on the context, the term mutant is also used to describe variations from the wild-type sequence that are natural, introduced at random and/or introduced into a gene or protein sequence specifically. Likewise, a fragment is used to describe a fragment of the complete length of the translated polypeptide, whether natural or not. Often, the skilled artisan will design fragments that include or avoid certain amino acid that may affect, e.g., synthesis or cause steric hindrance or other design requirements. When designing alternate peptide constructs with enhanced anti-viral properties, substitutions may be used which modulate one or more properties of the molecule. Variants typically include the exchange of one amino acid for another at one or more sites within the peptide. For example, certain amino acids may be substituted for other amino acids in a peptide structure in order to enhance the interactive binding capacity of the structures. Certain amino acid substitutions can be made in a protein sequence (or its underlying DNA coding sequence) to create a peptide with superior functional characteristics. In particular, those changes that enhance the amphipathic, α-helical nature may be desired.

As used herein, the term “candidate compound” refers to any molecule that may inhibit influenza viral growth. The candidate substance may be a protein or fragment thereof, a small molecule, or even a nucleic acid molecule. Various commercial sources of small molecule libraries meet the basic criteria for useful drugs in an effort to “brute force” the identification of useful candidate compounds. Screening of such libraries, including libraries generated combinatorially (e.g., peptide libraries, aptamer libraries, small molecule libraries), is a rapid and efficient way to screen large number of related (and unrelated) compounds for activity. Combinatorial approaches also lend themselves to rapid evolution of potential drugs by the creation of second, third and fourth generation compounds modeled of active, but otherwise undesirable compounds. Candidate compounds may be screened from large libraries of synthetic or natural compounds. One example of a candidate compound library is an FDA-approved library of compounds that can be used by humans. Synthetic compound libraries are commercially available from a number of companies including Maybridge Chemical Co. (Trevillet, Cornwall, UK), Comgenex (Princeton, N.J.), Brandon Associates (Merrimack, N.H.), and Microsource (New Milford, Conn.) and a rare chemical library is available from Aldrich (Milwaukee, Wis.). Combinatorial libraries are available or can be prepared. Alternatively, libraries of natural candidate compounds in the form of bacterial, fungal, plant and animal extracts are also available from, for example, Pan Laboratories (Bothell, Wash.) or MycoSearch (N.C.), or can be readily prepared by methods well known in the art. Candidate compounds isolated from natural sources, such as animals, bacteria, fungi, plant sources, including leaves and bark, and marine samples may be assayed as candidates for the presence of potentially useful pharmaceutical agents. It will be understood that the pharmaceutical agents to be screened could also be derived or synthesized from chemical compositions or man-made compounds.

The amino acid sequence of the NS1A protein of Influenza A virus, A/Udorn/72:

(SEQ ID NO.: 1)   1  MDPNTVSSFQ VDCFLWHVRK RVADQELGDA PFLDRLRRDQ  KSLRGRGSTL GLDIETATRA  61 GKQIVERILK EESDEALKMT MASVPASRYL TDMTLEEMSR  EWSMLIPKQK VAGPLCIRMD 121 QAIMDKNIIL KANFSVIFDR LETLILLRAF TEEGAIVGEI  SPLPSLPGHT AEDVKNAVGV 181 LIGGLEWNDN TVRVSETLQR FAWRSSNENG RPPLTPKQKR  EMAGTIRSEV.

The anti-viral agents disclosed herein may be used in conjunction with methods to reduce virus growth, infectivity, burden, shed, development of anti-viral resistance, and to enhance the efficacy of traditional anti-viral therapies.

The amino acid sequence of the relevant fragments of human CPSF30 (UniProt id 095639):

(SEQ ID NO.: 13)   1 MQEIIASVDH IKFDLEIAVE QQLGAQPLPF  50 PGMDKSGAAV CEFFLKAACG  51 KGGMCPFRHI SGEKTVVCKH WLRGLCKKGD 100 QCEFLHEYDM TKMPECYFYS 101 KFGECSNKEC PFLHIDPESK IKDCPWYDRG 150 FCKHGPLCRH RHTRRVICVN 151 YLVGFCPEGP SCKFMHPRFE LPMGTTEQPP 200 LPQQTQPPAK QSNNPPLQRS 201 SSLIQLTSQN SSPNQQRTPQ VIGVMQSQNS 250 SAGNRGPRPL EQVTCYKCGE 251 KGHYANRCTK GHLAFLSGQ 

The amino acid sequence of the relevant fragments of human CPSF30 discussed in this patent are:

F1 Zn-Finger Domain: residues 41-59;

F2 Zn-Finger Domain: residues 68-86;

F3 Zn-Finger Domain: residues 96-114;

F4 Zn-Finger Domain: residues 124-142;

F5 Zn-Finger Domain: residues 148-166; and

F5 Zn-Finger Domain: residues 243-260.

As used herein F2F2 are residues 61-121 of SEQ ID NO.: 13:

 61 SGEKTVVCKH WLRGLCKKGD QCEFLHEYDM  100 TKMPECYFYS 101 KFGECSNKEC PFLHIDPESK I 121

As used herein F1F2F3 are residues 39-121 of SEQ ID NO.: 13:

 39 AV CEFFLKAACG  50  51 KGGMCPFRHI SGEKTVVCKH WLRGLCKKGD 100 QCEFLHEYDM TKMPECYFYS 101 KFGECSNKEC PFLHIDPESK 121

The anti-viral properties of the peptides disclosed herein allow them to be included in formulations to inhibit virus growth and proliferation. The purified anti-viral peptides may be used without further modifications or they may be diluted in a pharmaceutically acceptable carrier. The invention may be administered to humans or animals, included in food and pharmaceutical preparations. They anti-viral agents may also be used in medicinal and pharmaceutical products (such as fluid containers, iv. bags, tubing, syringes, etc.), as well as in cosmetic products, hygienic products, cleaning products and cleaning agents, as well as any material to which the peptides could be sprayed on or adhered to wherein the inhibition of virucidal growth on such a material is desired.

The dosage of an anti-viral peptide necessary to prevent viral growth and proliferation depends upon a number of factors including the types of virus that might be present, the environment into which the peptide is being introduced, and the time that the peptide is envisioned to remain in a given area.

As used herein, the phrases “pharmaceutically” or “pharmacologically acceptable” refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal or a human. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well know in the art. Except insofar as any conventional media or agent is incompatible with the vectors or cells of the present invention, its use in therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.

The active antiviral agents of the present invention may be formulated into classic pharmaceutical preparations and administered via any common route so long as the target tissue is available via that route. These routes of administration include, e.g., oral, alveolar, nasal, buccal, rectal, vaginal or topical. In particular, use of the anti-viral peptides of the present invention in a condom or diaphragm, optionally in conjunction with a spermicidal or other contraceptive substance, is envisioned. Alternatively, administration may be orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal or intravenous. The antiviral agent may also be administered parenterally or intraperitoneally. Solutions of the antiviral agent may be compounded into a free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The antiviral agent(s) will generally be provided in a pharmaceutical dosage form suitable for injectable use, e.g., sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For widespread use, the antiviral agents may be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The antiviral agents will commonly be provided with a carrier, e.g., a solvent or dispersion medium that may include, e.g., water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. Proper dosage fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and/or antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, the dosage form will include isotonic agents, e.g., sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Generally, sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle that includes the basic dispersion medium and the required other ingredients from those enumerated above. Preparation of sterile powders for injectable solutions maybe prepared by, e.g., vacuum-drying, spray-freezing, freeze-drying or other techniques that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

As used herein, a “pharmaceutically acceptable carrier” refers to solvents, dispersion media, coatings, antibacterial and anti-fungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

For oral administration, the antiviral agent(s) of the present invention may be incorporated with excipients and used in the form of ingestible or non-ingestible mouthwashes and dentifrices. A mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, the antiviral agent(s) may be incorporated into an antiseptic wash containing sodium borate, glycerin and potassium bicarbonate. The antiviral agent(s) may also be dispersed in dentifrices, e.g., gels, pastes, powders and slurries. The antiviral agent(s) may be added in a therapeutically effective amount to a paste dentifrice that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.

The antiviral agent(s) may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric and the like. Salts may also be formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

Upon formulation, the antiviral agent(s) will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug release capsules and the like. Sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure, e.g., Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams & Wilkins (2005), relevant portions incorporated herein by reference. Some variation in dosage will necessarily occur depending on the condition of the subject being treated for which the skilled artisan will determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

In one embodiment, the vaccine comprises a pharmaceutically acceptable vehicle. The suitable vehicles may be both aqueous and non-aqueous. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, immunostimulats, immunosuppressants, wetting agents, emulsifying and suspending agents, or any combination thereof.

Examples of suitable adjuvants include, without limitation, incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum, Stimulon® QS-21 (Aquila Biopharmaceuticals, Inc., Framingham, Mass.), MPL® (3-0-deacylated monophosphoryl lipid A; Corixa, Hamilton, Mont.), and interleukin-12 (Genetics Institute, Cambridge, Mass.).

A person of the ordinary skill in the art has a sufficient expertise to determine the dosage of the vaccines of the instant invention. Such dosage depends on the pathogenicity of the virus included in the vaccine and on the ability of the antigen to elicit an appropriate immune response. In different embodiments of the invention, a virus vaccine composition of the instant invention may comprise from about 10²-10⁹ plaque forming units (PFU)/ml, or any range or value therein (e.g., 10³, 10⁴, 10⁵, 10⁶, 10⁷, or 10⁸) where the virus is attenuated. A vaccine composition comprising an inactivated virus can comprise an amount of virus corresponding to about 0.1 to 200 μg of the amino acid sequences of the instant invention per ml, or any range or value therein.

The vaccines of the instant invention can be applied in multiple ways. According to one embodiment of the invention, the intranasal administration is via the mucosal route. The intranasal administration of the vaccine composition can be formulated, for example, in liquid form such as, for example, nose drops, spray, or suitable for inhalation. In other embodiment, the vaccine may be administered as a powder, or a cream, or an emulsion.

In another embodiment, the vaccines of the instant invention are applied by an injection, including, without limitation, intradermal, transdermal, intramuscular, intraperitoneal and intravenous. According to another embodiment of the invention, the administration is oral and the vaccine may be presented, for example, in the form of a tablet or encased in a gelatin capsule or a microcapsule, which simplifies oral application. The production of these forms of administration is within the general knowledge of a technical expert.

As used herein, “detectable labels” refer to compounds and/or elements that can be detected due to their specific functional properties and/or chemical characteristics, the use of which allows the agent to which they are attached to be detected, and/or further quantified if desired, such as, e.g., an enzyme, an antibody, a linker, a radioisotope, an electron dense particle, a magnetic particle or a chromophore. The detectable label may be half of a fluorescence resonance energy transfer (FRET) pair (for FRET variations see, e.g., U.S. Pat. No. 6,593,091, issued to Keys, relevant portions incorporated herein by reference). There are many types of detectable labels, including fluorescent labels, which are easily handled, inexpensive and nontoxic. Another example of a detection method relies on hydrogel-coated donor and acceptor beads providing functional groups for conjugation to biomolecules. AlphaScreen® by Berthold Technologies (Bad Wildbad, Germany)(Rouleau, N., Turcotte, S., Mondou, M. H., Roby, P. & Bosse, R. (2003) J Biomol Screen 8, 191-7.).

The present inventors recognized that certain regions of the NS1A protein can be targeted for the development of antiviral drugs. The NS1A protein is a multi-functional dimeric protein that participates in both protein-RNA and protein-protein interactions (Krug et al., 2003). The effector domain, which comprises the C-terminal two-thirds of the NS1A protein, contains the binding site for the 30-kDa subunit of the cellular cleavage and polyadenylation specificity factor (CPSF30) (Nemeroff et al., 1998; Li et al., 2001). This interaction results in the inhibition of 3′ end processing of all cellular pre-mRNAs in infected cells, and as a consequence the production of mature mRNAs encoding antiviral proteins (such as interferon, IFN) is severely inhibited during infection (Shimizu et al., 1999; Kim et al., 2002; Noah et al., 2003). This inhibition is crucial to viral replication and spread, because influenza A virus, like several other RNA viruses (Yoneyama et al., 2004; Sumpter et al., 2005; Seth et al., 2006), efficiently activates the RIG-I RNA helicase and thereby triggers both the activation of IRF-3 and NF-kB and the synthesis of IFN-beta and other antiviral pre-mRNAs (Geiss et al., 2002; Kim et al., 2002; Siren et al., 2006). A recombinant influenza A/Udorn/72 virus expressing a NS1A protein with a mutated binding epitope for CPSF30 induced high levels of IFN-beta mRNA during infection and was highly attenuated (100-1000-fold) (Noah et al., 2003; Twu et al., 2006). A 61-amino-acid domain of CPSF30, comprising two of its zinc fingers (i.e., the F2F3 fragment), was found to bind efficiently to the NS1A protein (Twu et al., 2006). The expression of the F2F3 domain in cells leads to the inhibition of influenza A virus replication and increased production of IFN-beta mRNA, indicating that F2F3 likely blocks the binding of endogenous CPSF30 to the NS1A protein (Twu et al., 2006). These results validate the binding epitope on NS1A for CPSF30 as a potential target for the development of small molecule antiviral drugs directed against influenza A virus and as a target for engineering strains of virus that can be used as live attenuated vaccines.

Previous studies showed that residues 184-188 in the protein sequence of the NS1A protein are required for functional binding of CPSF30 (Li et al., 2001; Noah et al., 2003). Thus, this region is required for the binding of CPSF30 in vitro (Li et al., 2001), and mutation of amino acids 184-188 in the NS1A protein of a recombinant Udorn virus results in high attenuation coupled with increased synthesis of IFN-beta (Noah et al., 2003). These data demonstrate that this binding epitope is essential for virus replication. As shown by the structural studies described below, the 184-188 region of the NS1A protein sequence constitutes a subset of the CPSF30 binding epitope, observed in the 3D structure of the complex between NS1A effector domain and F2F3 which is disclosed for the first time in this Disclosure.

Studies with the NS1A proteins of H5N1 viruses established that the Met (M) residue at position 106 is required for functional F2F3/CPSF30 binding. We showed that the NS1A protein encoded by a pathogenic H5N1 virus that was transmitted to humans in 1997 (A/HK/483/97; HK97) lacks a binding epitope for CPSF30, whereas the NS1A protein encoded by a pathogenic 2004 H5N1 virus (A/Vietnam/1203/04; VN04) has acquired this binding epitope. We were able to generate a CPSF30 binding epitope in the HK97 NS1A protein by changing two of its amino acids to the corresponding amino acids in the VN04 NS1A protein, specifically by changing I at position 106 to M and L at 103 to F. To determine the effects of these two amino acid changes in the HK97 NS 1A protein during virus infection, a recombinant Udorn virus was generated in which the Udom NS gene was replaced by a HK97 NS gene encoding a NS1A protein with these two mutations (Ud/dmHK97 recombinant). The recombinant virus was then compared to the recombinant Ud virus containing the wild-type HK97 NS gene (Ud/HK97 recombinant). During multiple cycle growth the rate of replication and virus yield of the Ud/dmHK97 recombinant was 100-fold greater than with the Ud/HK97 recombinant virus (FIG. 1A), and is thus similar to the Udorn parent virus. During single-cycle growth, the Ud/HK97 virus induced a high level of IFN-beta mRNA production, which was almost completely suppressed in the cells infected by the Ud/dmHK97 virus (FIG. 1B). Most importantly, the replication of the Ud/dmHK97 virus was inhibited in F2F3-expressing cells (data not shown), indicating that the dmHK97 NS1A protein binds F2F3 in infected cells. The roles of Phe at 103 and the Met at 106 in the NS1A protein in forming the F2F3/CPSF30 complex is elucidated by the herein disclosed X-ray crystal structure of the NS1A:F2F3 complex, which reveals that amino acids 103 and 106 are required for CPSF30 binding because their hydrophobic interactions stabilize a tetrameric structure of the NS1A:F2F3 complex (see below). It should also be emphasized that essentially all (>98%) of the influenza A viruses (H3N2, H2N2 and H1N1) that have been isolated from humans, including the 1918 H1N1 virus, and include M and F at positions 106 and 103 in their NS1A proteins, respectively, indicating that these two amino acids, which are critical for CPSF30 binding and the resulting suppression of the production of IFN-β mRNA, are conserved in human influenza A viruses. Accordingly, the tetrameric complex described in this disclosure is anticipated to be critical for the CSPF30 binding function of all such human influenza A viruses.

EXAMPLE 1 Process for Discovering, Designing, and Optimizing Small Molecule Inhibitors of Influenza A Viruses, Including H5N1 Viruses

Novel Reagents and Structural Data. To further delineate the interface between F2F3 of CPSF30 and the NS1A protein the inventors determined the three-dimensional (3D) structure of the tetrameric F2F3:NS1A complex. Ninety (90) different constructs (Table 2) were screened in order to find constructs suitable for crystallization and NMR analysis. These variants, summarized in Tables 3 and 4, included 8-11 different full-length or subsequences of NS1A with N-terminal (N-His) and C-terminal (C-His) affinity purification tags, prepared as described in Acton et al., 2005 from influenza A strains A/South Carolina/1/181918 (the 1918 pandemic virusH1N1 strain), HK97 (A/HK/483/97, 1997 Hong Kong), VN04 (A/Vietnam/1203/04, 2005 Vietnam), and Udom (A/Udorn/72), respectively. These were assessed in terms of expression level and solubility (Tables 3 and 4), ability to purify, and biophysical properties, including 2D ¹⁵N-¹H heteronuclear single quantum coherence correlation spectroscopy (HSQC). Many of these reagents, disclosed for the first time here, are useful for influenza A research purposes and for structural studies. The inventors focused on two specific constructs that provide particularly high expression and solubility, making them especially useful for biochemical and biophysical studies: the C-terminal hexaHis-tagged 85-215 amino acid fragments of the NS1A proteins from (i) influenza A/Udorn/72 (A/Udom) and (ii) the H5N1 strain A/Vietnam/1203/04 (A/VN04). These highly soluble constructs can be produced in tens of milligram per liter quantities, and have been produced with SeMet labeling, for crystallography, and with ¹⁵N-enrichment for NMR studies. Excellent quality HSQC NMR spectra can be obtained for these two constructs in the pH range 5.5 to 6.5 (FIG. 2). Under these conditions, these constructs are of sufficiently good quality to indicate high feasibility for further NMR studies. They are also useful for small molecule screening studies. In addition, the F2F3 fragment of CPSF30 has been cloned into a pET expression vector with a N-terminal hexaHis tag (tag sequences are defined in Acton et al., 2005), produced with uniform ¹³C, ¹⁵N enrichment, and complete backbone and sidechain resonance assignments have been determined using standard triple resonance NMR methods (Montelione et al., 1999). These NMR-optimized sample conditions and resonance assignments are useful for small molecule screening, lead optimization, and structure-function studies of F2F3:NS1A interactions.

Because virus studies have used influenza A/Udorn/72 virus to identify CPSF30 binding activity during virus infection CPSF30 (Li et al., 2001; Noah et al., 2003), we have developed an assay for the binding of the NS1A Udorn effector domain to the F2F3 fragment of CPSF30 in vitro, using analytical gel filtration with detection of effluent by simultaneous refractive index and static light scattering measurements. The chromatography system used for this assay is described in Acton et al., 2005, in which it is used for other applications. In these studies, illustrated in FIG. 3, the NS1A Udorn (85-215) construct elutes as a dimer, with molecular weight of ˜30 kDa. When this effector domain construct is first mixed with the 8.5 kDa F3F3 fragment, the resulting complex elutes with a molecular weight of ˜50 kDa, indicating a stoichiometry of 2 F2F3:2 NS1A effector domains. This gel filtration assay provides a convenient qualitative measure of F2F3 binding by NS1A effector domains.

Suitable samples of NS1A Udorn (85-215); the NS1A-Udorn(85-215):F2F3 complex, and other constructs listed in Table 2 and their complexes with F2F3 and CPSF30-derived constructs, can be produced and assessed using this gel filtration assay. These can then be crystallized for X-ray crystallographic analysis. Initial crystals of the NS1A-Udorn(85-215):F2F3 complex were obtained by high-throughput robotic screening using service facilities available through the Hauptman Woodward Res. Inst. (Buffalo N.Y.) (Luft et al., 2003; Acton et al., 2005). Crystallization optimization was then carried out for the NS1A-Udorn(85-215):F2F3 complex at Rutgers, yielding diffraction quality bi-pyramid crystal of size 0.15×0.15×0.25 mm³. Conditions providing crystals, and a description of these crystals, are presented herein below. Three-wavelength Se-Met multiple anomalous diffraction (MAD) (2.3 A resolution) and a complete native (1.95 Å resolution) data sets were collected at X25 beam line at Brookhaven National Laboratories. The structure was solved by MAD techniques (Hendrickson, 1991) and refined to 1.95 Å resolution, and is currently refined to a R factor of 0.225 and R free of 0.245, respectively.

Crystallization of NS1A Udorn (85-215):F2F3 Complex. Initial crystallization conditions for NS1A Udorn (85-215):F2F3 complex were obtained by using robotic crystallization facility at the Buffalo facility described above. The most promising condition use 1.77 M potassium nitrate (KNO₃) at pH 5.0 as precipitant. This initial crystallization condition was optimized manually at Rutgers. Good quality crystals were obtained using 0.25-1.0 M KNO₃ and 10-20% sucrose/glucose as precipitant at pH 5-6. Diffraction quality crystals were obtained when P94S mutant F2F3 was used in the complex, though similar conditions are expected to provide crystals of the complex with the wild-type (P94) F2F3 sequence. The NS1A Udorn (85-215):F2F3 complex was crystallized with the symmetry of the space group P4₁ with cell parameters a=b=50.96, c=205.39 Å and α=β=γ=90°. A variant used in the X-ray crystal structure determination of NS1(85-215):F2F3 complex has Ser in place of Pro at position 94.

FIGS. 4A and 4B disclose the crystal structure of the Udorn NS1A effector domain (residues 85-215) bound to the F2F3 fragment of CPSF30. Consistent with gel filtration data, the complex forms a tetrameric complex, in which two F2F3 molecules bridge two NS1A effector domains. The structure reveals for the first time the novel spatial arrangement of the subunits in the 2 NS1A: 2 F2F3 complex. This tetrameric arrangement was completely unexpected and novel.

Key residues Met106/Met106′ of NS1A are packed in the core of the tetrameric interface or “tetramerization epitope,” explaining its critical role in CPSF30 binding, as discussed above. However, while Met 106/Met106′ are at the core of the tetrameric complex, they are not part of the primary F2F3/CPSF30 binding pocket. FIG. 5 illustrates the F2F3 binding pocket on the surface the Udorn NS1A effector domain. Specific interactions in this primary binding pocket involve residues K110, 1117, 1119, Q121, V180, G183, G184, and W187 of NS1A and residues F97, F98, F103, and K110 of the F3 finger of CPSF30. It should be noted that these residues include not only amino acids in, or adjacent to, the 184-188 sequence previously identified as part of the CPSF30 binding epitope by mutagenesis studies, but also amino acids in other regions in the NS1A protein not previously recognized to be essential for CPSF30 binding. Mutation of residues G183 or G184 in NS1A(85-215) each to Arg or Asp disrupts or reduces F2F2 binding affinity and/or tetramer formation, based on analytical gel filtration measurements without significantly disrupting the native structure of NS1A(85-215) indicated by ¹⁵N-¹H HSQC NMR spectra (data not shown), demonstrating a functional role of these sites within the CPSF30 binding epitope of NS1A. Recombinant Udorn viruses encoding NS1A proteins in which either G184 or W187 was changed to Arg are attenuated (data not shown), further demonstrating that these amino acids are required for virus replication. The eight residues in the CPSF30-binding epitope of NS1A (FIG. 5) are almost 100% conserved amongst influenza A viruses isolated from humans (Macken et al., 2001), except for Ile117 which is frequently replaced by Met. Based on this structure, disclosed for the first time here, we propose disruption of 2NS1A:2F2F3 tetramerization as a strategy to inhibit influenza A virus in human. Based on our structural data, we further propose that a small molecule inhibitor that binds tightly to the above described conserved epitope and surrounding regions will disrupt CPSF30 binding and will inhibit influenza A virus in humans. This pocket on the surface of the NS1A effector domain is the target of our proposed drug discovery process.

Table 1 describes some of the specific location of the epitopes described herein as the tetramerization, RNA binding and CPSF30 binding epitopes of NS1A.

TABLE 1 Tetramerization, RNA binding and CPSF30 binding epitopes of NS1A. NS1A Interacting amino amino acids of acids F2F3 Remark F103 L72, Y88, F103 contributes to both the tetramer interface and the CPSF30- M93, P111 binding epitope F103 interacts with F2 and F3 domains of CPSF30, may play a role in defining angle between F2 and F3 appropriately; mutation of 103 could affect an intermolecular salt bridge between R73 and D125. L105 P111, F112, L105 contributes to both the tetramer interface and the CPSF30- M124 (NS1A- binding epitope Adjacent to F103 and also interacting at the tetramer 2) interface with a 2^(nd) NS1A molecule. M106 N107 M106 contributes to both the tetramer interface and the CPSF30- binding epitope. M106I mutation would effect the positioning of N107 (of F2F3) and/or Q121 (NS1A same molecule) involved in F2F3- NS1A H-bonds. K110 K110 K110 contributes to the CPSF30-binding epitope. K110 has H-bond with the main-chain carbonyl of K101 of F2F3. I117 F102 I117 contributes to the CPSF30-binding epitope. Part of the hydrophobic pocket that binds F3 I119 F98, F102 I119 contributes to the CPSF30-binding epitope. Part of the hydrophobic pocket that binds F3 Q121 S105, S106 Q121 contributes to the CPSF30-binding epitope. H-bond with amino group of S106 and O_(γ) of 105 (both from CPSF30) D125 R73 D125 contributes to the CPSF30-binding epitope. Salt bridge with R73 (of CPSF30) L144 No inter- L144 is buried into the hydrophobic core of NS1A that probably molecular defines the fold of the protein. A mutation of L144 may alter the shape interaction of NS1A, resulting in reduced CPSF30 and/or dsRNA binding activities V180 Y97, K101, V180 contributes to the CPSF30-binding epitope. Part of the F3- F102 binding pocket. G183 Y97 G183 contributes to the CPSF30-binding epitope. Part of a helix that forms a wall of the F3-binding pocket. A side-chain may affect (enhance or disrupt) the binding of F3. G184 Y97, F98 G184 contributes to the CPSF30-binding epitope. Part of a helix that forms a wall of the F3-binding pocket. Positioned between Y97 and F98 side chains. A mutation of G184 would alter the shape of the pocket and can severely affect the binding of F3. W187 C96, Y97, F98, W187 contributes to the CPSF30-binding epitope. Participates in the F112 pocket formation.

Recently, the crystal structure of the NS lA effector domain (residues 79 to 205) of the influenza A/PR8/34 (PR8) virus strain was reported (Bornholdt and Prasad, 2006). This PR8 influenza strain is adapted for passage in mouse, presumably as a result of mouse adaptation, the PR8 NS gene attenuates virus growth in mammalian cells in tissue culture (Ozaki et al, 2004). The PR8 NS1A protein does not bind F2F3 because it lacks the consensus human sequence at positions 106 (I instead of M) and 103 (S instead of F) (Macken et al, 2001), therefore we can determine if the attenuation of growth in mammalian cells is caused primarily by the changed amino acids at positions 106 and 103 in the PR8 NS1A protein (data not shown). The absence of a CPSF30 binding epitope in the PR8 NS1A protein presumably resulted from the large number of passages in mice that have adapted the virus for replication in mice. Consequently, the 3D structure of effector domain of the PR8 NS1A protein (Bornholdt and Prasad, 2006) is not suitable for structure-based drug discovery efforts. In addition, its structure may differ from that of a NS1A protein containing a functional CPSF30 binding epitope. Indeed, the 3D structures of the Udorn effector domain monomers in our complex are similar to, but not identical with, the structure of the monomers of the PR8 NS1A effector domain structure (FIG. 6). The PR8 NS1A structure does not have a F2F3-binding epitope like that observed in the 3D structure of the Udorn NS1A structure described herein. In particular, the PR8 NS1A structures lack the hydrophobic pocket that binds F2F3 in the NS1A:F2F3 complex. Moreover, the dimeric interface in crystal structure of the PR8 NS1A effector domain has an intermolecular beta-sheet interaction (FIG. 7) that is completely different from the interface in the crystal structure of the Udorn NS1A effector domain bound to F2F3. Therefore, the dimer of the effector domain of the PR8 NS1A protein is not relevant for the binding of CPSF 30 and to our proposed drug-design strategy.

Fluorescence polarization (FP) assay. Fluorescence polarization (FP) is a spectroscopic method that measures the rotational rate of a sample in solution. It applies polarized light to excite a fluorophore and measures the polarization characteristics of the emitted light (Nasir and Jolley, 1999; Roehrl et al., 2004b). If the sample tumbles slowly compared to the lifetime of the fluorescence, the emitted light retains some of the incident polarization. However, if the sample tumbles fast, the emitted light is isotropic. Therefore, the degree of anisotropy (polarization) of the fluorescent light emitted from a sample provides a measure of the fluorophore's rotational correlation time in the bound state. Given appropriate bound-state lifetimes, rotational correlation times, and changes in rotational correlation upon complex formation, FP assays can be used to measure binding affinities and to screen for binding inhibitors (Schade et al., 1996; Seethala and Menzel, 1998; Roehrl et al., 2004a).

FP with fluorescently-labeled F2F3. A FP assay of F2F3 binding by NS1A is being implemented. As mentioned above, complex formation between F2F3 and various effector domain constructs is observed in gel filtration studies (see FIG. 3), indicating a dissociation constant K_(d) tighter than low micromolar. These data of FIG. 3 demonstrate the feasibility of implementing a FP assay for detecting NS1A:F2F3 binding. Moreover, excellent HSQC spectra and essentially complete NMR resonance assignments are available for the F2F3 construct (data not shown); these will be used to assess the native structural integrity of fluorescently-labeled CPSF30 fragments.

In one embodiment of the invention, we will generate a fluorescein (or other fluorophore)—labeled F2F3 (Fluo-F2F3) substrate for FP assay. The F2F3 sequence of human CPSF30 contains 7 Lys and 6 Cys residues, and fluorophore labeling requires careful consideration to ensure proper folding with Zn ligation by these six Cys residues. Two primary strategies will be pursued for labeling F2F3: (i) chemical synthesis with a fluorophore label and (ii) synthesis or biosynthesis of an analog suitable for specific labeling. The 61-residue F2F3 is sufficiently short to allow fluorophore labeling by solid phase peptide synthesis (for example, by a commercial supplier, such as New England Peptide, Inc. Gardner, Mass.). The crystal structure of F2F3 bound to the NS1A effector domain indicates that the N-terminal region is not involved in key binding interactions, and suggests that it may be possible to generate shorter constructs with similar binding affinities.

Those constructs that show tight binding can be synthesized in 100 mg amounts and assayed for structural integrity by ¹⁵N-¹H HSQC NMR analysis at natural isotopic abundance using a 800 MHz NMR system with cryoprobe.

If for some reason this approach is not successful, fluorophone-labeled F2F3 will be produced by overexpression with a ‘flash’ peptide sequence tag (Griffin et al., 1998; Griffin et al., 2000; Abrams, 2002). When the tetra-cysteine tag [NH₂-Cys-Cys-Pro-Gly-Cys-Cys . . . ] is incorporated into proteins/peptides it can be specifically conjugated to a biarsenyl-fluorophore ligand (sold by Invitrogen as their Lumio-technology). The modification can even specifically label the tetra-cysteine tag in vivo (Griffin et al., 2000), and thus should not react with any of the six cysteine residues on F2F3. If even both of these approaches prove to be problematic for this tandem Zn-finger domain, alternative strategies for fluorophore labeling are available, such as the method of Ting and colleagues (Chen and Ting, 2005) that utilizes biotin ligase together with appropriate cofactors to introduce fluorescein in a short N-terminal acceptor peptide lacking any Cys residues, allowing the fluorophore to be introduced subsequent to forming the Zn fingers.

Using any of the above labeling approaches, or other possible approaches, the labeled F2F3 can then be folded with Zn ligation using the same protocol we have developed for unlabeled F2F3. In exploring each of these approaches, we will verify that the fluorophore in the N-terminal tag becomes sufficiently immobilized in the complex to provide a significant change in fluorescence anisotropy. If required, a more immobilized Cys residue within the F2F3 sequence with be introduced without interfering with Zn-finger formation, using our 3D structure of the NS1A (85-215):F2F3 complex as a guide. Using one of these labeling routes, or any approach for introducing the fluorescence tag, the resulting FP assay will be validated by measuring competition with unlabeled F2F3.

The crystal structure of the complex between NS1A Udorn(85-215) and the F2F3 CPSF30 reveals that most of the intermolecular interactions between NS1A and F2F3 involve the F3 Zn-finger domain (FIG. 5). Accordingly, a smaller flourescein-labeled F3 finger (Fluo-F3), with ˜4 kDa molecular weight, may have preferential properties in developing a FP assay. Though the binding of the NS1A effector domain to Fluo-F3 is likely to be somewhat weaker than the binding to F2F3, the change in rotational correlation time, and thus the signal-to-noise of the FP assay, will be significantly higher using Fluo-F3 than using Fluo-F2F3. These design principles may be advantageous in development of a high throughput FP assay useful in screening for inhibitors of CPSF30 (or variants, mutants, or fragments thereof) binding to NS1A (or variants, mutants, or fragments thereof).

The crystal structure of the complex between NS1A Udorn (85-215) and the F2F3 fragment further suggests that a tandem repeat of the F2F3 fragment, connected by a short flexible linker, F2F3-F2F3, could also bind in a manner similar to the two independent F2F3 molecules, though potentially with much tighter binding affinity. Accordingly, we will generate a variety of F2F3-F2F3 constructs, as outlined below, assay their binding, and assess the oligomerization states of these complexes by gel filtration with light scattering detection. If indeed a tandem repeat F2F3-F2F3 construct can be generated with even tighter binding than F2F3 itself, it will be used in a more sensitive FP assay, capable of detecting only more tightly-binding inhibitors.

The magnitude of the change in fluorescence anisotropy, which determines the signal-to-noise of the FP assay, depends on the change in rotational correlation time of the fluorophore upon complex formation. If required to enhance this change in rotational correlation time, the relative size of the NS1A component of NS1A:CSPF30 (or fragments thereof) complexes described above can be further increased by expression as a larger fusion protein (e.g., fused to maltose binding protein), or by attachment to beads or microscopic particles using, for example, already available constructs of Tables 2, 3, and 4 with either N- or C-terminal hexHis tags, or using other affinity tags.

EXAMPLE 2 Constructs to be Used in Developing Fluorescence Polarization Assay

The crystal structure of the complex between NS1A Udorn (85-215) and the F2F3 fragment was examined to identify potential linking sites so that the C-terminus of one segment of F2F3 (or portion thereof) would have a favorable path for linking to the N-terminus of the second segment. Considerations for favorable linking geometry include the distance between termini to be linked, the path the linker would need to take, and linker composition and length. A common peptide linker composition used for connecting domains in engineered proteins is some combination of Gly and Ser residues, allowing for conformational flexibility and solubility while remaining somewhat neutral in chemical content, e.g. -Gly-Ser-, or -Gly-Ser-Gly, etc.

Constructs were designed based on the crystal structure of the influenza virus NS1A-CTD protein complex with the F2F3 fragment from the human CPSF30 protein, disclosed for this first time in this Disclosure. The expectation is that a single-chain construct of the F2F3 binding regions observed in the crystal structure would bind more tightly to the NS1A dimer than the separate domains, and might have significant antiviral activity.

The structure was examined to identify potential linking sites so that the C-terminus of one segment of F2F3 (or portion thereof) would have a favorable path for linking to the N-terminus of the second segment. Considerations for favorable linking geometry include the distance between termini to be linked, the path the linker would need to take, and linker composition and length. A common peptide linker composition used for connecting domains in engineered proteins is some combination of Gly and Ser residues, allowing for conformational flexibility and solubility while remaining somewhat neutral in chemical content, e.g. -Gly-Ser-, or -Gly-Ser-Gly, etc.

The sequence of CPSF30 F2F3 used for the specific designs is that used in the crystal structure determination, but amino acid replacements can be considered. The N-terminal portion might include a hexa-His or other tag for convenient purification; alternatively a tag might be encoded at the C-terminus of the construct. Other purification tags may be preferable to oligo-His owing to potential interference with the chelation of zinc ions by the F2 and F3 “Zn finger” segments, which is required for the integrity of the three-dimensional structure and for effective binding to NS1A. In all of these F2F3 sequences, residue Pro92 may be substituted by Ser.

The constructs involving single F3 domains (“one finger”) as opposed to F2F3 domains (“two fingers”) are potentially valuable as minimal/miniature versions because the interaction between separate F2F3 chains in the dimer (chains F2F3-A and F2F3-B) is mediated entirely by residues in F3 and does not involve any residues from F2. The F3 domain itself, or variants, could be used as an antiviral drug.

Relatively few of the residues in F2 make important interactions with the NS1A protein in the dimer of dimers; notable exceptions are Leu72 and Arg73, whose side chains interact extensively with NS1A. The Leu72 and Arg73 interactions could be maintained by a strategic linkage of a Leu-Arg or Arg-Leu peptide to Thr91 (proposed N-terminus of the F3 domain construct). L72-T91 distance is 14.2 A; R73-T91 distance is 17.6 A. Possible extensions to the one-finger F3 domain construct would be Leu-Arg-GSGSG-F3 or Arg-Leu-GSGSG-F3 (see proposed constructs 5a and 5b).

F2F3 sequence (numbered as in human CPSF30 protein):

(SEQ ID NO.: 2) 61           71         81         91          M SGEKTVVCKH WLRGLCKKGD QCEFLHEYDM TKMPECYFYS  101        111 KFGECSNKEC PFLHIDPESK I

Construct 1. F3-F3: Single F3-linker-F3 construct (tandem F3 construct)(abbreviated: (91-116)-linker(11+)-(91-116)). Distance from F2F3-A Asp116 Ca to F2F3-B Thr91 Ca is 33.3 A; linker can be 10+ flexible amino acids;

11: - (SEQ ID NO.: 3) GSGSGSGSGSG- also written as -(GS)₅G-; 13: - (SEQ ID NO.: 4) GSGSGSGSGSGSG- also written as -(GS)₆G-; (SEQ ID NO.: 5) 91         101        111     linker    116 TKMPECYFYS KFGECSNKEC PFLHID -(GS)_(N)G -  91         101        111 TKMPECYFYS KFGECSNKEC PFLHID

C-terminal residue of tandem construct can be D116 or any extension up to 1121; crystal structure extends only to P117 in one copy and E118 in the other. Both N- and C-termini can have extensions including hexaHis and other tags for convenient purification as discussed in the text.

Construct 2. F2F3-F3: Same as previous construct except that the N-terminal portion of the construct encompasses entire F2F3 segment (abbreviated) (60-116)-linker(11+)-(91-116):

(SEQ ID NO.: 6) 61           71         81         91          M SGEKTVVCKH WLRGLCKKGD QCEFLHEYDM TKMPECYFYS  101         111  KFGECSNKEC PFLHID - linker   91         101        111  116 (GS)_(N)G - TKMPECYFYS KFGECSNKEC PFLHID

Construct 3. F2F3-F2F3: F2F3-linker-F2F3 construct (tandem F2F3 construct)(abbreviated: (60-116)-linker(15+)-(62-116)). Distance from F2F3-A Asp116 Ca to F2F3-B Gly62 Ca is 51.1 Å; linker should be 14+ flexible amino acids:

15: - (SEQ ID NO.: 7) GSGSGSGSGSGSGSG- also written as -(GS)₇G-;  17: - (SEQ ID NO.: 8) GSGSGSGSGSGSGSGSG- also written as -(GS)₈G-; (SEQ ID NO.: 9) 61    71           81      91         101  M SGEKTVVCKH WLRGLCKKGD QCEFLHEYDM TKMPECYFYS      111 KFGECSNKEC PFLHID - linker   62        71         81                  (GS)_(N)G - GEKTVVCKH WLRGLCKKGD QCEFLHEYDM   91        101         111 TKMPECYFYS KFGECSNKEC PFLHID.

Construct 4. F3 -F2F3: F3 -linker-F2F3 construct (abbreviated: (91-116)-linker(15+)-(62-116)). Distance from F2F3-A Asp116 Ca to F2F3-B Gly62 Ca is 51.1 Å; linker should be 14+ flexible amino acids.

(SEQ ID NO.: 10) 91         101        111  116  linker TKMPECYFYS KFGECSNKEC PFLHID - (GS) _(N) G - 62        71         81         91  GEKTVVCKH WLRGLCKKGD QCEFLHEYDM TKMPECYFYS  101        111 KFGECSNKEC PFLHID

Construct 5. XF3-F3: Extended F3-linker-F3 construct. Linker 1 will link a Leu-Arg or Arg-Leu dipeptide to the one-finger F3 domain in a mode to incorporate the important L72 and R73 side-chain interactions from F2 that are otherwise missing. Linker 2 can be 10+ flexible amino acids:

Construct 5a (abbreviated: Leu-Arg-linker(5+)-(91-116)-linker(11+)-(91-116)):

(SEQ ID NO.: 11) 72  73   linker 1  91          101        Leu-Arg  - GSGSG - TKMPECYFYS KFGECSNKEC  111 116  linker 2 PFLHID - (GS)_(N)G - 91         101        111 116 TKMPECYFYS KFGECSNKEC PFLHID

Construct 5b (abbreviated: Arg-Leu-linker(5+)-(91-116)-linker(11+)-(91-116)):

(SEQ ID NO.: 12) 73  72  linker 1  91        101  Arg-Leu - GSGSG - TKMPECYFYS KFGECSNKEC  111  116  linker 2 PFLHID - (GS)_(N)G - 91         101        111 116 TKMPECYFYS KFGECSNKEC PFLHID

Each of the constructs 1-5b above, and variants thereof, will inhibit CPSF30 binding by NS1A, and can potentially be used as lead compounds for drug development and/or as antiviral drugs useful in preventing or treating influenza A infection in humans, poultry (e.g. chicken), and other animals.

Structure-based Lead Optimization using X-ray Crystallography and NMR. The sample preparation and structural characterization of NS1A effector domains from multiple influenza strains, allow the use of both NMR and X-ray crystallography in hit validation, lead compound optimization, and drug discovery.

Crystallography for lead optimization. X-ray analysis has historically been very important to structure-based inhibitor design. Compounds identified as inhibitor “hits” by kinetic assays can be used to form complexes with the target protein. X-ray analysis will reveal the mode of inhibitor binding and act as a basis for further inhibitor design. Crystal inhibitor complexes can also be formed by soaking inhibitors into preformed crystals, or complexes may be grown by co-crystallization. The latter case may be necessary if the complex triggers conformational changes. In either case, diffraction data is collected on a rotating anode source, processed, and converted to electron density maps. The orientation and occupancy of the inhibitors will be observed and compared with binding modes predicted from virtua 1 screening or models from earlier design cycles. In this way, inhibitors analyzed in one cycle of design will feed into subsequent rounds of structural analysis and re-design in the general process of structure-based drug design (Kuhn 2002; Scapin 2006)

Cocrystallization and Crystal soaks. Using crystallization conditions that we have already optimized for the NS1A effector domains, described above, cocrystallizations and crystal soaks can be carried out with lead compounds identified in our high throughput screening efforts. Trials will be carried out to crystallize NS1A effector domain:lead compound complexes. Diffraction data can be collected using either home or synchrotron X-ray sources and the resulting difference electron density maps and 3D structures can be used to characterize small molecule binding epitopes and bound-state conformations. These data can be used screening for lead compounds either one at a time or in high throughput format, lead compound validation, and optimization of lead compounds, using methods familiar to a person skilled in the art.

NMR for lead identification optimization. NMR is also a powerful method for validating intermolecular interactions, and is used extensively in commercial pharmaceutical drug discovery efforts to identify lead compounds and their protein binding sites (Shuker et al., 1996; Hajduk et al., 1997; Moore, 1999a, 1999b; Muegge et al., 1999; Moy et al., 2001; Powers, 2002; Lepre et al., 2004; Rush and Powers, 2004; Mercier et al., 2006; Petros et al., 2006). NMR chemical shift perturbations, of either the protein or the ligand, can be used for screening for small molecule lead compounds, validating initial small molecule hits identified with htp or virtual screening assays, locating the corresponding binding site in the 3D protein structure, and to guide rational lead optimization. NMR methods uniquely complement crystallography studies. Strengths of NMR analysis methods include (i) the ability to detect even weak (k_(d) up to ˜500 micromolar) binding interactions, (ii) compatibility with systems that undergo structural changes upon ligand binding which may not be accommodated by a crystalline lattice, (iii) the ability to adjust solvent conditions over a wide range, and (iv) high sensitivity and very low sample requirements.

Using NS1A effector domain constructs that have already been shown to provide high quality HSQC spectra (e.g., FIG. 2), NMR chemical shift perturbation can be used to validate initial small molecule hits identified with high-throughput (htp) or virtual screening assays, locating the corresponding binding site in the 3D protein structure, and for rational lead optimization. Hits identified in htp FP assays will be characterized by assessing perturbations in HSQC spectra for which resonance assignments will be available, and interpreting these effects on the available 3D structures of NS1 effector domains. Some methods suitable for lead compound screening, identification, and optimization envisioned for use with our invention are summarized in C. A. Lepre, J. M, Moore, and J. W. Peng, Theory and Applications of NMR-based Screening in Pharmaceutical Research (Chem. Rev. 104, 3641-3675 (2004)), which is incorporated herein by reference. The NMR infrastructure required for such work are available at most large research institutions, including by not limited to Rutgers University, and include 5 mm 600 and 800 MHz NMR cryoprobe systems, as well as a 1 mm 600 MHz NMR equipped with an automated sample changer. The cryoprobes enable recording of high-quality HSQC data using 150 microliter samples at protein concentrations as low as 10 micromolar, and the 1 mm NMR probe provides high quality HSQC data on 7 microliter samples at 100 micromolar concentrations. Such NMR technologies allow NMR screening for lead compound optimization with as little as ˜500 nanomoles of each sample. Where appropriate, the 3D structures of tightly bound small molecule lead compounds may also be determined by NMR methods if they cannot be solved by crystallographic methods. These data will be used in redesign and lead optimization as outlined for crystallographic data above.

Expressed soluble constructs of NS1A outlined in Tables 2, 3 and 4, or their variants, can also be used to screen for small molecule lead compounds using NMR detection of resonances of the small molecule, using limits desribed by (but not limited to) C. A. Lepre, J. M. Moore, and J. W. Peng, Theory and Applications of NMR-based Screening in Pharmaceutical Research (Chem. Rev. 104, 3641-3675 (2004)).

Where appropriate, the 3D structures of tightly bound small molecule lead compounds may also be determined by NMR methods if they cannot be solved by crystallographic methods. These data will be used in redesign and lead optimization using synthetic chemistry, as outlined for crystallographic data above.

Antiviral assays. Having identified inhibitors of the interaction between NS1A and CPSF30, the inhibitors would be tested for their ability to inhibit influenza A virus replication in tissue culture studies. Plaque reduction assays in MDCK cells will be used to assay compounds for their ability to inhibit influenza A virus replication (Twu et al., 2006). Monolayers of MDCK cells will be infected with approximately 100 plaque-forming units (PFU) of influenza A/Udorn/72 virus, and after virus adsorption the cells will be overlaid with agar containing a concentration of a compound ranging from 0.001 micrograms/ml to 10 micrograms/ml. Plaques will be counted in duplicate plates and compared to the number of plaques in controls not exposed to the chemical. In parallel cytotoxicity evaluations of lead compounds would be carried out on MDCK cells using the Roche reagent WST-1 (Berridge et al., 2005). The rate of WST-1 cleavage by mitochondrial dehydrogenases, yielding a product with absorbance at 450 nm, correlates with the number of viable cells. These assays will be carried out in 96-well tissue culture plates, and cell viability will be assayed by determining absorbance at 450nm using an ELISA plate reader. Once the most promising lead compounds with low cytotoxicity in both MDCK and human (A549) cells have been identified, we will determine the effect of several concentrations of the compounds on the rate and extent of virus replication during multiple-cycle growth in MDCK cells. The compounds with the greatest inhibitory activity at the lowest concentrations will be used for subsequent studies in a suitable animal model (ferrets).

Applications of NS1A:CPSF30 Inhibitors. These inhibitors can be developed into antiviral drugs that will be effective in the control of influenza virus epidemics and pandemics in humans. Because there is the potential for such epidemics to be man-made, i.e., using influenza A virus as a bioterrorist weapon, such antivirals would also be crucial in this situation. Influenza antiviral drugs will also be important for the control of influenza A infections in commercial poultry stocks, such as chickens.

TABLE 2 pET-based vectors for NS1A proteins and fragments from various flu strains. 1918 HK97 VN04 Udorn Full-length N-His and C-His N-His and C-His N-His and C-His N-His and C-His  1-215 N-His and C-His N-His and C-His N-His and C-His N-His and C-His 73-215 N-His and C-His N-His and C-His N-His and C-His N-His and C-His 85-215 N-His and C-His N-His and C-His N-His and C-His N-His and C-His 91-215 C-His Not attempted C-His C-His  1-211 N-His and C-His N-His and C-His N-His and C-His N-His and C-His 85-211 N-His and C-His N-His and C-His N-His and C-His N-His and C-His 73-211 N-His and C-His N-His and C-His N-His and C-His N-His and C-His 91-211 C-His Not attempted Not attempted Not attempted 85-204 C-His C-His C-His C-His 91-204 C-His Not attempted C-His C-His

TABLE 3 N-terminal His tag NS1 Expression/Solubility results for NS1A proteins and fragments from various flu strains. 1918 HK97 VN04 Udorn FL yes/low yes/low no/na yes/low  1-215 yes/low yes/low yes/no yes/low 73-215 yes/no yes/med yes/no yes/low 85-215 yes/low yes/low yes/low yes/med  1-211 yes/no yes/low yes/no yes/low 85-211 yes/low yes/no yes/med yes/med 73-211 yes/low yes/no yes/med yes/low

TABLE 4 C-terminal His tag NS1 Expression/Solubility results for NS1A proteins and fragments from various flu strains. 1918 HK97 VN04 Udorn FL yes/low yes/no no/na yes/low  1-215 yes/no yes/medium yes/no yes/no 73-215 na na yes/no yes/low 85-215 yes/medium yes/good yes/low yes/low 91-215 yes/low yes/low na yes/low  1-211 no/na na yes/no na 85-211 yes/no yes/no yes/low yes/no 73-211 na yes/no yes/good yes/no 91-211 yes/no na na na 85-204 yes/low yes/low yes/low yes/low 91-204 yes/no yes/no na yes/no

Creating Attenuated Influenza Virus Strains Suitable for Avian and Human Influenza Vaccine Development. The structural information disclosed here can be combined with site-directed mutagenesis data for NS1A to engineer attenuated influenza A virus strains suitable for use as live attenuated vaccines in humans and livestock. Multiple, weakly attenuating mutations will be created in the CPSF30 and dsRNA-binding epitopes to generate NS1 proteins with reduced binding affinity in vitro. The effects of these mutations on the structural integrity of NS1A variants can be assessed with HSQC NMR data and/or crystallization and X-ray crystallography. These data will then be used to engineer viral strains of influenza A with various degrees of attenuation. These viral strains will be engineered to contain multiple base changes to minimize the potential of the virus to revert to virulence. Such influenza A viruses would be attenuated in normal cells, and in humans and animals, but would not be attenuated in cells lacking interferon genes (e.g. cell culture Vero cells), thereby enabling the production of large amounts of these attenuated viruses suitable for use as a live virus vaccine.

Methods for development of attenuated flu vaccines are described in U.S. Provisional Patent Application Ser. No. 60/737,742, “Novel Compositions and Vaccines Against Influenza and Influenza B Infections,”, and PTC Patent Application Filed Nov. 17, 2006 “Novel Compositions and Vaccines Against Influenza and Influenza B Infections,” relevant portions and tables incorporated herein by reference, relevant portions incorporated herein by reference.

A person of ordinary skill in the art will understand that because of the degeneracy of the genetic code, a large number of nucleic acid sequences can be generated in accordance with this invention. The production of the viruses of the instant invention (or the respective recombinant NS1A protein or respective NS1B protein comprising said amino acid sequences) can be achieved by recombinant DNA technology. Nucleic acid sequences encoding the amino acid sequences of the instant invention can be produced using methods well known in the art, including, for example, chemical synthesis, PCR and site-directed mutagenesis.

The instant invention provides recombinant influenza A virus comprising the amino acid sequences which are at least 70% identical but less than 100% identical either to dsRNA binding domains of NS1A. These viruses may be generated, for example, by reverse genetic system, whereby influenza virus can be generated by transfection of multiple DNAs without a helper virus. This technique was described in Fodor et al., 1999. Essentially, in that study the technique involved transfecting into a host cell a combination of plasmids containing cDNAs for the viral RNA segments (including NS1 proteins), proteins of viral RNA dependent polymerase complex (PB1, PB2, and PA), and nucleoprotein. Further, it is possible to transfect host cells (such as, for example 293 cells or Vero cells) with a plasmid encoding a recombinant NS1A protein (for rescuing influenza A viral phenotype) containing the appropriate amino acid sequence of the instant invention. The resulting viruses may be used for creation of vaccines, as described below.

In another embodiment, the virus can be propagated in suitable host, such as, for example, chicken eggs, without a need for transforming a host cell with multiple plasmids. In this embodiment, essentially, clinical isolates of human influenza virus are taken from infected patients and are reassorted in embryonated chicken eggs with laboratory-adapted master strains of high-growth donor viruses.

To prepare the recombinant NS1A viruses for different purposes (including, without limitations, the use of the virus as a vaccine or a part thereof), each of these mutations may be carried out individually on constructs of NS1A suitable for biochemical characterization, possibly including but not limited to the constructs outlined in Tables 3 and 4. Other variants of NS1A or affinity tags (e.g. FLAG tags) may also be used. These proteins may be purified and characterized with respect to structural integrity by comparing the circular dichroism and/or NMR spectrum and/or X-ray crystal structures with those of the corresponding wild-type NS1 construct. The several constructs may then be assayed for dsRNA binding as described elsewhere (Chien et al., 2004), or using other methods of assessing protein-dsRNA binding affinities commonly used for such studies, such as, for example, sedimentation equilibrium, gel electrophoresis, or gel filtration chromatography. These data will be used to assess the effect of single site mutants at these sites revealed by the structural models to be important for dsRNA recognition. Further, sets of double, triple, and quadruple mutants of residues in the CPSF30 binding epitope, tetramer interface, dsRNA binding epitope, and combinations thereof would also be generated in these NS1A constructs and assessed for structural integrity and binding activities in vitro. This experimental design will allow a person of the ordinary skill in the art to identify mutant forms of NS1A and NS1A varients with minimal structural disruption but with reduced CPSF30 and/or dsRNA binding affinity.

The invention encompasses methods of selecting viruses which have the desired phenotype, i.e., viruses which have low or no dsRNA binding activity, whether obtained from natural variants, spontaneous variants (i.e., variants which evolve during virus propagation), mutagenized natural variants, reassortants and/or genetically engineered viruses. Such viruses can be best screened in differential growth assays that compare growth in host systems which have attenuated and normal immune response to influenza A viruses. Viruses which demonstrate better growth in the hosts having the attenuated response versus the normal response are selected; preferably, viruses which grow to titers at least one log greater in the host systems with the attenuated response as compared to the host system with the normal response are selected.

The present invention also encompasses methods of growing and isolating mutated viruses having altered dsRNA binding activity in cells and cell lines which naturally exhibit an attenuated response to viral infections as compared to wild-type cells. In a particular preferred embodiment, the present invention relates to methods of growing the viruses of the instant invention in Vero cells.

It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method, kit, reagent, or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.

It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims.

All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

The term “or combinations thereof” as used herein refers to all permutations and combinations of the listed items preceding the term. For example, “A, B, C, or combinations thereof” is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, AB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.

All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

Abrams, J. M. 2002. Competition and compensation: coupled to death in development and cancer. Cell 110: 403-6.

Acton, T. B., Gunsalus, K. C., Xiao, R., Ma, L. C., Aramini, J., Baran, M. C., Chiang, Y.-W., Climent, T., Cooper, B., Denissova, N. G., Douglas, S. M., Everett, J. K., Ho, C. K., Macapagal, D., Paranji, R. K., Shastry, R., Shih, L. Y., Swapna, G. V. T., Wilson, M., Wu, M., Gerstein, M., Inouye, M., Hunt, J. F., and Montelione, G. T. 2005. Robotic cloning and protein production platform of the Northeast Structural Genomics Consortium. Meth. Enzymol. 394: 210-43.

Berridge, M. V., Herst, P. M., and Tan, A. S. 2005. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11: 127-52.Bornholdt, Z. A., and Prasad, B. V. 2006. X-ray structure of influenza virus NS1 effector domain. Nat Struct Mol Biol 13: 559-60.

Chen, I., and Ting, A. Y. 2005. Site-specific labeling of proteins with small molecules in live cells. Curr Opin Biotechnol 16: 35-40.

Chizhmakov, I. V., Geraghty, F. M., Ogden, D. C., Hayhurst, A., Antoniou, M., and Hay, A. J. 1996. Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. J. Physiol 494 (Pt 2): 329-36.

Cox, N. J., and Subbarao, K. 1999. Influenza. Lancet 354: 1277-82.

Crescenzo-Chaigne, B., van der Werf, S., and Naffakh, N. 2002. Differential effect of nucleotide substitutions in the 3′ arm of the influenza A virus vRNA promoter on transcription/replication by avian and human polymerase complexes is related to the nature of PB2 amino acid 627. Virology 303: 240-52.

de Jong, M. D., Tran, T. T., Truong, H. K., Vo, M. H., Smith, G. J., Nguyen, V. C., Bach, V. C., Phan, T. Q., Do, Q. H., Guan, Y., Peiris, J. S., Tran, T. H., and Farrar, J. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-72.

Ferguson, N. M., Cummings, D. A., Cauchemez, S., Fraser, C., Riley, S., Meeyai, A., Iamsirithaworn, S., and Burke, D. S. 2005. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437: 209-14.

Ferguson, N. M., Cummings, D. A., Fraser, C., Cajka, J. C., Cooley, P. C., and Burke, D. S. 2006. Strategies for mitigating an influenza pandemic. Nature 442: 448-52.

Geiss, G. K., Salvatore, M., Tumpey, T. M., Carter, V. S., Wang, X., Basler, C. F., Taubenberger, J. K., Bumgarner, R. E., Palese, P., Katze, M. G., and Garcia-Sastre, A. 2002. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci USA 99: 10736-41.

Germann, T. C., Kadau, K., Longini, I. M., Jr., and Macken, C. A. 2006. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A 103: 5935-40.

Griffin, B. A., Adams, S. R., Jones, J., and Tsien, R. Y. 2000. Fluorescent labeling of recombinant proteins in living cells with F1AsH. Methods Enzymol 327: 565-78.

Griffin, B. A., Adams, S. R., and Tsien, R. Y. 1998. Specific covalent labeling of recombinant protein molecules inside live cells. Science 281: 269-72.

Gubareva, L. V., Penn, C. R., and Webster, R. G. 1995 Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 212: 323-30.

Hajduk, P. J., Dinges, J., Miknis, G. F., Merlock, M., Middleton, T., Kempf, D. J., Egan, D. A., Walter, K. A., Robins, T. S., Shuker, S. B., Holzman, T. F., and Fesik, S. W. 1997. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J Med Chem 40: 3144-50.

Hatta, M., Gao, P., Halfmann, P., and Kawaoka, Y. 2001. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293: 1840-2.

Hendrickson, W. A. 1991. Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. Science 254: 51-8.

Horimoto, T., and Kawaoka, Y. 2005. Influenza: Lessons from past pandemics, warnings from current incidents. Nature Revs. Microbiol. 3: 591.

Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., Laver, W. G., and Stevens, R. C. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 681-90.

Kim, M. J., Latham, A. G., and Krug, R. M. 2002. Human influenza viruses activate an interferon-independent transcription of cellular antiviral genes: outcome with influenza A virus is unique. Proc Natl Acad Sci USA 99: 10096-101.

Krug, R. M., Yuan, W., Noah, D. L., and Latham, A. G. 2003. Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology 309: 181-9.

Lamb, R. A., and Krug, R. M. 2001. Orthomyxoviridae: the viruses and their replication. 1487-531 In: Fields Virology, vol. 1, eds. D. M. Knipe and P. M. Howley, Lippincott, Williams, and Wilkins, Philadephia.

Le, Q. M., Kiso, M., Someya, K., Sakai, Y. T., Nguyen, T. H., Nguyen, K. H., Pham, N. D., Ngyen, H. H., Yamada, S., Muramoto, Y., Horimoto, T., Takada, A., Goto, H., Suzuki, T., Suzuki, Y., and Y., K. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108.

Lepre, C. A., Moore, J. M., and Peng, J. W. 2004. Theory and applications of NMR-based screening in pharmaceutical research. Chem Rev 104: 3641-76.

Li, Y., Chen, Z. Y., Wang, W., Baker, C. C., and Krug, R. M. 2001. The 3′-end-processing factor CPSF is required for the splicing of single-intron pre-mRNAs in vivo. Rna 7: 920-31.

Longini, I. M., Jr., Nizam, A., Xu, S., Ungchusak, K., Hanshaoworakul, W., Cummings, D. A., and Halloran, M. E. 2005. Containing pandemic influenza at the source. Science 309: 1083-7.

Luft, J. R., Collins, R. J., Fehrman, N. A., Lauricella, A. M., Veatch, C. K., and DeTitta, G. T. 2003. A deliberate approach to screening for initial crystallization conditions of biological macromolecules. J Struct Biol 142: 170-9.

Macken, C., Lu, H., Goodman, J., and Boykin, L. 2001. The value of a database in surveillance and vaccine selection. 103-06 In: Options for the control of influenza IV, eds. N. C. A. W. H. A. D. M. E. Osterhaus, N. Cox and A. W. Hampson Elsevier Science, Amsterdam.

Maines, T. R., Chen, L. M., Matsuoka, Y., Chen, H., Rowe, T., Ortin, J., Falcon, A., Nguyen, T. H., Mai le, Q., Sedyaningsih, E. R., Harun, S., Tumpey, T. M., Donis, R. O., Cox, N. J., Subbarao, K., and Katz, J. M. 2006. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci USA 103: 12121-6.

Mendel, D. B., Tai, C. Y., Escarpe, P. A., Li, W., Sidwell, R. W., Huffman, J. H., Sweet, C., Jakeman, K. J., Merson, J., Lacy, S. A., Lew, W., Williams, M. A., Zhang, L., Chen, M. S., Bischofberger, N., and Kim, C. U. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42: 640-6.

Mercier, K. A., Germer, K., and Powers, R. 2006. Design and characterization of a functional library for NMR screening against novel protein targets. Comb Chem High Throughput Screen 9: 515-34.

Montelione, G. T., Rios, C. B., Swapna, G. V. T., and Zimmerman, D. E. 1999. NMR pulse sequences and computational approaches for automated analysis of sequence-specific backbone resonance assignments of proteins. 81-130 In: Biological Magnetic Resonance Vol 17, vol. 17, eds. N. R. Krishna and L. J. Berliner, Kluwer Academic/Plenum publishers, New York.

Moore, J. M. 1999a. NMR screening in drug discovery. Curr Opin Biotechnol 10: 54-8.

Moore, J. M. 1999b. NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery. Biopolymers 51: 221-43.

Moy, F. J., Haraki, K., Mobilio, D., Walker, G., Powers, R., Tabei, K., Tong, H., and Siegel, M. M. 2001. MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. Anal Chem 73: 571-81.

Muegge, I., Martin, Y. C., Hajduk, P. J., and Fesik, S. W. 1999. Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. J Med Chem 42: 2498-503.

Nasir, M. S., and Jolley, M. E. 1999. Fluorescence polarization: an analytical tool for immunoassay and drug discovery. Comb. Chem. High Throughput Screen 2: 177-90.

Nemeroff, M., Barabino, S. M. L., Keller, W., and Krug, R. M. 1998. Influenza virus NS1 protein interacts with the 30 kD subunit of cleavage and specificity factor and inhibits 3′ end formation of cellular pre-mRNAs. Mol. Cell 1: 991-1000.

Noah, D. L., and Krug, R. M. 2005. Influenza virus virulence and its molecular determinants. Adv Virus Res 65: 121-45.

Noah, D. L., Twu, K. Y., and Krug, R. M. 2003. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3′ end processing of cellular pre-mRNAS. Virology 307: 386-95.

Ozaki, H., Govorkova, E. A., Li, C., Xiong, X., Webster, R. G. and Webby, R. J. 2004. Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J. Virol. 78: 1851-7.

Petros, A. M., Dinges, J., Augeri, D. J., Baumeister, S. A., Betebenner, D. A., Bures, M. G., Elmore, S. W., Hajduk, P. J., Joseph, M. K., Landis, S. K., Nettesheim, D. G., Rosenberg, S. H., Shen, W., Thomas, S., Wang, X., Zanze, I., Zhang, H., and Fesik, S. W. 2006. Discovery of a potent inhibitor of the antiapoptotic protein Bc1-xL from NMR and parallel synthesis. J Med Chem 49: 656-63.

Pinto, L. H., Holsinger, L. J., and Lamb, R. A. 1992. Influenza virus M2 protein has ion channel activity. Cell 69: 517-28.

Powers, R. 2002. Applications of NMR to structure-based drug design in structural genomics. J Struct Funct Genomics 2: 113-23.

Prevention. 2005. Background on Influenza. http://www.cdc.gov/flu/background/professionals/background.

Puthavathana, P., Auewarakul, P., Charoenying, P. C., Sangsiriwut, K., Pooruk, P., Boonnak, K., Khanyok, R., Thawachsupa, P., Kijphati, R., and Sawanpanyalert, P. 2005. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J. Gen. Virol. 86: 423-33.

Reid, A. H., Taubenberger, J. K., and Fanning, T. G. 2001. The 1918 Spanish influenza: integrating history and biology. Microbiol. Infect. 3: 81-7.

Reid, A. H., Taubenberger, J. K., and Fanning, T. G. 2004. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. Nat Rev Microbiol 2: 909-14.

Roehrl, M. H. A., Wang, J. Y., and Wagner, G. 2004a. Disovery of small-molecule inhibitors of the NFAT-calcineurin interaction by competitive high-throughput fluorescence polarization screening. Biochemistry 43: 16067-75.

Roehrl, M. H. A., Wang, J. Y., and Wagner, G. 2004b. A general framework for development and data analysis of competitive high-throughput screens for small-molecule inhibitors of protein-protein interactions by fluorescence polarization. Biochemistry 43: 16056-66.

Rush, T. S., 3rd, and Powers, R. 2004. The application of x-ray, NMR, and molecular modeling in the design of MMP inhibitors. Curr Top Med Chem 4: 1311-27.

Ryan, D. M., Ticehurst, J., Dempsey, M. H., and Penn, C. R. 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 38: 2270-5.

Schade, S. Z., Jolley, M. E., J., S. B., and Simonson, L. G. 1996. BODIPY-alpha-casein, a pH-independent protein substrate for protease assays using fluorescence polarization. Anal. Biochem. 24: 31-37.

Seethala, R., and Menzel, R. 1998. A fluorescence polarization competition immunoassay for tyrosine kinases. Anal. Biochem 255: 257-62.

Seth, R. B., Sun, L., and Chen, Z. J. 2006. Antiviral innate immunity pathways. Cell Res 16: 141-7.

Shimizu, K., Iguchi, A., Gomyou, R., and Ono, Y. 1999. Influenza virus inhibits cleavage of the HSP70 pre-mRNAs at the polyadenylation site. Virology 254: 213-9.

Shinya, K., Hamm, S., Hatta, M., Ito, H., Ito, T., and Kawaoka, Y. 2004. PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology 320: 258-66.

Shuker, S. B., Hajduk, P. J., Meadows, R. P., and Fesik, S. W. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274: 1531-4.

Siren, J., Imaizumi, T., Sarkar, D., Pietila, T., Noah, D. L., Lin, R., Hiscott, J., Krug, R. M., Fisher, P. B., Julkunen, I., and Matikainen, S. 2006. Retinoic acid inducible gene-I and mda-5 are involved in influenza A virus-induced expression of antiviral cytokines Microbes Infect 8: 2013-20.

Sumpter, R., Jr., Loo, Y. M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S. M., and Gale, M., Jr. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79: 2689-99.

Suzuki, H., Saito, R., Masuda, H., Oshitani, H., Sato, M., and Sato, I. 2003. Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother 9: 195-200.

Taubenberger, J. K., Reid, A. H., Lourens, R. M., Wang, R., Jin, G., and Fanning, T. G. 2005. Characterization of the 1918 influenza virus polymerase genes. Nature 437: 889-93.

Thompson, J. D., Higgins, D. G. and Gibson, T. J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-80.

Twu, K. Y., Noah, D. L., Rao, P., Kuo, R. L., and Krug, R. M. 2006. The CPSF30 binding site on the NS lA protein of influenza A virus is a potential antiviral target. J Virol 80: 3957-65.

von Itzstein, M., Wu, W. Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., and et al. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418-23.

Wang, C., Takeuchi, K., Pinto, L. H., and Lamb, R. A. 1993. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 67: 5585-94.

WHO. 2006. Pandemic influenza.

Woods, J. M., Bethell, R. C., Coates, J. A., Healy, N., Hiscox, S. A., Pearson, B. A., Ryan, D. M., Ticehurst, J., Tilling, J., Walcott, S. M., and et al. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 37: 1473-9.

Wright, P. F., and Webster, R. G. 2001. Orthomyxoviruses. 1533-79 In: Fields Virology, eds. D. M. Knipe and P. M. Howley, Lippincott Williams & Wilkins, Philadelphia.

Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., and Fujita, T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5: 730-7.

HEADER −−−− XX−XXX−XX xxxx COMPND −−− REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM: REFMAC 5.2.0005 REMARK 3 AUTHORS: MURSHUDOV, VAGIN, DODSON REMARK 3 REMARK 3 REFINEMENT TARGET: MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS): 1.95 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS): 25.00 REMARK 3 DATA CUTOFF (SIGMA(F)): NONE REMARK 3 COMPLETENESS FOR RANGE (%): 97.88 REMARK 3 NUMBER OF REFLECTIONS: 35935 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS−VALIDATION METHOD: THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION: RANDOM REMARK 3 R VALUE (WORKING + TEST SET): 0.19912 REMARK 3 R VALUE (WORKING SET): 0.19794 REMARK 3 FREE R VALUE: 0.23607 REMARK 3 FREE R VALUE TEST SET SIZE (%): 3.1 REMARK 3 FREE R VALUE TEST SET COUNT: 1159 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED: 20 REMARK 3 BIN RESOLUTION RANGE HIGH: 1.950 REMARK 3 BIN RESOLUTION RANGE LOW: 2.000 REMARK 3 REFLECTION IN BIN (WORKING SET): 2372 REMARK 3 BIN COMPLETENESS (WORKING(%): 87.48 REMARK 3 BIN R VALUE (WORKING SET): 0.251 REMARK 3 BIN FREE R VALUE SET COUNT: 66 REMARK 3 BIN FREE R VALUE: 0.310 REMARK 3 REMARK 3 NUMBER OF NON−HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 ALL ATOMS: 3121 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2): NULL REMARK 3 MEAN B VALUE (OVERALL, A**2): 36.438 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2): 1.36 REMARK 3 B22 (A**2): 1.36 REMARK 3 B33 (A**2): −2.71 REMARK 3 B12 (A**2): 0.00 REMARK 3 B13 (A**2): 0.00 REMARK 3 B23 (A**2): 0.00 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.143 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.138 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.102 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 3.568 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO−FC: 0.956 REMARK 3 CORRELATION COEFFICIENT FO−FC FREE: 0.942 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2997 ; 0.020 ; 0.022 REMARK 3 BOND ANGLES REFINED ATOMS 4042 ; 1.715 ; 1.956 (DEGREES): REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 357 ; 6.180 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 137 ; 34.186 ; 24.015 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 548 ; 14.846 ; 15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 16 ; 17.200 ; 15.000 REMARK 3 CHIRAL- CENTER RESTRAINTS (A**3): 435 ; 0.126 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2240 ; 0.007 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED 1262 ; 0.212 ; 0.200 ATOMS (A): REMARK 3 NON- BONDED TORSION REFINED 2012 ; 0.311 ; 0.200 ATOMS (A): REMARK 3 H- BOND (X...Y) REFINED ATOMS (A): 162 ; 0.165 ; 0.200 REMARK 3 POTENTIAL METAL−ION REFINED 1 ; 0.109 ; 0.200 ATOMS (A): REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 85 ; 0.232 ; 0.200 REMARK 3 SYMMETRY H−BOND REFINED 14 ; 0.182 ; 0.200 ATOMS (A): REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR COUNT RMS WEIGHT RESTRAINTS. REMARK 3 MAIN- CHAIN BOND REFINED ATOMS 1889 ; 1.376 ; 1.500 (A**2): REMARK 3 MAIN- CHAIN ANGLE REFINED ATOMS 2920 ; 2.197 ; 2.000 (A**2): REMARK 3 SIDE- CHAIN BOND REFINED ATOMS 1300 ; 2.913 ; 3.000 (A**2): REMARK 3 SIDE- CHAIN ANGLE REFINED ATOMS 1122 ; 4.495 ; 4.500 (A**2): REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF NCS GROUPS: NULL REMARK 3 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS: NULL REMARK 3 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED: MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS: 1.20 REMARK 3 ION PROBE RADIUS: 0.80 REMARK 3 SHRINKAGE RADIUS: 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REMARK 3 HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS REMARK 3 CRYST1 50.961 50.961 205.387 90.00 90.00 90.00 P 41 SCALE1 0.019623 0.000000 0.000000 0.00000 SCALE2 0.000000 0.019623 0.000000 0.00000 SCALE3 0.000000 0.000000 0.004869 0.00000 ATOM 1 N PRO A 85 −26.122 32.840 39.164 1.00 67.70 N ATOM 2 CA PRO A 85 −26.884 33.641 38.196 1.00 67.41 C ATOM 3 CB PRO A 85 −26.347 35.071 38.415 1.00 67.69 C ATOM 4 CG PRO A 85 −25.675 35.066 39.826 1.00 68.21 C ATOM 5 CD PRO A 85 −25.736 33.625 40.355 1.00 68.25 C ATOM 6 C PRO A 85 −26.665 33.197 36.735 1.00 66.66 C ATOM 7 O PRO A 85 −25.599 32.636 36.413 1.00 67.05 O ATOM 8 N ALA A 86 −27.666 33.441 35.876 1.00 65.01 N ATOM 9 CA ALA A 86 −27.562 33.211 34.427 1.00 63.22 C ATOM 10 CB ALA A 86 −28.909 33.479 33.746 1.00 63.77 C ATOM 11 C ALA A 86 −26.438 34.049 33.773 1.00 61.60 C ATOM 12 O ALA A 86 −26.536 35.280 33.715 1.00 61.58 O ATOM 13 N SER A 87 −25.385 33.361 33.294 1.00 59.11 N ATOM 14 CA SER A 87 −24.164 33.987 32.734 1.00 56.32 C ATOM 15 CB SER A 87 −23.014 32.968 32.609 1.00 56.60 C ATOM 16 OG SER A 87 −22.933 32.092 33.722 1.00 55.71 O ATOM 17 C SER A 87 −24.439 34.600 31.365 1.00 54.09 C ATOM 18 O SER A 87 −25.441 34.273 30.727 1.00 53.42 O ATOM 19 N ARG A 88 −23.560 35.507 30.928 1.00 51.11 N ATOM 20 CA ARG A 88 −23.691 36.103 29.599 1.00 49.05 C ATOM 21 CB ARG A 88 −22.704 37.255 29.435 1.00 49.01 C ATOM 22 CG ARG A 88 −23.079 38.587 30.081 1.00 52.03 C ATOM 23 CD ARG A 88 −21.921 39.576 29.841 1.00 51.77 C ATOM 24 NE ARG A 88 −21.495 39.538 28.437 1.00 56.44 N ATOM 25 CZ ARG A 88 −20.325 39.972 27.964 1.00 56.82 C ATOM 26 NH1 ARG A 88 −19.396 40.504 28.770 1.00 52.97 N ATOM 27 NH2 ARG A 88 −20.093 39.853 26.662 1.00 58.69 N ATOM 28 C ARG A 88 −23.391 35.056 28.527 1.00 45.17 C ATOM 29 O ARG A 88 −22.545 34.198 28.745 1.00 43.46 O ATOM 30 N TYR A 89 −24.092 35.139 27.399 1.00 42.80 N ATOM 31 CA TYR A 89 −23.763 34.336 26.204 1.00 42.12 C ATOM 32 CB TYR A 89 −24.984 33.639 25.610 1.00 43.89 C ATOM 33 CG TYR A 89 −25.584 32.586 26.481 1.00 49.25 C ATOM 34 CD1 TYR A 89 −26.692 32.877 27.301 1.00 53.80 C ATOM 35 CE1 TYR A 89 −27.278 31.876 28.129 1.00 55.07 C ATOM 36 CZ TYR A 89 −26.745 30.583 28.120 1.00 53.29 C ATOM 37 OH TYR A 89 −27.307 29.603 28.924 1.00 52.63 O ATOM 38 CE2 TYR A 89 −25.633 30.272 27.320 1.00 52.65 C ATOM 39 CD2 TYR A 89 −25.059 31.275 26.501 1.00 51.55 C ATOM 40 C TYR A 89 −23.103 35.144 25.095 1.00 39.05 C ATOM 41 O TYR A 89 −23.578 36.222 24.734 1.00 39.30 O ATOM 42 N ILE A 90 −22.007 34.604 24.565 1.00 35.95 N ATOM 43 CA ILE A 90 −21.374 35.101 23.343 1.00 33.00 C ATOM 44 CB ILE A 90 −19.815 35.017 23.400 1.00 33.20 C ATOM 45 CG1 ILE A 90 −19.213 35.693 24.659 1.00 31.66 C ATOM 46 CD1 ILE A 90 −19.623 37.181 24.946 1.00 34.93 C ATOM 47 CG2 ILE A 90 −19.218 35.494 22.065 1.00 32.68 C ATOM 48 C ILE A 90 −21.815 34.214 22.179 1.00 31.70 C ATOM 49 O ILE A 90 −21.772 32.988 22.277 1.00 30.65 O ATOM 50 N THR A 91 −22.206 34.848 21.084 1.00 30.72 N ATOM 51 CA THR A 91 −22.721 34.177 19.892 1.00 30.64 C ATOM 52 CB THR A 91 −24.272 34.313 19.747 1.00 30.93 C ATOM 53 OG1 THR A 91 −24.641 35.693 19.595 1.00 31.58 O ATOM 54 CG2 THR A 91 −25.010 33.726 20.961 1.00 31.12 C ATOM 55 C THR A 91 −21.973 34.698 18.654 1.00 30.39 C ATOM 56 O THR A 91 −22.425 35.616 18.014 1.00 29.92 O ATOM 57 N ASP A 92 −20.789 34.150 18.367 1.00 29.53 N ATOM 58 CA ASP A 92 −20.088 34.437 17.103 1.00 29.38 C ATOM 59 CB ASP A 92 −18.705 33.737 16.987 1.00 29.06 C ATOM 60 CG ASP A 92 −17.630 34.283 17.934 1.00 30.61 C ATOM 61 OD1 ASP A 92 −17.802 35.375 18.537 1.00 29.26 O ATOM 62 OD2 ASP A 92 −16.577 33.585 18.121 1.00 25.92 O ATOM 63 C ASP A 92 −20.917 33.920 15.919 1.00 29.87 C ATOM 64 O ASP A 92 −20.852 34.518 14.848 1.00 30.63 O ATOM 65 N MET A 93 −21.646 32.798 16.090 1.00 28.80 N ATOM 66 CA MET A 93 −22.334 32.178 14.985 1.00 28.53 C ATOM 67 CB MET A 93 −22.254 30.625 15.045 1.00 28.56 C ATOM 68 CG MET A 93 −20.873 30.056 14.617 1.00 23.17 C ATOM 69 SD MET A 93 −20.816 28.244 14.793 1.00 22.81 S ATOM 70 CE MET A 93 −20.351 28.121 16.505 1.00 21.77 C ATOM 71 C MET A 93 −23.785 32.591 14.932 1.00 31.52 C ATOM 72 O MET A 93 −24.416 32.810 15.973 1.00 32.72 O ATOM 73 N THR A 94 −24.311 32.686 13.709 1.00 33.84 N ATOM 74 CA THR A 94 −25.754 32.818 13.520 1.00 35.14 C ATOM 75 CB THR A 94 −26.080 33.245 12.094 1.00 35.65 C ATOM 76 OG1 THR A 94 −25.554 32.285 11.173 1.00 35.99 O ATOM 77 CG2 THR A 94 −25.481 34.615 11.807 1.00 36.80 C ATOM 78 C THR A 94 −26.448 31.512 13.841 1.00 35.97 C ATOM 79 O THR A 94 −25.818 30.446 13.913 1.00 34.20 O ATOM 80 N ILE A 95 −27.761 31.587 14.029 1.00 36.97 N ATOM 81 CA ILE A 95 −28.575 30.410 14.266 1.00 38.79 C ATOM 82 CB ILE A 95 −30.070 30.801 14.496 1.00 38.82 C ATOM 83 CG1 ILE A 95 −30.205 31.659 15.779 1.00 41.36 C ATOM 84 CD1 ILE A 95 −31.709 31.841 16.326 1.00 42.00 C ATOM 85 CG2 ILE A 95 −30.911 29.558 14.598 1.00 41.63 C ATOM 86 C ILE A 95 −28.396 29.378 13.116 1.00 37.69 C ATOM 87 O ILE A 95 −28.268 28.199 13.365 1.00 38.70 O ATOM 88 N GLU A 96 −28.378 29.842 11.878 1.00 36.92 N ATOM 89 CA GLU A 96 −28.104 28.999 10.700 1.00 36.29 C ATOM 90 CB GLU A 96 −28.239 29.823 9.409 1.00 36.39 C ATOM 91 CG GLU A 96 −28.227 29.016 8.087 1.00 38.37 C ATOM 92 CD GLU A 96 −26.817 28.589 7.614 1.00 40.56 C ATOM 93 OE1 GLU A 96 −25.874 29.406 7.689 1.00 39.66 O ATOM 94 OE2 GLU A 96 −26.666 27.421 7.174 1.00 40.00 O ATOM 95 C GLU A 96 −26.709 28.344 10.788 1.00 35.41 C ATOM 96 O GLU A 96 −26.605 27.137 10.614 1.00 33.83 O ATOM 97 N GLU A 97 −25.657 29.114 11.117 1.00 34.89 N ATOM 98 CA GLU A 97 −24.290 28.538 11.192 1.00 34.19 C ATOM 99 CB GLU A 97 −23.215 29.612 11.389 1.00 34.50 C ATOM 100 CG GLU A 97 −22.913 30.437 10.153 1.00 34.90 C ATOM 101 CD GLU A 97 −22.021 31.629 10.505 1.00 38.47 C ATOM 102 OE1 GLU A 97 −22.183 32.188 11.630 1.00 34.46 O ATOM 103 OE2 GLU A 97 −21.153 31.993 9.675 1.00 39.78 O ATOM 104 C GLU A 97 −24.222 27.492 12.285 1.00 34.41 C ATOM 105 O GLU A 97 −23.610 26.431 12.128 1.00 33.26 O ATOM 106 N LEU A 98 −24.931 27.757 13.379 1.00 33.38 N ATOM 107 CA LEU A 98 −24.975 26.854 14.496 1.00 33.56 C ATOM 108 CB LEU A 98 −25.625 27.616 15.676 1.00 35.16 C ATOM 109 CG LEU A 98 −25.697 27.103 17.089 1.00 36.28 C ATOM 110 CD1 LEU A 98 −24.280 27.030 17.629 1.00 37.99 C ATOM 111 CD2 LEU A 98 −26.556 28.164 17.855 1.00 36.53 C ATOM 112 C LEU A 98 −25.721 25.558 14.186 1.00 33.48 C ATOM 113 O LEU A 98 −25.383 24.495 14.740 1.00 31.52 O ATOM 114 N SER A 99 −26.735 25.649 13.311 1.00 32.52 N ATOM 115 CA SER A 99 −27.648 24.548 13.055 1.00 34.15 C ATOM 116 CB SER A 99 −29.071 25.062 12.750 1.00 33.43 C ATOM 117 OG SER A 99 −29.498 25.903 13.802 1.00 40.37 O ATOM 118 C SER A 99 −27.246 23.698 11.864 1.00 32.87 C ATOM 119 O SER A 99 −27.754 22.584 11.728 1.00 32.22 O ATOM 120 N ARG A 100 −26.348 24.228 11.031 1.00 31.55 N ATOM 121 CA ARG A 100 −25.947 23.591 9.759 1.00 31.41 C ATOM 122 CB ARG A 100 −24.975 24.509 9.028 1.00 30.90 C ATOM 123 CG ARG A 100 −24.884 24.295 7.526 1.00 30.96 C ATOM 124 CD ARG A 100 −23.727 25.099 6.940 1.00 30.21 C ATOM 125 NE ARG A 100 −23.929 26.551 7.061 1.00 31.23 N ATOM 126 CZ ARG A 100 −22.966 27.437 6.886 1.00 33.84 C ATOM 127 NH1 ARG A 100 −21.733 27.018 6.593 1.00 32.14 N ATOM 128 NH2 ARG A 100 −23.220 28.737 7.013 1.00 33.44 N ATOM 129 C ARG A 100 −25.234 22.286 10.023 1.00 30.72 C ATOM 130 O ARG A 100 −24.495 22.186 10.990 1.00 31.73 O ATOM 131 N ASP A 101 −25.459 21.277 9.193 1.00 30.35 N ATOM 132 CA ASP A 101 −24.662 20.072 9.267 1.00 30.10 C ATOM 133 CB ASP A 101 −25.502 18.809 9.060 1.00 30.91 C ATOM 134 CG ASP A 101 −26.681 18.707 10.025 1.00 31.96 C ATOM 135 OD1 ASP A 101 −26.458 18.846 11.256 1.00 33.73 O ATOM 136 OD2 ASP A 101 −27.815 18.479 9.538 1.00 31.46 O ATOM 137 C ASP A 101 −23.617 20.188 8.171 1.00 29.73 C ATOM 138 O ASP A 101 −23.823 20.894 7.189 1.00 30.58 O ATOM 139 N TRP A 102 −22.472 19.540 8.345 1.00 29.30 N ATOM 140 CA TRP A 102 −21.402 19.662 7.352 1.00 26.90 C ATOM 141 CB TRP A 102 −20.371 20.709 7.759 1.00 27.28 C ATOM 142 CG TRP A 102 −19.709 20.410 9.076 1.00 26.50 C ATOM 143 CD1 TRP A 102 −20.266 20.538 10.322 1.00 28.05 C ATOM 144 NE1 TRP A 102 −19.366 20.185 11.298 1.00 25.18 N ATOM 145 CE2 TRP A 102 −18.179 19.851 10.700 1.00 27.63 C ATOM 146 CD2 TRP A 102 −18.363 19.979 9.285 1.00 27.61 C ATOM 147 CE3 TRP A 102 −17.290 19.692 8.432 1.00 24.42 C ATOM 148 CZ3 TRP A 102 −16.064 19.254 9.001 1.00 24.78 C ATOM 149 CH2 TRP A 102 −15.922 19.115 10.407 1.00 27.13 C ATOM 150 CZ2 TRP A 102 −16.979 19.406 11.266 1.00 27.85 C ATOM 151 C TRP A 102 −20.799 18.285 7.086 1.00 27.67 C ATOM 152 O TRP A 102 −21.014 17.347 7.844 1.00 26.73 O ATOM 153 N PHE A 103 −20.040 18.169 5.999 1.00 27.38 N ATOM 154 CA PHE A 103 −19.555 16.865 5.544 1.00 26.65 C ATOM 155 CB PHE A 103 −20.066 16.694 4.095 1.00 27.13 C ATOM 156 CG PHE A 103 −19.353 15.647 3.275 1.00 29.74 C ATOM 157 CD1 PHE A 103 −19.838 14.339 3.223 1.00 32.10 C ATOM 158 CE1 PHE A 103 −19.198 13.365 2.419 1.00 29.36 C ATOM 159 CZ PHE A 103 −18.095 13.730 1.649 1.00 31.44 C ATOM 160 CE2 PHE A 103 −17.614 15.036 1.668 1.00 34.30 C ATOM 161 CD2 PHE A 103 −18.245 15.993 2.478 1.00 33.21 C ATOM 162 C PHE A 103 −18.031 16.886 5.539 1.00 25.08 C ATOM 163 O PHE A 103 −17.427 17.901 5.181 1.00 25.47 O ATOM 164 N MET A 104 −17.418 15.781 5.953 1.00 24.11 N ATOM 165 CA MET A 104 −15.946 15.601 5.888 1.00 24.78 C ATOM 166 CB MET A 104 −15.339 15.135 7.242 1.00 23.15 C ATOM 167 CG MET A 104 −15.578 16.116 8.425 1.00 25.55 C ATOM 168 SD MET A 104 −15.331 15.278 10.011 1.00 27.07 S ATOM 169 CE MET A 104 −16.966 14.670 10.253 1.00 27.39 C ATOM 170 C MET A 104 −15.672 14.532 4.832 1.00 24.85 C ATOM 171 O MET A 104 −16.247 13.450 4.874 1.00 25.29 O ATOM 172 N LEU A 105 −14.780 14.842 3.893 1.00 25.30 N ATOM 173 CA LEU A 105 −14.315 13.870 2.911 1.00 24.88 C ATOM 174 CB LEU A 105 −13.577 14.626 1.795 1.00 24.53 C ATOM 175 CG LEU A 105 −13.109 13.799 0.593 1.00 30.23 C ATOM 176 CD1 LEU A 105 −14.315 13.128 −0.104 1.00 27.68 C ATOM 177 CD2 LEU A 105 −12.328 14.697 −0.333 1.00 31.62 C ATOM 178 C LEU A 105 −13.473 12.817 3.534 1.00 24.44 C ATOM 179 O LEU A 105 −13.600 11.624 3.187 1.00 25.09 O ATOM 180 N MET A 106 −12.600 13.229 4.472 1.00 23.86 N ATOM 181 CA MET A 106 −11.733 12.325 5.187 1.00 23.48 C ATOM 182 CB MET A 106 −10.253 12.672 4.853 1.00 23.02 C ATOM 183 CG MET A 106 −9.897 12.294 3.344 1.00 25.01 C ATOM 184 SD MET A 106 −8.226 12.780 2.955 1.00 24.98 S ATOM 185 CE MET A 106 −8.504 13.050 1.171 1.00 33.15 C ATOM 186 C MET A 106 −11.987 12.547 6.702 1.00 24.02 C ATOM 187 O MET A 106 −11.212 13.271 7.351 1.00 22.17 O ATOM 188 N PRO A 107 −13.070 11.957 7.235 1.00 25.50 N ATOM 189 CA PRO A 107 −13.453 12.363 8.597 1.00 25.66 C ATOM 190 CB PRO A 107 −14.813 11.708 8.812 1.00 26.36 C ATOM 191 CG PRO A 107 −15.014 10.716 7.645 1.00 27.67 C ATOM 192 CD PRO A 107 −13.963 10.924 6.649 1.00 26.26 C ATOM 193 C PRO A 107 −12.456 11.954 9.666 1.00 26.62 C ATOM 194 O PRO A 107 −11.874 10.860 9.627 1.00 25.19 O ATOM 195 N LYS A 108 −12.231 12.859 10.610 1.00 27.63 N ATOM 196 CA LYS A 108 −11.452 12.532 11.791 1.00 26.56 C ATOM 197 CB LYS A 108 −10.124 13.291 11.818 1.00 27.79 C ATOM 198 CG LYS A 108 −9.108 13.047 10.659 1.00 28.05 C ATOM 199 CD LYS A 108 −8.192 11.916 10.934 1.00 31.20 C ATOM 200 CE LYS A 108 −8.719 10.611 10.548 1.00 30.45 C ATOM 201 NZ LYS A 108 −8.945 10.441 9.045 1.00 33.91 N ATOM 202 C LYS A 108 −12.304 13.026 12.953 1.00 27.72 C ATOM 203 O LYS A 108 −12.825 14.177 12.935 1.00 24.97 O ATOM 204 N GLN A 109 −12.403 12.194 13.977 1.00 27.58 N ATOM 205 CA GLN A 109 −13.182 12.573 15.157 1.00 30.64 C ATOM 206 CB GLN A 109 −14.621 12.111 15.006 1.00 29.87 C ATOM 207 CG GLN A 109 −15.459 12.288 16.241 1.00 39.27 C ATOM 208 CD GLN A 109 −16.683 11.376 16.235 1.00 46.13 C ATOM 209 OE1 GLN A 109 −16.724 10.376 16.970 1.00 48.01 O ATOM 210 NE2 GLN A 109 −17.666 11.693 15.375 1.00 46.81 N ATOM 211 C GLN A 109 −12.504 11.988 16.372 1.00 30.84 C ATOM 212 O GLN A 109 −12.006 10.853 16.332 1.00 31.32 O ATOM 213 N LYS A 110 −12.372 12.810 17.404 1.00 30.66 N ATOM 214 CA LYS A 110 −11.746 12.430 18.662 1.00 33.30 C ATOM 215 CB LYS A 110 −10.384 13.105 18.838 1.00 32.59 C ATOM 216 CG LYS A 110 −9.599 12.479 19.944 1.00 39.86 C ATOM 217 CD LYS A 110 −8.308 13.201 20.198 1.00 44.72 C ATOM 218 CE LYS A 110 −7.424 12.330 21.064 1.00 49.17 C ATOM 219 NZ LYS A 110 −5.981 12.798 21.028 1.00 51.75 N ATOM 220 C LYS A 110 −12.641 12.944 19.806 1.00 33.85 C ATOM 221 O LYS A 110 −13.014 14.135 19.846 1.00 32.23 O ATOM 222 N VAL A 111 −12.953 12.046 20.738 1.00 34.29 N ATOM 223 CA VAL A 111 −13.601 12.447 21.969 1.00 35.38 C ATOM 224 CB VAL A 111 −14.656 11.399 22.405 1.00 35.08 C ATOM 225 CG1 VAL A 111 −15.253 11.774 23.720 1.00 36.51 C ATOM 226 CG2 VAL A 111 −15.780 11.326 21.306 1.00 34.54 C ATOM 227 C VAL A 111 −12.464 12.658 22.927 1.00 36.40 C ATOM 228 O VAL A 111 −11.677 11.747 23.143 1.00 37.57 O ATOM 229 N GLU A 112 −12.287 13.899 23.387 1.00 36.90 N ATOM 230 CA GLU A 112 −11.288 14.204 24.400 1.00 38.96 C ATOM 231 CB GLU A 112 −10.265 15.217 23.913 1.00 39.19 C ATOM 232 CG GLU A 112 −9.175 14.530 23.156 1.00 46.21 C ATOM 233 CD GLU A 112 −7.912 15.349 22.990 1.00 51.55 C ATOM 234 OE1 GLU A 112 −7.283 15.197 21.928 1.00 53.26 O ATOM 235 OE2 GLU A 112 −7.547 16.134 23.906 1.00 56.88 O ATOM 236 C GLU A 112 −12.007 14.718 25.634 1.00 38.39 C ATOM 237 O GLU A 112 −12.469 15.865 25.685 1.00 36.96 O ATOM 238 N GLY A 113 −12.140 13.822 26.601 1.00 39.27 N ATOM 239 CA GLY A 113 −12.917 14.119 27.796 1.00 38.12 C ATOM 240 C GLY A 113 −14.353 14.437 27.464 1.00 36.64 C ATOM 241 O GLY A 113 −15.033 13.655 26.776 1.00 38.16 O ATOM 242 N PRO A 114 −14.849 15.576 27.964 1.00 33.88 N ATOM 243 CA PRO A 114 −16.237 15.943 27.762 1.00 32.13 C ATOM 244 CB PRO A 114 −16.492 16.931 28.916 1.00 32.60 C ATOM 245 CG PRO A 114 −15.165 17.627 29.055 1.00 31.81 C ATOM 246 CD PRO A 114 −14.126 16.576 28.781 1.00 34.84 C ATOM 247 C PRO A 114 −16.509 16.645 26.405 1.00 29.72 C ATOM 248 O PRO A 114 −17.657 17.067 26.146 1.00 28.42 O ATOM 249 N LEU A 115 −15.499 16.717 25.536 1.00 28.35 N ATOM 250 CA LEU A 115 −15.700 17.376 24.223 1.00 27.24 C ATOM 251 CB LEU A 115 −14.794 18.599 24.129 1.00 27.96 C ATOM 252 CG LEU A 115 −14.946 19.667 25.243 1.00 26.94 C ATOM 253 CD1 LEU A 115 −13.750 20.612 25.196 1.00 27.95 C ATOM 254 CD2 LEU A 115 −16.251 20.417 25.099 1.00 29.72 C ATOM 255 C LEU A 115 −15.357 16.470 23.033 1.00 27.21 C ATOM 256 O LEU A 115 −14.434 15.672 23.116 1.00 27.09 O ATOM 257 N CYS A 116 −16.031 16.713 21.914 1.00 27.45 N ATOM 258 CA CYS A 116 −15.783 15.992 20.659 1.00 26.39 C ATOM 259 CB CYS A 116 −17.108 15.497 20.090 1.00 26.69 C ATOM 260 SG CYS A 116 −16.868 14.551 18.501 1.00 31.80 S ATOM 261 C CYS A 116 −15.120 16.929 19.656 1.00 25.74 C ATOM 262 O CYS A 116 −15.639 18.029 19.409 1.00 25.83 O ATOM 263 N ILE A 117 −13.960 16.523 19.126 1.00 24.09 N ATOM 264 CA ILE A 117 −13.283 17.265 18.048 1.00 24.27 C ATOM 265 CB ILE A 117 −11.755 17.349 18.356 1.00 25.27 C ATOM 266 CG1 ILE A 117 −11.517 17.862 19.806 1.00 23.31 C ATOM 267 CD1 ILE A 117 −10.154 17.452 20.379 1.00 26.08 C ATOM 268 CG2 ILE A 117 −11.015 18.197 17.315 1.00 22.67 C ATOM 269 C ILE A 117 −13.472 16.573 16.692 1.00 23.94 C ATOM 270 O ILE A 117 −13.241 15.340 16.562 1.00 23.40 O ATOM 271 N ARG A 118 −13.839 17.358 15.693 1.00 22.86 N ATOM 272 CA ARG A 118 −13.972 16.851 14.336 1.00 23.41 C ATOM 273 CB ARG A 118 −15.425 16.931 13.889 1.00 24.33 C ATOM 274 CG ARG A 118 −16.195 15.760 14.310 1.00 26.67 C ATOM 275 CD ARG A 118 −17.648 16.145 14.171 1.00 36.06 C ATOM 276 NE ARG A 118 −18.440 15.040 14.612 1.00 41.48 N ATOM 277 CZ ARG A 118 −19.612 15.131 15.215 1.00 45.56 C ATOM 278 NH1 ARG A 118 −20.146 16.313 15.465 1.00 46.68 N ATOM 279 NH2 ARG A 118 −20.228 14.012 15.596 1.00 45.78 N ATOM 280 C ARG A 118 −13.198 17.713 13.379 1.00 23.69 C ATOM 281 O ARG A 118 −13.212 18.954 13.476 1.00 22.65 O ATOM 282 N ILE A 119 −12.562 17.060 12.409 1.00 23.73 N ATOM 283 CA ILE A 119 −11.831 17.816 11.420 1.00 24.09 C ATOM 284 CB ILE A 119 −10.412 18.129 11.928 1.00 24.22 C ATOM 285 CG1 ILE A 119 −9.636 18.940 10.882 1.00 26.11 C ATOM 286 CD1 ILE A 119 −8.270 19.415 11.340 1.00 27.40 C ATOM 287 CG2 ILE A 119 −9.677 16.828 12.269 1.00 26.48 C ATOM 288 C ILE A 119 −11.827 17.045 10.087 1.00 23.09 C ATOM 289 O ILE A 119 −11.823 15.831 10.101 1.00 24.06 O ATOM 290 N ASP A 120 −11.950 17.754 8.967 1.00 21.94 N ATOM 291 CA ASP A 120 −11.754 17.122 7.654 1.00 21.86 C ATOM 292 CB ASP A 120 −12.475 17.904 6.535 1.00 22.15 C ATOM 293 CG ASP A 120 −12.612 17.057 5.250 1.00 23.64 C ATOM 294 OD1 ASP A 120 −11.983 15.954 5.179 1.00 24.29 O ATOM 295 OD2 ASP A 120 −13.343 17.458 4.348 1.00 23.75 O ATOM 296 C ASP A 120 −10.269 17.079 7.331 1.00 21.18 C ATOM 297 O ASP A 120 −9.679 18.112 7.116 1.00 21.54 O ATOM 298 N GLN A 121 −9.681 15.887 7.316 1.00 21.00 N ATOM 299 CA GLN A 121 −8.259 15.688 6.914 1.00 21.84 C ATOM 300 CB GLN A 121 −7.873 14.225 7.121 1.00 22.28 C ATOM 301 CG GLN A 121 −6.428 13.911 6.740 1.00 24.84 C ATOM 302 CD GLN A 121 −5.968 12.511 7.069 1.00 25.52 C ATOM 303 OE1 GLN A 121 −6.754 11.585 7.276 1.00 23.53 O ATOM 304 NE2 GLN A 121 −4.627 12.340 7.096 1.00 25.16 N ATOM 305 C GLN A 121 −7.981 16.150 5.467 1.00 22.62 C ATOM 306 O GLN A 121 −6.829 16.437 5.080 1.00 21.93 O ATOM 307 N ALA A 122 −9.054 16.261 4.685 1.00 21.71 N ATOM 308 CA ALA A 122 −8.912 16.617 3.256 1.00 21.69 C ATOM 309 CB ALA A 122 −10.181 16.141 2.494 1.00 19.71 C ATOM 310 C ALA A 122 −8.662 18.107 3.052 1.00 22.50 C ATOM 311 O ALA A 122 −8.187 18.546 1.985 1.00 23.74 O ATOM 312 N ILE A 123 −8.969 18.924 4.058 1.00 22.64 N ATOM 313 CA ILE A 123 −8.908 20.394 3.883 1.00 22.96 C ATOM 314 CB ILE A 123 −9.911 21.109 4.803 1.00 23.42 C ATOM 315 CG1 ILE A 123 −11.364 20.728 4.413 1.00 24.78 C ATOM 316 CD1 ILE A 123 −11.800 21.234 3.011 1.00 28.40 C ATOM 317 CG2 ILE A 123 −9.756 22.634 4.681 1.00 22.20 C ATOM 318 C ILE A 123 −7.508 20.981 4.108 1.00 25.70 C ATOM 319 O ILE A 123 −6.947 20.792 5.178 1.00 25.29 O ATOM 320 N MET A 124 −6.943 21.662 3.092 1.00 25.17 N ATOM 321 CA MET A 124 −5.579 22.183 3.163 1.00 28.51 C ATOM 322 CB MET A 124 −4.655 21.297 2.337 1.00 27.78 C ATOM 323 CG MET A 124 −4.771 19.813 2.656 1.00 30.26 C ATOM 324 SD MET A 124 −3.484 18.782 1.811 1.00 33.51 S ATOM 325 CE MET A 124 −2.059 19.361 2.723 1.00 37.42 C ATOM 326 C MET A 124 −5.578 23.562 2.553 1.00 28.55 C ATOM 327 O MET A 124 −6.493 23.905 1.787 1.00 27.92 O ATOM 328 N ASP A 125 −4.559 24.344 2.895 1.00 29.74 N ATOM 329 CA ASP A 125 −4.215 25.614 2.253 1.00 32.07 C ATOM 330 CB ASP A 125 −3.799 25.405 0.762 1.00 33.16 C ATOM 331 CG ASP A 125 −2.736 24.338 0.604 1.00 35.13 C ATOM 332 OD1 ASP A 125 −1.696 24.451 1.278 1.00 36.19 O ATOM 333 OD2 ASP A 125 −2.941 23.385 −0.186 1.00 41.35 O ATOM 334 C ASP A 125 −5.240 26.719 2.323 1.00 32.12 C ATOM 335 O ASP A 125 −5.180 27.626 1.509 1.00 33.38 O ATOM 336 N LYS A 126 −6.148 26.691 3.299 1.00 31.07 N ATOM 337 CA LYS A 126 −7.178 27.720 3.386 1.00 30.62 C ATOM 338 CB LYS A 126 −8.564 27.049 3.449 1.00 32.29 C ATOM 339 CG LYS A 126 −8.996 26.577 2.028 1.00 35.51 C ATOM 340 CD LYS A 126 −10.152 25.660 2.060 1.00 43.65 C ATOM 341 CE LYS A 126 −10.660 25.433 0.631 1.00 44.47 C ATOM 342 NZ LYS A 126 −11.170 26.689 −0.085 1.00 46.44 N ATOM 343 C LYS A 126 −6.952 28.713 4.534 1.00 29.60 C ATOM 344 O LYS A 126 −6.222 28.422 5.467 1.00 30.24 O ATOM 345 N ASN A 127 −7.527 29.897 4.438 1.00 29.11 N ATOM 346 CA ASN A 127 −7.523 30.805 5.578 1.00 29.06 C ATOM 347 CB ASN A 127 −7.591 32.243 5.112 1.00 29.91 C ATOM 348 CG ASN A 127 −6.308 32.677 4.437 1.00 33.89 C ATOM 349 OD1 ASN A 127 −5.214 32.543 4.998 1.00 36.73 O ATOM 350 ND2 ASN A 127 −6.427 33.183 3.229 1.00 37.36 N ATOM 351 C ASN A 127 −8.789 30.387 6.358 1.00 28.50 C ATOM 352 O ASN A 127 −9.860 30.326 5.787 1.00 26.56 O ATOM 353 N ILE A 128 −8.625 30.078 7.639 1.00 27.29 N ATOM 354 CA ILE A 128 −9.706 29.462 8.437 1.00 27.38 C ATOM 355 CB ILE A 128 −9.295 28.032 8.952 1.00 27.42 C ATOM 356 CG1 ILE A 128 −9.024 27.037 7.799 1.00 27.03 C ATOM 357 CD1 ILE A 128 −10.184 26.824 6.863 1.00 28.44 C ATOM 358 CG2 ILE A 128 −10.342 27.441 9.962 1.00 26.81 C ATOM 359 C ILE A 128 −9.957 30.371 9.641 1.00 27.01 C ATOM 360 O ILE A 128 −9.014 30.865 10.239 1.00 27.70 O ATOM 361 N MET A 129 −11.206 30.566 10.031 1.00 27.13 N ATOM 362 CA MET A 129 −11.476 31.400 11.217 1.00 27.30 C ATOM 363 CB MET A 129 −12.306 32.631 10.834 1.00 27.31 C ATOM 364 CG MET A 129 −12.890 33.479 12.058 1.00 28.79 C ATOM 365 SD MET A 129 −11.620 34.344 12.939 1.00 32.60 S ATOM 366 CE MET A 129 −11.410 35.688 11.799 1.00 39.01 C ATOM 367 C MET A 129 −12.264 30.526 12.183 1.00 26.82 C ATOM 368 O MET A 129 −13.285 29.938 11.788 1.00 27.01 O ATOM 369 N LEU A 130 −11.813 30.470 13.432 1.00 26.13 N ATOM 370 CA LEU A 130 −12.575 29.765 14.497 1.00 26.12 C ATOM 371 CB LEU A 130 −11.618 29.297 15.610 1.00 24.84 C ATOM 372 CG LEU A 130 −10.485 28.337 15.243 1.00 27.14 C ATOM 373 CD1 LEU A 130 −10.087 27.626 16.479 1.00 22.57 C ATOM 374 CD2 LEU A 130 −10.891 27.282 14.117 1.00 22.23 C ATOM 375 C LEU A 130 −13.601 30.733 15.080 1.00 25.81 C ATOM 376 O LEU A 130 −13.231 31.837 15.498 1.00 26.04 O ATOM 377 N LYS A 131 −14.873 30.330 15.076 1.00 26.76 N ATOM 378 CA LYS A 131 −15.956 31.068 15.722 1.00 26.56 C ATOM 379 CB LYS A 131 −17.004 31.490 14.684 1.00 27.61 C ATOM 380 CG LYS A 131 −16.533 32.568 13.680 1.00 28.89 C ATOM 381 CD LYS A 131 −17.691 32.884 12.680 1.00 28.82 C ATOM 382 CE LYS A 131 −17.415 34.227 12.031 1.00 38.35 C ATOM 383 NZ LYS A 131 −18.327 34.532 10.898 1.00 41.90 N ATOM 384 C LYS A 131 −16.645 30.157 16.768 1.00 26.72 C ATOM 385 O LYS A 131 −16.730 28.927 16.598 1.00 24.29 O ATOM 386 N ALA A 132 −17.188 30.754 17.832 1.00 24.37 N ATOM 387 CA ALA A 132 −17.802 29.955 18.881 1.00 23.81 C ATOM 388 CB ALA A 132 −16.725 29.487 19.941 1.00 23.01 C ATOM 389 C ALA A 132 −18.968 30.664 19.540 1.00 24.34 C ATOM 390 O ALA A 132 −19.104 31.907 19.494 1.00 24.27 O ATOM 391 N ASN A 133 −19.845 29.844 20.107 1.00 24.68 N ATOM 392 CA ASN A 133 −20.919 30.315 20.981 1.00 24.43 C ATOM 393 CB ASN A 133 −22.314 29.912 20.475 1.00 23.91 C ATOM 394 CG ASN A 133 −22.739 30.645 19.185 1.00 27.90 C ATOM 395 OD1 ASN A 133 −21.937 31.202 18.437 1.00 29.10 O ATOM 396 ND2 ASN A 133 −24.037 30.641 18.941 1.00 29.92 N ATOM 397 C ASN A 133 −20.631 29.666 22.321 1.00 23.54 C ATOM 398 O ASN A 133 −20.369 28.458 22.420 1.00 21.57 O ATOM 399 N PHE A 134 −20.630 30.478 23.364 1.00 23.58 N ATOM 400 CA PHE A 134 −20.216 30.016 24.672 1.00 23.28 C ATOM 401 CB PHE A 134 −18.686 29.889 24.725 1.00 23.19 C ATOM 402 CG PHE A 134 −17.902 31.138 24.314 1.00 24.74 C ATOM 403 CD1 PHE A 134 −17.415 32.026 25.291 1.00 24.85 C ATOM 404 CE1 PHE A 134 −16.650 33.169 24.927 1.00 26.78 C ATOM 405 CZ PHE A 134 −16.343 33.397 23.561 1.00 24.67 C ATOM 406 CE2 PHE A 134 −16.823 32.475 22.585 1.00 25.59 C ATOM 407 CD2 PHE A 134 −17.603 31.398 22.973 1.00 22.93 C ATOM 408 C PHE A 134 −20.692 30.994 25.723 1.00 25.08 C ATOM 409 O PHE A 134 −20.852 32.198 25.446 1.00 24.04 O ATOM 410 N SER A 135 −20.907 30.505 26.947 1.00 27.07 N ATOM 411 CA SER A 135 −21.114 31.469 28.052 1.00 27.47 C ATOM 412 CB SER A 135 −22.052 30.866 29.115 1.00 28.10 C ATOM 413 OG SER A 135 −21.485 29.691 29.625 1.00 27.20 O ATOM 414 C SER A 135 −19.779 31.893 28.672 1.00 28.03 C ATOM 415 O SER A 135 −18.787 31.176 28.560 1.00 27.68 O ATOM 416 N VAL A 136 −19.759 33.076 29.322 1.00 27.28 N ATOM 417 CA VAL A 136 −18.598 33.610 29.998 1.00 27.41 C ATOM 418 CB VAL A 136 −18.080 34.893 29.301 1.00 27.85 C ATOM 419 CG1 VAL A 136 −17.743 34.601 27.826 1.00 26.37 C ATOM 420 CG2 VAL A 136 −19.146 35.948 29.291 1.00 28.25 C ATOM 421 C VAL A 136 −18.984 33.932 31.476 1.00 27.55 C ATOM 422 O VAL A 136 −20.127 34.219 31.766 1.00 28.10 O ATOM 423 N ILE A 137 −18.023 33.867 32.365 1.00 28.59 N ATOM 424 CA ILE A 137 −18.216 34.244 33.773 1.00 30.78 C ATOM 425 CB ILE A 137 −18.669 32.988 34.633 1.00 31.59 C ATOM 426 CG1 ILE A 137 −19.278 33.429 35.970 1.00 33.63 C ATOM 427 CD1 ILE A 137 −19.700 32.180 36.817 1.00 33.97 C ATOM 428 CG2 ILE A 137 −17.505 31.987 34.863 1.00 30.94 C ATOM 429 C ILE A 137 −16.849 34.653 34.155 1.00 29.64 C ATOM 430 O ILE A 137 −15.907 34.068 33.633 1.00 29.94 O ATOM 431 N PHE A 138 −16.694 35.682 35.016 1.00 29.62 N ATOM 432 CA PHE A 138 −15.376 36.106 35.473 1.00 27.79 C ATOM 433 CB PHE A 138 −14.703 35.101 36.440 1.00 28.87 C ATOM 434 CG PHE A 138 −15.633 34.568 37.491 1.00 31.41 C ATOM 435 CD1 PHE A 138 −15.510 33.255 37.960 1.00 33.05 C ATOM 436 CE1 PHE A 138 −16.400 32.772 38.924 1.00 32.87 C ATOM 437 CZ PHE A 138 −17.415 33.603 39.441 1.00 32.93 C ATOM 438 CE2 PHE A 138 −17.535 34.898 38.987 1.00 32.39 C ATOM 439 CD2 PHE A 138 −16.637 35.374 38.008 1.00 31.10 C ATOM 440 C PHE A 138 −14.432 36.427 34.313 1.00 27.04 C ATOM 441 O PHE A 138 −13.237 36.182 34.391 1.00 26.40 O ATOM 442 N ASP A 139 −14.950 37.048 33.271 1.00 27.25 N ATOM 443 CA ASP A 139 −14.059 37.476 32.165 1.00 28.11 C ATOM 444 CB ASP A 139 −12.995 38.467 32.686 1.00 26.07 C ATOM 445 CG ASP A 139 −12.315 39.241 31.545 1.00 24.48 C ATOM 446 OD1 ASP A 139 −13.054 39.624 30.621 1.00 23.66 O ATOM 447 OD2 ASP A 139 −11.077 39.441 31.582 0.50 20.56 O ATOM 448 C ASP A 139 −13.343 36.319 31.435 1.00 28.35 C ATOM 449 O ASP A 139 −12.247 36.500 30.876 1.00 29.04 O ATOM 450 N ARG A 140 −13.949 35.142 31.450 1.00 28.71 N ATOM 451 CA ARG A 140 −13.370 33.986 30.757 1.00 30.54 C ATOM 452 CB ARG A 140 −12.409 33.226 31.674 1.00 31.65 C ATOM 453 CG ARG A 140 −13.182 32.536 32.786 1.00 35.69 C ATOM 454 CD ARG A 140 −12.363 31.446 33.453 1.00 41.63 C ATOM 455 NE ARG A 140 −12.991 31.094 34.722 1.00 45.91 N ATOM 456 CZ ARG A 140 −13.998 30.238 34.861 1.00 49.56 C ATOM 457 NH1 ARG A 140 −14.524 29.612 33.793 1.00 48.61 N ATOM 458 NH2 ARG A 140 −14.475 30.001 36.082 1.00 49.00 N ATOM 459 C ARG A 140 −14.482 33.073 30.279 1.00 29.51 C ATOM 460 O ARG A 140 −15.596 33.103 30.785 1.00 30.10 O ATOM 461 N LEU A 141 −14.182 32.268 29.264 1.00 30.56 N ATOM 462 CA LEU A 141 −15.155 31.290 28.753 1.00 29.62 C ATOM 463 CB LEU A 141 −14.496 30.410 27.659 1.00 29.02 C ATOM 464 CG LEU A 141 −15.359 29.328 27.005 1.00 30.21 C ATOM 465 CD1 LEU A 141 −14.998 29.213 25.514 1.00 25.61 C ATOM 466 CD2 LEU A 141 −15.146 27.989 27.689 1.00 28.22 C ATOM 467 C LEU A 141 −15.579 30.396 29.907 1.00 29.31 C ATOM 468 O LEU A 141 −14.754 29.975 30.687 1.00 29.67 O ATOM 469 N GLU A 142 −16.862 30.108 29.994 1.00 28.07 N ATOM 470 CA GLU A 142 −17.352 29.241 31.047 1.00 28.71 C ATOM 471 CB GLU A 142 −18.590 29.848 31.667 1.00 29.55 C ATOM 472 CG GLU A 142 −19.167 28.964 32.766 1.00 32.35 C ATOM 473 CD GLU A 142 −20.382 29.575 33.338 1.00 38.85 C ATOM 474 OE1 GLU A 142 −20.438 29.665 34.586 1.00 43.19 O ATOM 475 OE2 GLU A 142 −21.250 30.017 32.550 1.00 42.00 O ATOM 476 C GLU A 142 −17.759 27.888 30.468 1.00 27.92 C ATOM 477 O GLU A 142 −17.164 26.875 30.802 1.00 28.27 O ATOM 478 N THR A 143 −18.763 27.910 29.593 1.00 27.95 N ATOM 479 CA THR A 143 −19.305 26.688 28.986 1.00 28.53 C ATOM 480 CB THR A 143 −20.710 26.388 29.572 1.00 28.46 C ATOM 481 OG1 THR A 143 −20.565 26.177 30.990 1.00 30.36 O ATOM 482 CG2 THR A 143 −21.331 25.138 28.946 1.00 32.14 C ATOM 483 C THR A 143 −19.370 26.837 27.462 1.00 27.05 C ATOM 484 O THR A 143 −20.027 27.702 26.949 1.00 28.79 O ATOM 485 N LEU A 144 −18.719 25.950 26.736 1.00 26.74 N ATOM 486 CA LEU A 144 −18.790 25.988 25.263 1.00 23.71 C ATOM 487 CB LEU A 144 −17.608 25.189 24.712 1.00 23.74 C ATOM 488 CG LEU A 144 −17.563 25.142 23.164 1.00 23.31 C ATOM 489 CD1 LEU A 144 −17.213 26.514 22.590 1.00 23.32 C ATOM 490 CD2 LEU A 144 −16.567 24.119 22.730 1.00 22.22 C ATOM 491 C LEU A 144 −20.119 25.426 24.797 1.00 24.71 C ATOM 492 O LEU A 144 −20.529 24.338 25.242 1.00 24.35 O ATOM 493 N ILE A 145 −20.821 26.133 23.923 1.00 23.45 N ATOM 494 CA ILE A 145 −21.970 25.538 23.265 1.00 25.19 C ATOM 495 CB ILE A 145 −23.055 26.592 23.018 1.00 25.84 C ATOM 496 CG1 ILE A 145 −23.640 27.052 24.388 1.00 30.13 C ATOM 497 CD1 ILE A 145 −24.255 28.496 24.272 1.00 38.82 C ATOM 498 CG2 ILE A 145 −24.150 26.089 22.057 1.00 26.97 C ATOM 499 C ILE A 145 −21.515 24.854 21.938 1.00 25.87 C ATOM 500 O ILE A 145 −21.817 23.679 21.687 1.00 23.59 O ATOM 501 N LEU A 146 −20.772 25.593 21.112 1.00 25.26 N ATOM 502 CA LEU A 146 −20.211 24.985 19.893 1.00 23.95 C ATOM 503 CB LEU A 146 −21.302 24.942 18.833 1.00 23.73 C ATOM 504 CG LEU A 146 −21.016 24.183 17.505 1.00 24.90 C ATOM 505 CD1 LEU A 146 −20.763 22.691 17.791 1.00 25.12 C ATOM 506 CD2 LEU A 146 −22.185 24.339 16.580 1.00 24.67 C ATOM 507 C LEU A 146 −19.118 25.874 19.383 1.00 23.11 C ATOM 508 O LEU A 146 −19.292 27.130 19.424 1.00 22.17 O ATOM 509 N LEU A 147 −18.034 25.281 18.835 1.00 22.70 N ATOM 510 CA LEU A 147 −17.008 26.058 18.122 1.00 21.78 C ATOM 511 CB LEU A 147 −15.647 25.947 18.857 1.00 22.68 C ATOM 512 CG LEU A 147 −14.450 26.653 18.206 1.00 22.20 C ATOM 513 CD1 LEU A 147 −13.385 27.062 19.271 1.00 20.77 C ATOM 514 CD2 LEU A 147 −13.814 25.775 17.088 1.00 19.37 C ATOM 515 C LEU A 147 −16.907 25.455 16.717 1.00 22.57 C ATOM 516 O LEU A 147 −16.910 24.212 16.593 1.00 20.70 O ATOM 517 N ARG A 148 −16.848 26.293 15.663 1.00 22.59 N ATOM 518 CA ARG A 148 −16.671 25.730 14.283 1.00 23.35 C ATOM 519 CB ARG A 148 −17.969 25.749 13.455 1.00 22.58 C ATOM 520 CG ARG A 148 −18.861 24.593 13.818 1.00 23.66 C ATOM 521 CD ARG A 148 −20.240 24.671 13.269 1.00 23.87 C ATOM 522 NE ARG A 148 −20.804 23.336 13.367 1.00 23.59 N ATOM 523 CZ ARG A 148 −22.035 22.980 12.978 1.00 25.11 C ATOM 524 NH1 ARG A 148 −22.902 23.870 12.516 1.00 22.41 N ATOM 525 NH2 ARG A 148 −22.395 21.722 13.079 1.00 22.69 N ATOM 526 C ARG A 148 −15.582 26.490 13.594 1.00 23.50 C ATOM 527 O ARG A 148 −15.329 27.665 13.935 1.00 23.78 O ATOM 528 N ALA A 149 −14.904 25.785 12.696 1.00 23.63 N ATOM 529 CA ALA A 149 −13.834 26.339 11.887 1.00 22.68 C ATOM 530 CB ALA A 149 −12.672 25.334 11.840 1.00 21.04 C ATOM 531 C ALA A 149 −14.403 26.626 10.477 1.00 23.39 C ATOM 532 O ALA A 149 −14.904 25.710 9.830 1.00 22.23 O ATOM 533 N PHE A 150 −14.330 27.903 10.033 1.00 23.42 N ATOM 534 CA PHE A 150 −14.947 28.333 8.761 1.00 24.77 C ATOM 535 CB PHE A 150 −15.867 29.532 9.015 1.00 24.60 C ATOM 536 CG PHE A 150 −17.135 29.184 9.792 1.00 26.17 C ATOM 537 CD1 PHE A 150 −17.133 29.193 11.188 1.00 25.87 C ATOM 538 CE1 PHE A 150 −18.268 28.861 11.919 1.00 27.48 C ATOM 539 CZ PHE A 150 −19.440 28.542 11.266 1.00 25.00 C ATOM 540 CE2 PHE A 150 −19.474 28.526 9.862 1.00 26.61 C ATOM 541 CD2 PHE A 150 −18.288 28.825 9.124 1.00 25.13 C ATOM 542 C PHE A 150 −13.895 28.796 7.717 1.00 24.98 C ATOM 543 O PHE A 150 −12.963 29.457 8.072 1.00 24.09 O ATOM 544 N THR A 151 −14.067 28.444 6.438 1.00 27.78 N ATOM 545 CA THR A 151 −13.220 28.983 5.382 1.00 29.28 C ATOM 546 CB THR A 151 −13.312 28.158 4.077 1.00 28.87 C ATOM 547 OG1 THR A 151 −14.613 28.302 3.542 1.00 29.93 O ATOM 548 CG2 THR A 151 −13.106 26.674 4.323 1.00 29.18 C ATOM 549 C THR A 151 −13.743 30.414 5.115 1.00 31.10 C ATOM 550 O THR A 151 −14.779 30.810 5.628 1.00 29.33 O ATOM 551 N GLU A 152 −13.033 31.168 4.282 1.00 33.68 N ATOM 552 CA GLU A 152 −13.425 32.530 3.902 1.00 36.84 C ATOM 553 CB GLU A 152 −12.347 33.131 2.999 1.00 37.30 C ATOM 554 CG GLU A 152 −11.005 33.248 3.642 1.00 39.17 C ATOM 555 CD GLU A 152 −10.026 34.031 2.777 1.00 48.59 C ATOM 556 OE1 GLU A 152 −9.561 33.489 1.748 1.00 51.49 O ATOM 557 OE2 GLU A 152 −9.735 35.191 3.123 1.00 49.86 O ATOM 558 C GLU A 152 −14.765 32.567 3.170 1.00 37.80 C ATOM 559 O GLU A 152 −15.468 33.595 3.173 1.00 39.18 O ATOM 560 N GLU A 153 −15.098 31.444 2.547 1.00 38.19 N ATOM 561 CA GLU A 153 −16.337 31.296 1.834 1.00 39.91 C ATOM 562 CB GLU A 153 −16.145 30.349 0.633 1.00 41.25 C ATOM 563 CG GLU A 153 −15.204 30.939 −0.498 1.00 47.72 C ATOM 564 CD GLU A 153 −15.857 32.067 −1.366 1.00 56.46 C ATOM 565 OE1 GLU A 153 −17.009 32.489 −1.073 1.00 59.59 O ATOM 566 OE2 GLU A 153 −15.213 32.532 −2.361 1.00 59.71 O ATOM 567 C GLU A 153 −17.466 30.825 2.747 1.00 39.18 C ATOM 568 O GLU A 153 −18.595 30.594 2.283 1.00 40.28 O ATOM 569 N GLY A 154 −17.183 30.645 4.037 1.00 36.32 N ATOM 570 CA GLY A 154 −18.270 30.319 4.947 1.00 33.51 C ATOM 571 C GLY A 154 −18.506 28.837 5.178 1.00 31.90 C ATOM 572 O GLY A 154 −19.430 28.472 5.925 1.00 31.26 O ATOM 573 N ALA A 155 −17.682 27.983 4.576 1.00 29.65 N ATOM 574 CA ALA A 155 −17.837 26.524 4.714 1.00 28.90 C ATOM 575 CB ALA A 155 −17.137 25.812 3.566 1.00 28.42 C ATOM 576 C ALA A 155 −17.242 26.021 6.058 1.00 27.62 C ATOM 577 O ALA A 155 −16.182 26.465 6.447 1.00 27.58 O ATOM 578 N ILE A 156 −17.872 25.034 6.677 1.00 26.27 N ATOM 579 CA ILE A 156 −17.329 24.438 7.943 1.00 25.83 C ATOM 580 CB ILE A 156 −18.495 23.902 8.878 1.00 24.89 C ATOM 581 CG1 ILE A 156 −19.502 25.006 9.143 1.00 25.36 C ATOM 582 CD1 ILE A 156 −20.917 24.545 9.521 1.00 25.07 C ATOM 583 CG2 ILE A 156 −17.916 23.352 10.265 1.00 24.02 C ATOM 584 C ILE A 156 −16.376 23.290 7.644 1.00 25.13 C ATOM 585 O ILE A 156 −16.737 22.408 6.867 1.00 25.16 O ATOM 586 N VAL A 157 −15.170 23.316 8.241 1.00 24.13 N ATOM 587 CA VAL A 157 −14.131 22.283 8.038 1.00 24.32 C ATOM 588 CB VAL A 157 −12.963 22.870 7.253 1.00 24.35 C ATOM 589 CG1 VAL A 157 −13.491 23.401 5.896 1.00 24.56 C ATOM 590 CG2 VAL A 157 −12.253 24.009 8.052 1.00 23.30 C ATOM 591 C VAL A 157 −13.643 21.653 9.369 1.00 24.38 C ATOM 592 O VAL A 157 −12.742 20.787 9.381 1.00 24.39 O ATOM 593 N GLY A 158 −14.280 22.055 10.480 1.00 22.71 N ATOM 594 CA GLY A 158 −13.817 21.558 11.800 1.00 22.42 C ATOM 595 C GLY A 158 −14.768 22.001 12.869 1.00 22.76 C ATOM 596 O GLY A 158 −15.476 22.988 12.689 1.00 22.09 O ATOM 597 N GLU A 159 −14.778 21.272 13.985 1.00 22.77 N ATOM 598 CA GLU A 159 −15.685 21.643 15.055 1.00 23.62 C ATOM 599 CB GLU A 159 −17.076 21.080 14.702 1.00 23.86 C ATOM 600 CG GLU A 159 −18.105 20.927 15.738 1.00 27.75 C ATOM 601 CD GLU A 159 −19.298 20.220 15.110 1.00 30.96 C ATOM 602 OE1 GLU A 159 −19.649 19.085 15.511 1.00 33.41 O ATOM 603 OE2 GLU A 159 −19.793 20.784 14.126 1.00 31.84 O ATOM 604 C GLU A 159 −15.224 21.096 16.400 1.00 23.45 C ATOM 605 O GLU A 159 −14.503 20.083 16.451 1.00 23.41 O ATOM 606 N ILE A 160 −15.623 21.803 17.461 1.00 21.90 N ATOM 607 CA ILE A 160 −15.490 21.267 18.833 1.00 22.61 C ATOM 608 CB ILE A 160 −14.472 21.994 19.660 1.00 22.90 C ATOM 609 CG1 ILE A 160 −13.072 21.846 19.064 1.00 20.56 C ATOM 610 CD1 ILE A 160 −12.068 22.911 19.659 1.00 23.51 C ATOM 611 CG2 ILE A 160 −14.473 21.422 21.160 1.00 20.30 C ATOM 612 C ILE A 160 −16.868 21.407 19.432 1.00 23.34 C ATOM 613 O ILE A 160 −17.471 22.524 19.438 1.00 21.20 O ATOM 614 N SER A 161 −17.418 20.269 19.860 1.00 25.69 N ATOM 615 CA SER A 161 −18.758 20.307 20.418 1.00 28.95 C ATOM 616 CB SER A 161 −19.773 19.669 19.476 1.00 30.16 C ATOM 617 OG SER A 161 −19.433 18.304 19.310 1.00 36.69 O ATOM 618 C SER A 161 −18.770 19.573 21.739 1.00 31.31 C ATOM 619 O SER A 161 −18.092 18.550 21.879 1.00 32.13 O ATOM 620 N PRO A 162 −19.565 20.074 22.721 1.00 32.42 N ATOM 621 CA PRO A 162 −19.717 19.308 23.967 1.00 32.99 C ATOM 622 CB PRO A 162 −20.635 20.208 24.823 1.00 33.01 C ATOM 623 CG PRO A 162 −21.460 21.013 23.754 1.00 34.38 C ATOM 624 CD PRO A 162 −20.382 21.303 22.712 1.00 31.98 C ATOM 625 C PRO A 162 −20.416 17.973 23.669 1.00 34.31 C ATOM 626 O PRO A 162 −21.251 17.896 22.770 1.00 33.06 O ATOM 627 N LEU A 163 −20.094 16.942 24.424 1.00 35.01 N ATOM 628 CA LEU A 163 −20.872 15.726 24.360 1.00 39.63 C ATOM 629 CB LEU A 163 −20.148 14.628 25.128 1.00 37.49 C ATOM 630 CG LEU A 163 −18.770 14.289 24.594 1.00 38.56 C ATOM 631 CD1 LEU A 163 −18.110 13.411 25.596 1.00 42.42 C ATOM 632 CD2 LEU A 163 −18.870 13.613 23.197 1.00 37.70 C ATOM 633 C LEU A 163 −22.287 15.986 24.964 1.00 43.24 C ATOM 634 O LEU A 163 −22.429 16.761 25.922 1.00 42.85 O ATOM 635 N PRO A 164 −23.329 15.347 24.407 1.00 47.70 N ATOM 636 CA PRO A 164 −24.713 15.544 24.904 1.00 50.86 C ATOM 637 CB PRO A 164 −25.488 14.431 24.216 1.00 50.96 C ATOM 638 CG PRO A 164 −24.731 14.153 22.964 1.00 50.70 C ATOM 639 CD PRO A 164 −23.272 14.390 23.288 1.00 48.08 C ATOM 640 C PRO A 164 −24.778 15.330 26.404 1.00 53.85 C ATOM 641 O PRO A 164 −25.371 16.133 27.144 1.00 55.14 O ATOM 642 N SER A 165 −24.109 14.268 26.836 1.00 56.89 N ATOM 643 CA SER A 165 −24.161 13.771 28.201 1.00 59.40 C ATOM 644 CB SER A 165 −23.132 12.627 28.372 1.00 59.96 C ATOM 645 OG SER A 165 −22.736 11.981 27.151 1.00 61.14 O ATOM 646 C SER A 165 −23.886 14.862 29.261 1.00 60.68 C ATOM 647 O SER A 165 −24.578 14.937 30.285 1.00 61.29 O ATOM 648 N PHE A 166 −22.862 15.683 29.014 1.00 61.57 N ATOM 649 CA PHE A 166 −22.397 16.669 29.980 1.00 61.86 C ATOM 650 CB PHE A 166 −20.878 16.850 29.924 1.00 62.01 C ATOM 651 CG PHE A 166 −20.108 15.569 29.780 1.00 62.40 C ATOM 652 CD1 PHE A 166 −19.110 15.241 30.690 1.00 63.33 C ATOM 653 CE1 PHE A 166 −18.373 14.035 30.563 1.00 65.13 C ATOM 654 CZ PHE A 166 −18.651 13.167 29.514 1.00 64.22 C ATOM 655 CE2 PHE A 166 −19.666 13.493 28.597 1.00 64.14 C ATOM 656 CD2 PHE A 166 −20.371 14.691 28.729 1.00 62.88 C ATOM 657 C PHE A 166 −23.042 18.021 29.748 1.00 62.36 C ATOM 658 O PHE A 166 −23.417 18.368 28.598 1.00 62.89 O ATOM 659 N PRO A 167 −23.210 18.775 30.845 1.00 62.06 N ATOM 660 CA PRO A 167 −23.394 20.224 30.872 1.00 61.87 C ATOM 661 CB PRO A 167 −24.570 20.379 31.857 1.00 61.66 C ATOM 662 CG PRO A 167 −24.317 19.276 32.881 1.00 62.79 C ATOM 663 CD PRO A 167 −23.353 18.232 32.208 1.00 62.77 C ATOM 664 C PRO A 167 −22.130 20.921 31.431 1.00 60.38 C ATOM 665 O PRO A 167 −22.154 22.141 31.695 1.00 61.90 O ATOM 666 N GLY A 168 −21.050 20.148 31.606 1.00 57.49 N ATOM 667 CA GLY A 168 −19.868 20.625 32.321 1.00 53.21 C ATOM 668 C GLY A 168 −18.504 20.149 31.843 1.00 49.27 C ATOM 669 O GLY A 168 −18.198 18.926 31.777 1.00 49.67 O ATOM 670 N HIS A 169 −17.681 21.149 31.549 1.00 44.84 N ATOM 671 CA HIS A 169 −16.297 20.976 31.148 1.00 40.46 C ATOM 672 CB HIS A 169 −16.170 20.820 29.602 1.00 38.65 C ATOM 673 CG HIS A 169 −16.962 21.841 28.822 1.00 33.52 C ATOM 674 ND1 HIS A 169 −18.188 21.564 28.261 1.00 31.35 N ATOM 675 CE1 HIS A 169 −18.660 22.637 27.660 1.00 28.39 C ATOM 676 NE2 HIS A 169 −17.796 23.616 27.828 1.00 28.28 N ATOM 677 CD2 HIS A 169 −16.724 23.149 28.553 1.00 30.88 C ATOM 678 C HIS A 169 −15.680 22.280 31.615 1.00 39.31 C ATOM 679 O HIS A 169 −16.410 23.196 32.044 1.00 40.25 O ATOM 680 N THR A 170 −14.353 22.339 31.567 1.00 36.78 N ATOM 681 CA THR A 170 −13.572 23.479 32.029 1.00 35.94 C ATOM 682 CB THR A 170 −12.377 23.065 32.927 1.00 35.25 C ATOM 683 OG1 THR A 170 −11.388 22.393 32.139 1.00 34.72 O ATOM 684 CG2 THR A 170 −12.827 22.132 34.101 1.00 36.64 C ATOM 685 C THR A 170 −13.000 24.216 30.823 1.00 35.21 C ATOM 686 O THR A 170 −12.946 23.678 29.710 1.00 34.35 O ATOM 687 N ILE A 171 −12.568 25.444 31.058 1.00 33.91 N ATOM 688 CA ILE A 171 −11.914 26.233 30.027 1.00 33.18 C ATOM 689 CB ILE A 171 −11.670 27.696 30.532 1.00 32.72 C ATOM 690 CG1 ILE A 171 −11.151 28.586 29.382 1.00 33.82 C ATOM 691 CD1 ILE A 171 −11.256 30.068 29.689 1.00 32.91 C ATOM 692 CG2 ILE A 171 −10.725 27.732 31.733 1.00 33.57 C ATOM 693 C ILE A 171 −10.620 25.547 29.575 1.00 32.14 C ATOM 694 O ILE A 171 −10.221 25.637 28.412 1.00 31.34 O ATOM 695 N GLU A 172 −9.965 24.841 30.492 1.00 31.90 N ATOM 696 CA GLU A 172 −8.761 24.099 30.150 1.00 32.76 C ATOM 697 CB GLU A 172 −8.014 23.596 31.399 1.00 33.50 C ATOM 698 CG GLU A 172 −7.752 24.691 32.487 1.00 38.99 C ATOM 699 CD GLU A 172 −8.749 24.570 33.660 1.00 46.04 C ATOM 700 OE1 GLU A 172 −8.553 23.659 34.517 1.00 53.70 O ATOM 701 OE2 GLU A 172 −9.725 25.351 33.744 1.00 48.14 O ATOM 702 C GLU A 172 −9.055 22.916 29.185 1.00 31.70 C ATOM 703 O GLU A 172 −8.256 22.649 28.286 1.00 31.20 O ATOM 704 N ASP A 173 −10.171 22.207 29.399 1.00 31.31 N ATOM 705 CA ASP A 173 −10.650 21.204 28.408 1.00 30.63 C ATOM 706 CB ASP A 173 −12.011 20.603 28.808 1.00 29.29 C ATOM 707 CG ASP A 173 −11.929 19.745 30.069 1.00 32.36 C ATOM 708 OD1 ASP A 173 −10.912 19.089 30.317 1.00 36.48 O ATOM 709 OD2 ASP A 173 −12.885 19.746 30.820 1.00 29.46 O ATOM 710 C ASP A 173 −10.859 21.898 27.049 1.00 29.18 C ATOM 711 O ASP A 173 −10.512 21.341 25.994 1.00 28.08 O ATOM 712 N VAL A 174 −11.483 23.071 27.081 1.00 27.66 N ATOM 713 CA VAL A 174 −11.768 23.785 25.829 1.00 27.50 C ATOM 714 CB VAL A 174 −12.677 25.024 26.047 1.00 28.13 C ATOM 715 CG1 VAL A 174 −12.760 25.860 24.766 1.00 27.42 C ATOM 716 CG2 VAL A 174 −14.062 24.576 26.464 1.00 26.02 C ATOM 717 C VAL A 174 −10.459 24.167 25.150 1.00 28.12 C ATOM 718 O VAL A 174 −10.288 23.952 23.912 1.00 26.80 O ATOM 719 N LYS A 175 −9.517 24.720 25.913 1.00 27.32 N ATOM 720 CA LYS A 175 −8.229 25.090 25.333 1.00 29.37 C ATOM 721 CB LYS A 175 −7.336 25.851 26.319 1.00 29.49 C ATOM 722 CG LYS A 175 −7.873 27.277 26.719 1.00 31.65 C ATOM 723 CD LYS A 175 −7.042 27.779 27.947 1.00 34.24 C ATOM 724 CE LYS A 175 −6.548 29.216 27.757 1.00 43.77 C ATOM 725 NZ LYS A 175 −5.086 29.241 28.061 1.00 49.63 N ATOM 726 C LYS A 175 −7.475 23.894 24.764 1.00 29.15 C ATOM 727 O LYS A 175 −6.905 23.989 23.676 1.00 29.98 O ATOM 728 N ASN A 176 −7.464 22.772 25.485 1.00 28.78 N ATOM 729 CA ASN A 176 −6.806 21.577 24.971 1.00 29.56 C ATOM 730 CB ASN A 176 −7.002 20.378 25.906 1.00 29.89 C ATOM 731 CG ASN A 176 −6.190 20.483 27.181 1.00 37.18 C ATOM 732 OD1 ASN A 176 −6.501 19.795 28.175 1.00 42.17 O ATOM 733 ND2 ASN A 176 −5.141 21.338 27.178 1.00 41.19 N ATOM 734 C ASN A 176 −7.387 21.203 23.614 1.00 27.60 C ATOM 735 O ASN A 176 −6.648 20.894 22.683 1.00 27.59 O ATOM 736 N ALA A 177 −8.705 21.202 23.527 1.00 25.47 N ATOM 737 CA ALA A 177 −9.386 20.816 22.292 1.00 25.42 C ATOM 738 CB ALA A 177 −10.899 20.715 22.505 1.00 23.91 C ATOM 739 C ALA A 177 −9.070 21.744 21.148 1.00 24.79 C ATOM 740 O ALA A 177 −8.944 21.266 20.001 1.00 25.02 O ATOM 741 N ILE A 178 −9.013 23.060 21.440 1.00 23.30 N ATOM 742 CA ILE A 178 −8.731 24.063 20.464 1.00 24.16 C ATOM 743 CB ILE A 178 −8.883 25.496 21.039 1.00 23.64 C ATOM 744 CG1 ILE A 178 −10.344 25.862 21.218 1.00 23.43 C ATOM 745 CD1 ILE A 178 −10.566 27.275 21.940 1.00 24.62 C ATOM 746 CG2 ILE A 178 −8.167 26.518 20.104 1.00 24.53 C ATOM 747 C ILE A 178 −7.307 23.869 19.924 1.00 25.28 C ATOM 748 O ILE A 178 −7.076 23.950 18.708 1.00 23.52 O ATOM 749 N GLY A 179 −6.361 23.568 20.821 1.00 25.82 N ATOM 750 CA GLY A 179 −4.994 23.233 20.391 1.00 24.95 C ATOM 751 C GLY A 179 −4.920 22.005 19.483 1.00 26.34 C ATOM 752 O GLY A 179 −4.115 21.988 18.537 1.00 25.96 O ATOM 753 N VAL A 180 −5.757 20.999 19.713 1.00 25.94 N ATOM 754 CA VAL A 180 −5.748 19.794 18.840 1.00 27.50 C ATOM 755 CB VAL A 180 −6.549 18.632 19.443 1.00 28.63 C ATOM 756 CG1 VAL A 180 −6.696 17.436 18.427 1.00 30.08 C ATOM 757 CG2 VAL A 180 −5.898 18.139 20.725 1.00 29.50 C ATOM 758 C VAL A 180 −6.301 20.114 17.428 1.00 27.72 C ATOM 759 O VAL A 180 −5.723 19.737 16.403 1.00 27.57 O ATOM 760 N LEU A 181 −7.435 20.811 17.415 1.00 26.46 N ATOM 761 CA LEU A 181 −8.043 21.334 16.195 1.00 26.40 C ATOM 762 CB LEU A 181 −9.400 22.036 16.521 1.00 25.50 C ATOM 763 CG LEU A 181 −10.103 22.583 15.258 1.00 25.35 C ATOM 764 CD1 LEU A 181 −10.370 21.411 14.239 1.00 23.23 C ATOM 765 CD2 LEU A 181 −11.377 23.348 15.605 1.00 25.48 C ATOM 766 C LEU A 181 −7.092 22.262 15.412 1.00 25.60 C ATOM 767 O LEU A 181 −6.849 22.045 14.207 1.00 23.63 O ATOM 768 N ILE A 182 −6.577 23.300 16.058 1.00 24.97 N ATOM 769 CA ILE A 182 −5.652 24.214 15.375 1.00 26.01 C ATOM 770 CB ILE A 182 −5.196 25.420 16.291 1.00 26.44 C ATOM 771 CG1 ILE A 182 −6.341 26.404 16.468 1.00 26.81 C ATOM 772 CD1 ILE A 182 −6.078 27.572 17.483 1.00 25.50 C ATOM 773 CG2 ILE A 182 −4.006 26.171 15.657 1.00 26.76 C ATOM 774 C ILE A 182 −4.401 23.498 14.849 1.00 27.06 C ATOM 775 O ILE A 182 −3.903 23.798 13.737 1.00 27.99 O ATOM 776 N GLY A 183 −3.903 22.544 15.625 1.00 26.95 N ATOM 777 CA GLY A 183 −2.733 21.763 15.236 1.00 27.09 C ATOM 778 C GLY A 183 −2.939 20.942 13.966 1.00 27.16 C ATOM 779 O GLY A 183 −2.035 20.852 13.118 1.00 25.04 O ATOM 780 N GLY A 184 −4.143 20.391 13.798 1.00 26.79 N ATOM 781 CA GLY A 184 −4.454 19.527 12.642 1.00 26.69 C ATOM 782 C GLY A 184 −4.633 20.410 11.450 1.00 26.33 C ATOM 783 O GLY A 184 −4.127 20.120 10.380 1.00 26.17 O ATOM 784 N LEU A 185 −5.313 21.534 11.638 1.00 26.30 N ATOM 785 CA LEU A 185 −5.499 22.492 10.565 1.00 24.55 C ATOM 786 CB LEU A 185 −6.415 23.616 11.001 1.00 23.84 C ATOM 787 CG LEU A 185 −7.888 23.220 11.293 1.00 23.68 C ATOM 788 CD1 LEU A 185 −8.599 24.422 12.020 1.00 23.04 C ATOM 789 CD2 LEU A 185 −8.559 22.845 9.959 1.00 21.51 C ATOM 790 C LEU A 185 −4.175 23.072 10.089 1.00 26.07 C ATOM 791 O LEU A 185 −3.967 23.195 8.863 1.00 24.84 O ATOM 792 N GLU A 186 −3.320 23.489 11.021 1.00 24.68 N ATOM 793 CA GLU A 186 −1.974 24.029 10.643 1.00 26.89 C ATOM 794 CB GLU A 186 −1.271 24.702 11.828 1.00 26.28 C ATOM 795 CG GLU A 186 −1.956 25.957 12.224 1.00 29.68 C ATOM 796 CD GLU A 186 −1.329 26.627 13.460 1.00 30.75 C ATOM 797 OE1 GLU A 186 −0.559 25.977 14.192 1.00 36.73 O ATOM 798 OE2 GLU A 186 −1.625 27.804 13.670 1.00 33.71 O ATOM 799 C GLU A 186 −1.046 23.007 10.020 1.00 27.78 C ATOM 800 O GLU A 186 −0.236 23.366 9.102 1.00 28.87 O ATOM 801 N TRP A 187 −1.120 21.762 10.495 1.00 29.22 N ATOM 802 CA TRP A 187 −0.402 20.622 9.874 1.00 30.02 C ATOM 803 CB TRP A 187 −0.669 19.278 10.586 1.00 31.40 C ATOM 804 CG TRP A 187 −0.339 17.955 9.756 1.00 33.36 C ATOM 805 CD1 TRP A 187 −1.180 17.266 8.885 1.00 36.81 C ATOM 806 NE1 TRP A 187 −0.563 16.136 8.391 1.00 37.42 N ATOM 807 CE2 TRP A 187 0.699 16.083 8.919 1.00 38.06 C ATOM 808 CD2 TRP A 187 0.869 17.200 9.788 1.00 35.93 C ATOM 809 CE3 TRP A 187 2.079 17.363 10.464 1.00 35.96 C ATOM 810 CZ3 TRP A 187 3.041 16.448 10.268 1.00 38.27 C ATOM 811 CH2 TRP A 187 2.857 15.350 9.386 1.00 37.53 C ATOM 812 CZ2 TRP A 187 1.676 15.149 8.721 1.00 36.20 C ATOM 813 C TRP A 187 −0.753 20.517 8.387 1.00 29.83 C ATOM 814 O TRP A 187 0.135 20.246 7.539 1.00 27.61 O ATOM 815 N ASN A 188 −2.037 20.751 8.078 1.00 28.16 N ATOM 816 CA ASN A 188 −2.521 20.755 6.679 1.00 28.81 C ATOM 817 CB ASN A 188 −4.018 20.335 6.628 1.00 27.28 C ATOM 818 CG ASN A 188 −4.189 18.844 6.447 1.00 27.85 C ATOM 819 OD1 ASN A 188 −3.221 18.120 6.229 1.00 30.13 O ATOM 820 ND2 ASN A 188 −5.416 18.367 6.562 1.00 25.16 N ATOM 821 C ASN A 188 −2.317 22.083 5.939 1.00 28.69 C ATOM 822 O ASN A 188 −2.976 22.351 4.912 1.00 28.16 O ATOM 823 N ASP A 189 −1.417 22.916 6.453 1.00 28.38 N ATOM 824 CA ASP A 189 −1.064 24.186 5.841 1.00 29.63 C ATOM 825 CB ASP A 189 −0.361 23.927 4.472 1.00 30.44 C ATOM 826 CG ASP A 189 0.978 23.255 4.654 1.00 34.49 C ATOM 827 OD1 ASP A 189 1.747 23.745 5.545 1.00 36.20 O ATOM 828 OD2 ASP A 189 1.210 22.192 4.008 1.00 37.75 O ATOM 829 C ASP A 189 −2.195 25.185 5.706 1.00 29.23 C ATOM 830 O ASP A 189 −2.196 26.026 4.788 1.00 29.61 O ATOM 831 N ASN A 190 −3.161 25.105 6.622 1.00 28.19 N ATOM 832 CA ASN A 190 −4.158 26.126 6.724 1.00 27.21 C ATOM 833 CB ASN A 190 −5.511 25.547 7.254 1.00 25.60 C ATOM 834 CG ASN A 190 −6.073 24.485 6.339 1.00 24.16 C ATOM 835 OD1 ASN A 190 −6.548 24.789 5.248 1.00 25.54 O ATOM 836 ND2 ASN A 190 −5.995 23.233 6.751 1.00 22.44 N ATOM 837 C ASN A 190 −3.634 27.215 7.618 1.00 27.62 C ATOM 838 O ASN A 190 −2.931 26.923 8.583 1.00 28.53 O ATOM 839 N THR A 191 −4.001 28.457 7.307 1.00 28.23 N ATOM 840 CA THR A 191 −3.761 29.597 8.193 1.00 28.87 C ATOM 841 CB THR A 191 −3.396 30.833 7.361 1.00 29.15 C ATOM 842 OG1 THR A 191 −2.188 30.538 6.652 1.00 31.36 O ATOM 843 CG2 THR A 191 −3.171 32.049 8.277 1.00 31.30 C ATOM 844 C THR A 191 −5.006 29.843 9.099 1.00 27.84 C ATOM 845 O THR A 191 −6.096 30.157 8.622 1.00 27.93 O ATOM 846 N VAL A 192 −4.813 29.688 10.406 1.00 28.14 N ATOM 847 CA VAL A 192 −5.905 29.719 11.400 1.00 27.77 C ATOM 848 CB VAL A 192 −5.808 28.512 12.350 1.00 26.87 C ATOM 849 CG1 VAL A 192 −7.022 28.475 13.300 1.00 27.00 C ATOM 850 CG2 VAL A 192 −5.690 27.162 11.532 1.00 26.44 C ATOM 851 C VAL A 192 −5.905 31.048 12.235 1.00 29.05 C ATOM 852 O VAL A 192 −4.876 31.468 12.806 1.00 29.85 O ATOM 853 N ARG A 193 −7.048 31.703 12.284 1.00 27.96 N ATOM 854 CA ARG A 193 −7.233 32.827 13.169 1.00 29.69 C ATOM 855 CB ARG A 193 −7.559 34.100 12.385 1.00 29.62 C ATOM 856 CG ARG A 193 −6.444 34.579 11.482 1.00 33.74 C ATOM 857 CD ARG A 193 −6.956 35.638 10.516 1.00 41.01 C ATOM 858 NE ARG A 193 −5.825 36.233 9.767 1.00 50.62 N ATOM 859 CZ ARG A 193 −5.238 35.718 8.668 1.00 53.47 C ATOM 860 NH1 ARG A 193 −5.633 34.559 8.129 1.00 54.25 N ATOM 861 NH2 ARG A 193 −4.234 36.372 8.095 1.00 55.59 N ATOM 862 C ARG A 193 −8.438 32.451 14.049 1.00 29.25 C ATOM 863 O ARG A 193 −9.275 31.619 13.660 1.00 26.12 O ATOM 864 N VAL A 194 −8.523 33.085 15.219 1.00 30.07 N ATOM 865 CA VAL A 194 −9.676 32.896 16.113 1.00 29.06 C ATOM 866 CB VAL A 194 −9.270 32.162 17.470 1.00 31.71 C ATOM 867 CG1 VAL A 194 −8.265 31.013 17.189 1.00 29.70 C ATOM 868 CG2 VAL A 194 −8.693 33.093 18.509 1.00 29.72 C ATOM 869 C VAL A 194 −10.418 34.195 16.316 1.00 28.87 C ATOM 870 O VAL A 194 −9.806 35.286 16.243 1.00 27.66 O ATOM 871 N SER A 195 −11.728 34.104 16.556 1.00 27.12 N ATOM 872 CA SER A 195 −12.581 35.299 16.612 1.00 26.89 C ATOM 873 CB SER A 195 −14.036 34.898 16.873 1.00 27.31 C ATOM 874 OG SER A 195 −14.129 34.257 18.174 1.00 25.66 O ATOM 875 C SER A 195 −12.115 36.220 17.747 1.00 25.66 C ATOM 876 O SER A 195 −11.402 35.785 18.657 1.00 24.47 O ATOM 877 N LYS A 196 −12.566 37.463 17.725 1.00 26.32 N ATOM 878 CA LYS A 196 −12.108 38.399 18.767 1.00 27.97 C ATOM 879 CB LYS A 196 −12.581 39.815 18.418 1.00 27.76 C ATOM 880 CG LYS A 196 −11.677 40.430 17.375 1.00 34.20 C ATOM 881 CD LYS A 196 −12.432 41.396 16.488 1.00 42.92 C ATOM 882 CE LYS A 196 −11.522 41.909 15.355 1.00 47.63 C ATOM 883 NZ LYS A 196 −10.391 42.734 15.894 1.00 49.98 N ATOM 884 C LYS A 196 −12.635 37.965 20.148 1.00 27.45 C ATOM 885 O LYS A 196 −11.968 38.176 21.156 1.00 27.97 O ATOM 886 N THR A 197 −13.844 37.390 20.179 1.00 26.73 N ATOM 887 CA THR A 197 −14.400 36.946 21.454 1.00 27.39 C ATOM 888 CB THR A 197 −15.880 36.620 21.372 1.00 27.32 C ATOM 889 OG1 THR A 197 −16.083 35.558 20.440 1.00 28.59 O ATOM 890 CG2 THR A 197 −16.681 37.817 20.891 1.00 27.51 C ATOM 891 C THR A 197 −13.644 35.749 21.981 1.00 27.16 C ATOM 892 O THR A 197 −13.384 35.655 23.195 1.00 26.76 O ATOM 893 N LEU A 198 −13.258 34.825 21.092 1.00 26.56 N ATOM 894 CA LEU A 198 −12.361 33.734 21.518 1.00 26.73 C ATOM 895 CB LEU A 198 −12.098 32.702 20.382 1.00 27.47 C ATOM 896 CG LEU A 198 −13.233 31.710 20.187 1.00 26.53 C ATOM 897 CD1 LEU A 198 −12.970 30.817 18.963 1.00 29.55 C ATOM 898 CD2 LEU A 198 −13.370 30.815 21.453 1.00 24.14 C ATOM 899 C LEU A 198 −11.034 34.250 22.063 1.00 26.63 C ATOM 900 O LEU A 198 −10.534 33.728 23.060 1.00 26.63 O ATOM 901 N GLN A 199 −10.459 35.262 21.421 1.00 27.02 N ATOM 902 CA GLN A 199 −9.203 35.819 21.900 1.00 29.00 C ATOM 903 CB GLN A 199 −8.696 36.933 20.987 1.00 29.92 C ATOM 904 CG GLN A 199 −8.078 36.484 19.696 1.00 35.17 C ATOM 905 CD GLN A 199 −7.910 37.677 18.755 1.00 42.65 C ATOM 906 OE1 GLN A 199 −7.473 38.789 19.167 1.00 43.78 O ATOM 907 NE2 GLN A 199 −8.321 37.487 17.512 1.00 41.52 N ATOM 908 C GLN A 199 −9.405 36.416 23.278 1.00 28.53 C ATOM 909 O GLN A 199 −8.591 36.225 24.191 1.00 27.18 O ATOM 910 N ARG A 200 −10.498 37.155 23.408 1.00 28.92 N ATOM 911 CA ARG A 200 −10.796 37.871 24.666 1.00 27.60 C ATOM 912 CB ARG A 200 −12.077 38.707 24.481 1.00 28.09 C ATOM 913 CG ARG A 200 −12.551 39.551 25.731 1.00 27.90 C ATOM 914 CD ARG A 200 −13.718 40.446 25.377 1.00 26.48 C ATOM 915 NE ARG A 200 −13.279 41.396 24.356 1.00 30.07 N ATOM 916 CZ ARG A 200 −13.768 41.476 23.104 1.00 28.44 C ATOM 917 NH1 ARG A 200 −14.793 40.738 22.716 1.00 26.58 N ATOM 918 NH2 ARG A 200 −13.232 42.345 22.237 1.00 28.69 N ATOM 919 C ARG A 200 −10.968 36.934 25.859 1.00 28.34 C ATOM 920 O ARG A 200 −10.491 37.238 26.955 1.00 28.25 O ATOM 921 N PHE A 201 −11.706 35.848 25.660 1.00 28.84 N ATOM 922 CA PHE A 201 −12.244 35.004 26.738 1.00 28.86 C ATOM 923 CB PHE A 201 −13.772 34.828 26.559 1.00 28.35 C ATOM 924 CG PHE A 201 −14.568 36.097 26.766 1.00 25.52 C ATOM 925 CD1 PHE A 201 −14.554 36.770 27.997 1.00 27.82 C ATOM 926 CE1 PHE A 201 −15.273 37.974 28.166 1.00 27.90 C ATOM 927 CZ PHE A 201 −16.034 38.498 27.120 1.00 28.95 C ATOM 928 CE2 PHE A 201 −16.063 37.831 25.899 1.00 27.66 C ATOM 929 CD2 PHE A 201 −15.319 36.623 25.735 1.00 27.72 C ATOM 930 C PHE A 201 −11.563 33.627 26.884 1.00 30.86 C ATOM 931 O PHE A 201 −11.721 32.964 27.915 1.00 30.47 O ATOM 932 N ALA A 202 −10.780 33.200 25.895 1.00 31.85 N ATOM 933 CA ALA A 202 −10.326 31.801 25.894 1.00 34.65 C ATOM 934 CB ALA A 202 −11.347 30.904 25.154 1.00 32.12 C ATOM 935 C ALA A 202 −8.924 31.544 25.367 1.00 37.14 C ATOM 936 O ALA A 202 −8.222 30.715 25.921 1.00 38.77 O ATOM 937 N TRP A 203 −8.523 32.260 24.307 1.00 38.77 N ATOM 938 CA TRP A 203 −7.316 31.934 23.527 1.00 40.33 C ATOM 939 CB TRP A 203 −7.720 31.335 22.174 1.00 38.58 C ATOM 940 CG TRP A 203 −6.610 30.594 21.453 1.00 38.71 C ATOM 941 CD1 TRP A 203 −5.864 31.038 20.370 1.00 37.42 C ATOM 942 NE1 TRP A 203 −4.978 30.057 19.965 1.00 37.40 N ATOM 943 CE2 TRP A 203 −5.106 28.975 20.808 1.00 36.87 C ATOM 944 CD2 TRP A 203 −6.134 29.284 21.754 1.00 36.44 C ATOM 945 CE3 TRP A 203 −6.459 28.335 22.740 1.00 38.19 C ATOM 946 CZ3 TRP A 203 −5.762 27.090 22.750 1.00 37.22 C ATOM 947 CH2 TRP A 203 −4.749 26.813 21.786 1.00 36.78 C ATOM 948 CZ2 TRP A 203 −4.406 27.742 20.821 1.00 36.69 C ATOM 949 C TRP A 203 −6.525 33.207 23.251 1.00 42.00 C ATOM 950 O TRP A 203 −6.552 33.692 22.103 1.00 44.02 O ATOM 951 OXT TRP A 203 −5.876 33.797 24.117 1.00 42.42 O ATOM 952 N PRO B 85 7.442 25.386 −43.697 1.00 62.33 N ATOM 953 CA PRO B 85 8.153 26.040 −42.594 1.00 61.88 C ATOM 954 CB PRO B 85 7.082 26.935 −41.948 1.00 62.07 C ATOM 955 CG PRO B 85 6.069 27.170 −43.026 1.00 62.66 C ATOM 956 CD PRO B 85 6.075 25.911 −43.875 1.00 62.82 C ATOM 957 C PRO B 85 8.678 25.031 −41.572 1.00 60.95 C ATOM 958 O PRO B 85 7.988 24.045 −41.269 1.00 61.39 O ATOM 959 N ALA B 86 9.893 25.269 −41.064 1.00 59.55 N ATOM 960 CA ALA B 86 10.476 24.427 −40.026 1.00 58.13 C ATOM 961 CB ALA B 86 11.886 24.854 −39.737 1.00 58.01 C ATOM 962 C ALA B 86 9.618 24.453 −38.750 1.00 57.61 C ATOM 963 O ALA B 86 8.875 25.413 −38.517 1.00 57.45 O ATOM 964 N SER B 87 9.699 23.382 −37.955 1.00 56.80 N ATOM 965 CA SER B 87 9.094 23.341 −36.621 1.00 55.97 C ATOM 966 CB SER B 87 9.578 22.115 −35.841 1.00 56.09 C ATOM 967 OG SER B 87 9.096 20.914 −36.416 1.00 59.57 O ATOM 968 C SER B 87 9.504 24.568 −35.832 1.00 54.53 C ATOM 969 O SER B 87 10.638 25.044 −35.952 1.00 53.79 O ATOM 970 N ARG B 88 8.587 25.081 −35.022 1.00 53.11 N ATOM 971 CA ARG B 88 8.994 26.013 −33.978 1.00 51.52 C ATOM 972 CB ARG B 88 8.504 27.432 −34.252 1.00 52.04 C ATOM 973 CG ARG B 88 7.041 27.550 −34.529 1.00 54.33 C ATOM 974 CD ARG B 88 6.728 28.924 −35.062 1.00 57.93 C ATOM 975 NE ARG B 88 5.363 29.328 −34.759 1.00 60.15 N ATOM 976 CZ ARG B 88 5.012 30.052 −33.699 1.00 63.10 C ATOM 977 NH1 ARG B 88 5.932 30.458 −32.815 1.00 62.43 N ATOM 978 NH2 ARG B 88 3.730 30.373 −33.519 1.00 62.59 N ATOM 979 C ARG B 88 8.537 25.490 −32.617 1.00 49.39 C ATOM 980 O ARG B 88 7.619 24.684 −32.550 1.00 47.87 O ATOM 981 N TYR B 89 9.217 25.943 −31.567 1.00 47.24 N ATOM 982 CA TYR B 89 8.982 25.477 −30.204 1.00 45.49 C ATOM 983 CB TYR B 89 10.298 25.132 −29.498 1.00 46.96 C ATOM 984 CG TYR B 89 10.938 23.840 −29.949 1.00 49.23 C ATOM 985 CD1 TYR B 89 12.003 23.859 −30.844 1.00 51.93 C ATOM 986 CE1 TYR B 89 12.614 22.678 −31.274 1.00 53.21 C ATOM 987 CZ TYR B 89 12.159 21.453 −30.800 1.00 52.97 C ATOM 988 OH TYR B 89 12.793 20.295 −31.238 1.00 52.46 O ATOM 989 CE2 TYR B 89 11.089 21.403 −29.901 1.00 51.87 C ATOM 990 CD2 TYR B 89 10.485 22.596 −29.482 1.00 50.16 C ATOM 991 C TYR B 89 8.251 26.525 −29.391 1.00 43.03 C ATOM 992 O TYR B 89 8.599 27.718 −29.405 1.00 42.37 O ATOM 993 N ILE B 90 7.230 26.066 −28.685 1.00 39.81 N ATOM 994 CA ILE B 90 6.552 26.883 −27.712 1.00 37.00 C ATOM 995 CB ILE B 90 5.018 26.620 −27.746 1.00 37.76 C ATOM 996 CG1 ILE B 90 4.414 26.837 −29.163 1.00 37.36 C ATOM 997 CD1 ILE B 90 4.795 28.145 −29.862 1.00 39.19 C ATOM 998 CG2 ILE B 90 4.317 27.434 −26.660 1.00 34.76 C ATOM 999 C ILE B 90 7.120 26.456 −26.366 1.00 36.01 C ATOM 1000 O ILE B 90 7.290 25.244 −26.111 1.00 34.34 O ATOM 1001 N THR B 91 7.455 27.422 −25.516 1.00 35.22 N ATOM 1002 CA THR B 91 8.016 27.093 −24.204 1.00 35.55 C ATOM 1003 CB THR B 91 9.552 27.381 −24.113 1.00 36.05 C ATOM 1004 OG1 THR B 91 9.811 28.768 −24.427 1.00 37.96 O ATOM 1005 CG2 THR B 91 10.350 26.466 −25.020 1.00 37.46 C ATOM 1006 C THR B 91 7.286 27.902 −23.156 1.00 35.72 C ATOM 1007 O THR B 91 7.699 29.018 −22.827 1.00 35.37 O ATOM 1008 N ASP B 92 6.161 27.373 −22.666 1.00 35.05 N ATOM 1009 CA ASP B 92 5.366 28.077 −21.650 1.00 33.77 C ATOM 1010 CB ASP B 92 4.034 27.364 −21.361 1.00 33.89 C ATOM 1011 CG ASP B 92 2.992 27.502 −22.482 1.00 34.60 C ATOM 1012 OD1 ASP B 92 3.154 28.326 −23.431 1.00 35.61 O ATOM 1013 OD2 ASP B 92 1.975 26.774 −22.383 1.00 33.13 O ATOM 1014 C ASP B 92 6.146 28.082 −20.349 1.00 33.53 C ATOM 1015 O ASP B 92 6.056 29.033 −19.578 1.00 33.40 O ATOM 1016 N MET B 93 6.878 27.009 −20.083 1.00 32.58 N ATOM 1017 CA MET B 93 7.539 26.857 −18.794 1.00 32.30 C ATOM 1018 CB MET B 93 7.607 25.369 −18.402 1.00 32.52 C ATOM 1019 CG MET B 93 6.322 24.773 −17.914 1.00 29.43 C ATOM 1020 SD MET B 93 6.429 23.054 −17.472 1.00 28.89 S ATOM 1021 CE MET B 93 5.883 22.183 −18.940 1.00 26.92 C ATOM 1022 C MET B 93 8.983 27.427 −18.831 1.00 34.01 C ATOM 1023 O MET B 93 9.657 27.323 −19.864 1.00 32.66 O ATOM 1024 N THR B 94 9.457 27.980 −17.704 1.00 34.20 N ATOM 1025 CA THR B 94 10.880 28.311 −17.544 1.00 35.22 C ATOM 1026 CB THR B 94 11.120 29.178 −16.266 1.00 36.09 C ATOM 1027 OG1 THR B 94 10.674 28.440 −15.134 1.00 36.40 O ATOM 1028 CG2 THR B 94 10.354 30.513 −16.315 1.00 35.20 C ATOM 1029 C THR B 94 11.727 27.047 −17.428 1.00 34.67 C ATOM 1030 O THR B 94 11.199 25.961 −17.197 1.00 33.47 O ATOM 1031 N ILE B 95 13.051 27.175 −17.583 1.00 35.62 N ATOM 1032 CA ILE B 95 13.960 26.054 −17.369 1.00 36.37 C ATOM 1033 CB ILE B 95 15.499 26.465 −17.487 1.00 36.16 C ATOM 1034 CG1 ILE B 95 15.815 26.979 −18.895 1.00 39.79 C ATOM 1035 CD1 ILE B 95 17.240 27.642 −19.070 1.00 39.32 C ATOM 1036 CG2 ILE B 95 16.343 25.262 −17.243 1.00 36.87 C ATOM 1037 C ILE B 95 13.739 25.427 −15.998 1.00 35.94 C ATOM 1038 O ILE B 95 13.831 24.194 −15.836 1.00 36.49 O ATOM 1039 N GLU B 96 13.509 26.257 −14.993 1.00 36.30 N ATOM 1040 CA GLU B 96 13.309 25.726 −13.628 1.00 37.91 C ATOM 1041 CB GLU B 96 13.372 26.878 −12.596 1.00 38.48 C ATOM 1042 CG GLU B 96 13.421 26.440 −11.134 1.00 41.71 C ATOM 1043 CD GLU B 96 12.042 26.159 −10.555 1.00 45.38 C ATOM 1044 OE1 GLU B 96 11.042 26.752 −11.042 1.00 47.09 O ATOM 1045 OE2 GLU B 96 11.967 25.354 −9.600 1.00 46.98 O ATOM 1046 C GLU B 96 11.995 24.913 −13.517 1.00 36.88 C ATOM 1047 O GLU B 96 11.977 23.805 −12.997 1.00 36.45 O ATOM 1048 N GLU B 97 10.909 25.477 −14.028 1.00 36.87 N ATOM 1049 CA GLU B 97 9.602 24.789 −14.010 1.00 36.88 C ATOM 1050 CB GLU B 97 8.552 25.667 −14.663 1.00 36.11 C ATOM 1051 CG GLU B 97 8.177 26.883 −13.781 1.00 38.37 C ATOM 1052 CD GLU B 97 7.264 27.884 −14.452 1.00 38.94 C ATOM 1053 OE1 GLU B 97 7.424 28.160 −15.681 1.00 38.42 O ATOM 1054 OE2 GLU B 97 6.399 28.435 −13.725 1.00 41.47 O ATOM 1055 C GLU B 97 9.662 23.414 −14.664 1.00 36.23 C ATOM 1056 O GLU B 97 9.071 22.443 −14.171 1.00 36.44 O ATOM 1057 N LEU B 98 10.409 23.313 −15.760 1.00 35.44 N ATOM 1058 CA LEU B 98 10.447 22.090 −16.543 1.00 36.09 C ATOM 1059 CB LEU B 98 10.992 22.400 −17.941 1.00 37.24 C ATOM 1060 CG LEU B 98 10.961 21.395 −19.103 1.00 41.62 C ATOM 1061 CD1 LEU B 98 9.587 21.306 −19.833 1.00 41.32 C ATOM 1062 CD2 LEU B 98 12.004 21.864 −20.095 1.00 45.35 C ATOM 1063 C LEU B 98 11.290 21.025 −15.870 1.00 36.56 C ATOM 1064 O LEU B 98 11.003 19.822 −15.985 1.00 35.75 O ATOM 1065 N SER B 99 12.322 21.470 −15.156 1.00 37.20 N ATOM 1066 CA SER B 99 13.294 20.563 −14.547 1.00 38.65 C ATOM 1067 CB SER B 99 14.666 21.226 −14.525 1.00 39.66 C ATOM 1068 OG SER B 99 14.626 22.393 −13.710 1.00 45.01 O ATOM 1069 C SER B 99 12.934 20.161 −13.136 1.00 37.67 C ATOM 1070 O SER B 99 13.387 19.139 −12.682 1.00 37.38 O ATOM 1071 N ARG B 100 12.101 20.962 −12.457 1.00 38.83 N ATOM 1072 CA ARG B 100 11.673 20.677 −11.071 1.00 38.07 C ATOM 1073 CB ARG B 100 10.594 21.675 −10.658 1.00 39.03 C ATOM 1074 CG ARG B 100 10.454 21.834 −9.166 1.00 40.88 C ATOM 1075 CD ARG B 100 9.310 22.774 −8.836 1.00 40.98 C ATOM 1076 NE ARG B 100 9.423 24.092 −9.464 1.00 39.64 N ATOM 1077 CZ ARG B 100 8.392 24.898 −9.644 1.00 40.56 C ATOM 1078 NH1 ARG B 100 7.189 24.515 −9.231 1.00 44.30 N ATOM 1079 NH2 ARG B 100 8.550 26.090 −10.198 1.00 42.36 N ATOM 1080 C ARG B 100 11.121 19.261 −10.945 1.00 37.43 C ATOM 1081 O ARG B 100 10.438 18.783 −11.846 1.00 36.57 O ATOM 1082 N ASP B 101 11.453 18.564 −9.860 1.00 35.80 N ATOM 1083 CA ASP B 101 10.742 17.342 −9.523 1.00 35.10 C ATOM 1084 CB ASP B 101 11.651 16.271 −8.899 1.00 35.75 C ATOM 1085 CG ASP B 101 12.806 15.834 −9.812 1.00 37.07 C ATOM 1086 OD1 ASP B 101 12.570 15.518 −11.012 1.00 35.64 O ATOM 1087 OD2 ASP B 101 13.952 15.733 −9.275 1.00 38.34 O ATOM 1088 C ASP B 101 9.690 17.753 −8.500 1.00 34.47 C ATOM 1089 O ASP B 101 9.912 18.665 −7.681 1.00 35.01 O ATOM 1090 N TRP B 102 8.540 17.093 −8.525 1.00 33.32 N ATOM 1091 CA TRP B 102 7.468 17.502 −7.641 1.00 31.72 C ATOM 1092 CB TRP B 102 6.491 18.411 −8.419 1.00 32.70 C ATOM 1093 CG TRP B 102 5.866 17.687 −9.554 1.00 30.91 C ATOM 1094 CD1 TRP B 102 6.433 17.389 −10.754 1.00 31.44 C ATOM 1095 NE1 TRP B 102 5.544 16.652 −11.540 1.00 33.38 N ATOM 1096 CE2 TRP B 102 4.386 16.454 −10.833 1.00 34.03 C ATOM 1097 CD2 TRP B 102 4.562 17.079 −9.552 1.00 34.03 C ATOM 1098 CE3 TRP B 102 3.512 17.033 −8.620 1.00 33.01 C ATOM 1099 CZ3 TRP B 102 2.309 16.373 −8.993 1.00 30.04 C ATOM 1100 CH2 TRP B 102 2.188 15.734 −10.255 1.00 31.03 C ATOM 1101 CZ2 TRP B 102 3.206 15.764 −11.184 1.00 31.94 C ATOM 1102 C TRP B 102 6.829 16.320 −6.880 1.00 31.64 C ATOM 1103 O TRP B 102 7.038 15.140 −7.209 1.00 31.20 O ATOM 1104 N PHE B 103 6.114 16.653 −5.800 1.00 30.85 N ATOM 1105 CA PHE B 103 5.628 15.684 −4.827 1.00 29.60 C ATOM 1106 CB PHE B 103 6.029 16.180 −3.425 1.00 30.18 C ATOM 1107 CG PHE B 103 5.321 15.507 −2.268 1.00 31.54 C ATOM 1108 CD1 PHE B 103 5.742 14.284 −1.798 1.00 31.56 C ATOM 1109 CE1 PHE B 103 5.122 13.681 −0.692 1.00 30.41 C ATOM 1110 CZ PHE B 103 4.055 14.329 −0.046 1.00 31.78 C ATOM 1111 CE2 PHE B 103 3.635 15.599 −0.483 1.00 30.83 C ATOM 1112 CD2 PHE B 103 4.273 16.174 −1.597 1.00 33.14 C ATOM 1113 C PHE B 103 4.118 15.612 −4.935 1.00 27.88 C ATOM 1114 O PHE B 103 3.473 16.646 −5.063 1.00 28.45 O ATOM 1115 N MET B 104 3.598 14.391 −4.875 1.00 27.19 N ATOM 1116 CA MET B 104 2.163 14.120 −4.772 1.00 27.44 C ATOM 1117 CB MET B 104 1.715 13.163 −5.899 1.00 26.04 C ATOM 1118 CG MET B 104 1.798 13.758 −7.355 1.00 28.37 C ATOM 1119 SD MET B 104 1.632 12.389 −8.528 1.00 26.62 S ATOM 1120 CE MET B 104 3.295 11.830 −8.571 1.00 26.34 C ATOM 1121 C MET B 104 1.913 13.456 −3.389 1.00 27.60 C ATOM 1122 O MET B 104 2.502 12.434 −3.068 1.00 26.49 O ATOM 1123 N LEU B 105 1.056 14.072 −2.583 1.00 26.42 N ATOM 1124 CA LEU B 105 0.616 13.447 −1.317 1.00 26.58 C ATOM 1125 CB LEU B 105 −0.240 14.454 −0.508 1.00 25.53 C ATOM 1126 CG LEU B 105 −0.660 14.024 0.917 1.00 28.52 C ATOM 1127 CD1 LEU B 105 0.620 13.782 1.774 1.00 26.80 C ATOM 1128 CD2 LEU B 105 −1.509 15.149 1.416 1.00 28.79 C ATOM 1129 C LEU B 105 −0.185 12.189 −1.571 1.00 26.02 C ATOM 1130 O LEU B 105 −0.030 11.227 −0.858 1.00 26.32 O ATOM 1131 N MET B 106 −1.086 12.213 −2.572 1.00 26.57 N ATOM 1132 CA MET B 106 −1.909 11.043 −2.919 1.00 25.33 C ATOM 1133 CB MET B 106 −3.414 11.381 −2.722 1.00 24.16 C ATOM 1134 CG MET B 106 −3.718 11.818 −1.267 1.00 27.74 C ATOM 1135 SD MET B 106 −5.495 12.138 −1.007 1.00 25.66 S ATOM 1136 CE MET B 106 −5.818 10.701 0.032 1.00 35.03 C ATOM 1137 C MET B 106 −1.641 10.741 −4.397 1.00 26.10 C ATOM 1138 O MET B 106 −2.439 11.106 −5.263 1.00 24.95 O ATOM 1139 N PRO B 107 −0.515 10.079 −4.684 1.00 27.23 N ATOM 1140 CA PRO B 107 −0.083 9.969 −6.107 1.00 26.85 C ATOM 1141 CB PRO B 107 1.220 9.184 −6.024 1.00 26.93 C ATOM 1142 CG PRO B 107 1.622 9.205 −4.482 1.00 26.97 C ATOM 1143 CD PRO B 107 0.333 9.284 −3.763 1.00 26.75 C ATOM 1144 C PRO B 107 −1.085 9.168 −6.958 1.00 26.73 C ATOM 1145 O PRO B 107 −1.699 8.178 −6.490 1.00 26.39 O ATOM 1146 N LYS B 108 −1.238 9.625 −8.202 1.00 27.58 N ATOM 1147 CA LYS B 108 −2.047 8.964 −9.208 1.00 28.66 C ATOM 1148 CB LYS B 108 −3.361 9.741 −9.422 1.00 28.49 C ATOM 1149 CG LYS B 108 −4.375 9.513 −8.277 1.00 28.11 C ATOM 1150 CD LYS B 108 −4.773 8.044 −8.260 1.00 30.78 C ATOM 1151 CE LYS B 108 −5.300 7.575 −6.971 1.00 32.01 C ATOM 1152 NZ LYS B 108 −4.282 7.664 −5.906 1.00 33.62 N ATOM 1153 C LYS B 108 −1.212 9.009 −10.485 1.00 28.71 C ATOM 1154 O LYS B 108 −0.620 10.034 −10.802 1.00 28.16 O ATOM 1155 N GLN B 109 −1.132 7.879 −11.171 1.00 30.52 N ATOM 1156 CA GLN B 109 −0.373 7.809 −12.435 1.00 33.68 C ATOM 1157 CB GLN B 109 1.078 7.372 −12.187 1.00 34.23 C ATOM 1158 CG GLN B 109 1.943 7.302 −13.432 1.00 39.99 C ATOM 1159 CD GLN B 109 3.272 6.642 −13.153 1.00 47.20 C ATOM 1160 OE1 GLN B 109 4.126 7.218 −12.489 1.00 52.68 O ATOM 1161 NE2 GLN B 109 3.448 5.416 −13.636 1.00 51.24 N ATOM 1162 C GLN B 109 −1.066 6.845 −13.352 1.00 34.01 C ATOM 1163 O GLN B 109 −1.408 5.722 −12.931 1.00 34.27 O ATOM 1164 N LYS B 110 −1.283 7.290 −14.595 1.00 34.52 N ATOM 1165 CA LYS B 110 −1.941 6.463 −15.617 1.00 35.64 C ATOM 1166 CB LYS B 110 −3.318 7.045 −15.923 1.00 35.09 C ATOM 1167 CG LYS B 110 −4.199 6.200 −16.799 1.00 36.36 C ATOM 1168 CD LYS B 110 −5.256 7.078 −17.360 1.00 37.52 C ATOM 1169 CE LYS B 110 −6.197 6.331 −18.301 1.00 43.96 C ATOM 1170 NZ LYS B 110 −6.738 5.149 −17.583 1.00 45.73 N ATOM 1171 C LYS B 110 −1.073 6.512 −16.889 1.00 35.81 C ATOM 1172 O LYS B 110 −0.677 7.581 −17.306 1.00 34.99 O ATOM 1173 N VAL B 111 −0.765 5.344 −17.453 1.00 36.14 N ATOM 1174 CA VAL B 111 −0.183 5.256 −18.790 1.00 37.37 C ATOM 1175 CB VAL B 111 0.595 3.969 −18.988 1.00 38.40 C ATOM 1176 CG1 VAL B 111 1.096 3.874 −20.451 1.00 40.21 C ATOM 1177 CG2 VAL B 111 1.746 3.934 −18.025 1.00 39.38 C ATOM 1178 C VAL B 111 −1.329 5.314 −19.766 1.00 37.36 C ATOM 1179 O VAL B 111 −2.230 4.493 −19.737 1.00 37.69 O ATOM 1180 N GLU B 112 −1.367 6.331 −20.596 1.00 36.83 N ATOM 1181 CA GLU B 112 −2.436 6.329 −21.550 1.00 37.26 C ATOM 1182 CB GLU B 112 −3.334 7.501 −21.290 1.00 37.53 C ATOM 1183 CG GLU B 112 −4.730 7.186 −21.687 1.00 42.45 C ATOM 1184 CD GLU B 112 −5.518 8.434 −21.769 1.00 47.91 C ATOM 1185 OE1 GLU B 112 −6.665 8.423 −21.268 1.00 49.77 O ATOM 1186 OE2 GLU B 112 −4.951 9.421 −22.317 1.00 47.40 O ATOM 1187 C GLU B 112 −1.915 6.361 −22.986 1.00 36.04 C ATOM 1188 O GLU B 112 −1.497 7.415 −23.484 1.00 34.78 O ATOM 1189 N GLY B 113 −1.920 5.204 −23.644 1.00 35.37 N ATOM 1190 CA GLY B 113 −1.239 5.135 −24.935 1.00 33.99 C ATOM 1191 C GLY B 113 0.262 5.420 −24.706 1.00 32.46 C ATOM 1192 O GLY B 113 0.895 4.810 −23.819 1.00 33.59 O ATOM 1193 N PRO B 114 0.842 6.341 −25.484 1.00 30.86 N ATOM 1194 CA PRO B 114 2.254 6.728 −25.432 1.00 30.15 C ATOM 1195 CB PRO B 114 2.491 7.285 −26.845 1.00 30.38 C ATOM 1196 CG PRO B 114 1.188 7.915 −27.171 1.00 30.21 C ATOM 1197 CD PRO B 114 0.128 7.066 −26.553 1.00 31.78 C ATOM 1198 C PRO B 114 2.584 7.817 −24.386 1.00 28.89 C ATOM 1199 O PRO B 114 3.733 8.284 −24.323 1.00 27.26 O ATOM 1200 N LEU B 115 1.603 8.178 −23.538 1.00 27.32 N ATOM 1201 CA LEU B 115 1.751 9.275 −22.578 1.00 27.63 C ATOM 1202 CB LEU B 115 0.833 10.464 −22.938 1.00 26.73 C ATOM 1203 CG LEU B 115 0.951 11.005 −24.372 1.00 28.81 C ATOM 1204 CD1 LEU B 115 −0.120 12.044 −24.555 1.00 28.14 C ATOM 1205 CD2 LEU B 115 2.323 11.667 −24.558 1.00 27.61 C ATOM 1206 C LEU B 115 1.456 8.803 −21.149 1.00 27.69 C ATOM 1207 O LEU B 115 0.695 7.849 −20.937 1.00 28.97 O ATOM 1208 N CYS B 116 2.077 9.493 −20.204 1.00 28.03 N ATOM 1209 CA CYS B 116 1.923 9.240 −18.787 1.00 27.99 C ATOM 1210 CB CYS B 116 3.288 8.988 −18.165 1.00 28.84 C ATOM 1211 SG CYS B 116 3.202 8.685 −16.342 1.00 32.13 S ATOM 1212 C CYS B 116 1.275 10.452 −18.147 1.00 28.28 C ATOM 1213 O CYS B 116 1.700 11.596 −18.392 1.00 27.83 O ATOM 1214 N ILE B 117 0.204 10.204 −17.354 1.00 27.49 N ATOM 1215 CA ILE B 117 −0.572 11.279 −16.710 1.00 26.02 C ATOM 1216 CB ILE B 117 −2.093 11.221 −17.073 1.00 26.73 C ATOM 1217 CG1 ILE B 117 −2.262 11.134 −18.605 1.00 27.69 C ATOM 1218 CD1 ILE B 117 −3.458 10.398 −19.049 1.00 28.54 C ATOM 1219 CG2 ILE B 117 −2.878 12.453 −16.465 1.00 25.95 C ATOM 1220 C ILE B 117 −0.391 11.052 −15.192 1.00 24.22 C ATOM 1221 O ILE B 117 −0.574 9.957 −14.719 1.00 26.21 O ATOM 1222 N ARG B 118 0.002 12.093 −14.495 1.00 24.83 N ATOM 1223 CA ARG B 118 0.151 12.069 −13.050 1.00 24.60 C ATOM 1224 CB ARG B 118 1.625 12.324 −12.676 1.00 26.12 C ATOM 1225 CG ARG B 118 2.554 11.240 −13.053 1.00 29.98 C ATOM 1226 CD ARG B 118 3.976 11.644 −12.680 1.00 36.27 C ATOM 1227 NE ARG B 118 4.833 10.487 −12.835 1.00 43.72 N ATOM 1228 CZ ARG B 118 5.739 10.363 −13.792 1.00 48.66 C ATOM 1229 NH1 ARG B 118 5.935 11.371 −14.654 1.00 50.62 N ATOM 1230 NH2 ARG B 118 6.456 9.235 −13.879 1.00 50.32 N ATOM 1231 C ARG B 118 −0.648 13.195 −12.465 1.00 23.69 C ATOM 1232 O ARG B 118 −0.738 14.276 −13.030 1.00 22.96 O ATOM 1233 N ILE B 119 −1.170 12.992 −11.254 1.00 24.51 N ATOM 1234 CA ILE B 119 −1.918 14.071 −10.630 1.00 23.38 C ATOM 1235 CB ILE B 119 −3.379 14.189 −11.220 1.00 25.08 C ATOM 1236 CG1 ILE B 119 −4.168 15.391 −10.625 1.00 24.01 C ATOM 1237 CD1 ILE B 119 −5.698 15.456 −11.077 1.00 24.74 C ATOM 1238 CG2 ILE B 119 −4.097 12.864 −11.167 1.00 26.19 C ATOM 1239 C ILE B 119 −1.927 13.744 −9.149 1.00 22.60 C ATOM 1240 O ILE B 119 −1.861 12.601 −8.768 1.00 23.10 O ATOM 1241 N ASP B 120 −1.893 14.786 −8.349 1.00 22.84 N ATOM 1242 CA ASP B 120 −2.059 14.611 −6.892 1.00 24.58 C ATOM 1243 CB ASP B 120 −1.358 15.710 −6.147 1.00 23.29 C ATOM 1244 CG ASP B 120 −1.252 15.431 −4.633 1.00 25.72 C ATOM 1245 OD1 ASP B 120 −1.856 14.473 −4.136 1.00 26.52 O ATOM 1246 OD2 ASP B 120 −0.495 16.173 −3.961 1.00 27.39 O ATOM 1247 C ASP B 120 −3.561 14.713 −6.580 1.00 22.94 C ATOM 1248 O ASP B 120 −4.145 15.773 −6.725 1.00 23.18 O ATOM 1249 N GLN B 121 −4.127 13.597 −6.196 1.00 23.75 N ATOM 1250 CA GLN B 121 −5.534 13.493 −5.718 1.00 24.41 C ATOM 1251 CB GLN B 121 −5.888 12.008 −5.498 1.00 23.59 C ATOM 1252 CG GLN B 121 −7.357 11.742 −4.999 1.00 24.61 C ATOM 1253 CD GLN B 121 −7.689 10.313 −4.820 1.00 25.20 C ATOM 1254 OE1 GLN B 121 −6.826 9.468 −4.792 1.00 24.43 O ATOM 1255 NE2 GLN B 121 −8.996 10.017 −4.688 1.00 28.25 N ATOM 1256 C GLN B 121 −5.863 14.386 −4.487 1.00 24.49 C ATOM 1257 O GLN B 121 −7.026 14.736 −4.267 1.00 24.40 O ATOM 1258 N ALA B 122 −4.842 14.834 −3.740 1.00 25.85 N ATOM 1259 CA ALA B 122 −5.058 15.623 −2.509 1.00 24.80 C ATOM 1260 CB ALA B 122 −3.813 15.587 −1.658 1.00 25.27 C ATOM 1261 C ALA B 122 −5.372 17.049 −2.846 1.00 25.48 C ATOM 1262 O ALA B 122 −5.871 17.837 −2.014 1.00 23.88 O ATOM 1263 N ILE B 123 −5.033 17.457 −4.065 1.00 25.50 N ATOM 1264 CA ILE B 123 −5.136 18.876 −4.370 1.00 26.71 C ATOM 1265 CB ILE B 123 −4.088 19.273 −5.469 1.00 27.03 C ATOM 1266 CG1 ILE B 123 −2.664 19.148 −4.895 1.00 28.82 C ATOM 1267 CD1 ILE B 123 −2.252 20.255 −3.962 1.00 28.25 C ATOM 1268 CG2 ILE B 123 −4.368 20.704 −6.006 1.00 29.25 C ATOM 1269 C ILE B 123 −6.541 19.345 −4.791 1.00 28.30 C ATOM 1270 O ILE B 123 −7.114 18.843 −5.810 1.00 28.00 O ATOM 1271 N MET B 124 −7.059 20.359 −4.072 1.00 27.99 N ATOM 1272 CA MET B 124 −8.433 20.849 −4.267 1.00 30.20 C ATOM 1273 CB MET B 124 −9.407 20.226 −3.257 1.00 28.85 C ATOM 1274 CG MET B 124 −9.245 18.768 −3.159 1.00 30.84 C ATOM 1275 SD MET B 124 −10.621 18.153 −2.165 1.00 33.91 S ATOM 1276 CE MET B 124 −10.006 16.631 −1.750 1.00 24.31 C ATOM 1277 C MET B 124 −8.505 22.326 −4.146 1.00 31.04 C ATOM 1278 O MET B 124 −7.600 22.948 −3.608 1.00 31.15 O ATOM 1279 N ASP B 125 −9.577 22.892 −4.694 1.00 33.33 N ATOM 1280 CA ASP B 125 −9.940 24.291 −4.503 1.00 34.92 C ATOM 1281 CB ASP B 125 −10.269 24.509 −3.012 1.00 36.08 C ATOM 1282 CG ASP B 125 −11.451 23.718 −2.579 1.00 38.58 C ATOM 1283 OD1 ASP B 125 −12.498 23.851 −3.285 1.00 46.09 O ATOM 1284 OD2 ASP B 125 −11.342 22.965 −1.572 1.00 41.80 O ATOM 1285 C ASP B 125 −8.930 25.325 −4.949 1.00 35.72 C ATOM 1286 O ASP B 125 −8.958 26.442 −4.455 1.00 36.05 O ATOM 1287 N LYS B 126 −8.045 24.987 −5.880 1.00 34.36 N ATOM 1288 CA LYS B 126 −7.079 25.938 −6.355 1.00 34.46 C ATOM 1289 CB LYS B 126 −5.654 25.347 −6.229 1.00 35.61 C ATOM 1290 CG LYS B 126 −5.123 25.518 −4.749 1.00 35.45 C ATOM 1291 CD LYS B 126 −4.231 24.371 −4.247 1.00 41.21 C ATOM 1292 CE LYS B 126 −4.235 24.232 −2.709 1.00 40.11 C ATOM 1293 NZ LYS B 126 −5.023 23.010 −2.047 1.00 39.60 N ATOM 1294 C LYS B 126 −7.410 26.445 −7.763 1.00 35.16 C ATOM 1295 O LYS B 126 −8.172 25.801 −8.495 1.00 34.91 O ATOM 1296 N ASN B 127 −6.917 27.635 −8.091 1.00 34.53 N ATOM 1297 CA ASN B 127 −6.852 28.104 −9.463 1.00 35.83 C ATOM 1298 CB ASN B 127 −6.784 29.634 −9.482 1.00 36.09 C ATOM 1299 CG ASN B 127 −8.059 30.259 −8.963 1.00 39.59 C ATOM 1300 OD1 ASN B 127 −9.151 29.895 −9.403 1.00 42.15 O ATOM 1301 ND2 ASN B 127 −7.935 31.181 −8.010 1.00 41.71 N ATOM 1302 C ASN B 127 −5.608 27.460 −10.123 1.00 35.83 C ATOM 1303 O ASN B 127 −4.471 27.660 −9.646 1.00 35.54 O ATOM 1304 N ILE B 128 −5.838 26.643 −11.153 1.00 34.49 N ATOM 1305 CA ILE B 128 −4.762 25.838 −11.739 1.00 34.62 C ATOM 1306 CB ILE B 128 −5.119 24.306 −11.680 1.00 34.79 C ATOM 1307 CG1 ILE B 128 −5.265 23.784 −10.233 1.00 32.44 C ATOM 1308 CD1 ILE B 128 −3.957 23.744 −9.465 1.00 36.65 C ATOM 1309 CG2 ILE B 128 −4.116 23.458 −12.496 1.00 33.81 C ATOM 1310 C ILE B 128 −4.571 26.280 −13.192 1.00 34.82 C ATOM 1311 O ILE B 128 −5.550 26.529 −13.892 1.00 35.00 O ATOM 1312 N MET B 129 −3.314 26.404 −13.643 1.00 35.61 N ATOM 1313 CA MET B 129 −2.996 26.814 −15.021 1.00 34.86 C ATOM 1314 CB MET B 129 −2.261 28.179 −15.048 1.00 35.13 C ATOM 1315 CG MET B 129 −1.751 28.640 −16.447 1.00 35.56 C ATOM 1316 SD MET B 129 −3.035 29.030 −17.670 1.00 38.68 S ATOM 1317 CE MET B 129 −3.538 30.686 −17.157 1.00 41.92 C ATOM 1318 C MET B 129 −2.130 25.742 −15.712 1.00 34.42 C ATOM 1319 O MET B 129 −1.032 25.415 −15.221 1.00 33.25 O ATOM 1320 N LEU B 130 −2.612 25.201 −16.832 1.00 33.00 N ATOM 1321 CA LEU B 130 −1.798 24.222 −17.574 1.00 32.79 C ATOM 1322 CB LEU B 130 −2.667 23.270 −18.395 1.00 33.33 C ATOM 1323 CG LEU B 130 −3.805 22.507 −17.746 1.00 34.39 C ATOM 1324 CD1 LEU B 130 −4.218 21.298 −18.640 1.00 35.78 C ATOM 1325 CD2 LEU B 130 −3.454 22.026 −16.355 1.00 33.03 C ATOM 1326 C LEU B 130 −0.867 25.000 −18.501 1.00 31.81 C ATOM 1327 O LEU B 130 −1.316 25.839 −19.251 1.00 31.56 O ATOM 1328 N LYS B 131 0.425 24.706 −18.407 1.00 31.06 N ATOM 1329 CA LYS B 131 1.487 25.276 −19.233 1.00 30.62 C ATOM 1330 CB LYS B 131 2.465 26.072 −18.367 1.00 31.05 C ATOM 1331 CG LYS B 131 1.907 27.398 −17.944 1.00 33.09 C ATOM 1332 CD LYS B 131 2.876 28.133 −17.055 1.00 35.17 C ATOM 1333 CE LYS B 131 2.199 29.374 −16.485 1.00 38.38 C ATOM 1334 NZ LYS B 131 3.249 30.258 −15.877 1.00 39.16 N ATOM 1335 C LYS B 131 2.215 24.125 −19.926 1.00 29.36 C ATOM 1336 O LYS B 131 2.375 23.043 −19.365 1.00 29.14 O ATOM 1337 N ALA B 132 2.596 24.318 −21.183 1.00 27.61 N ATOM 1338 CA ALA B 132 3.286 23.232 −21.881 1.00 26.94 C ATOM 1339 CB ALA B 132 2.302 22.385 −22.757 1.00 24.90 C ATOM 1340 C ALA B 132 4.443 23.733 −22.737 1.00 26.64 C ATOM 1341 O ALA B 132 4.454 24.875 −23.193 1.00 26.99 O ATOM 1342 N ASN B 133 5.405 22.846 −22.933 1.00 27.01 N ATOM 1343 CA ASN B 133 6.506 23.033 −23.898 1.00 27.23 C ATOM 1344 CB ASN B 133 7.863 22.830 −23.177 1.00 28.41 C ATOM 1345 CG ASN B 133 8.211 24.006 −22.255 1.00 30.04 C ATOM 1346 OD1 ASN B 133 7.344 24.721 −21.806 1.00 31.04 O ATOM 1347 ND2 ASN B 133 9.489 24.210 −21.993 1.00 34.78 N ATOM 1348 C ASN B 133 6.293 22.000 −25.026 1.00 27.01 C ATOM 1349 O ASN B 133 6.084 20.793 −24.784 1.00 25.65 O ATOM 1350 N PHE B 134 6.295 22.469 −26.277 1.00 28.15 N ATOM 1351 CA PHE B 134 5.929 21.577 −27.349 1.00 29.30 C ATOM 1352 CB PHE B 134 4.400 21.283 −27.328 1.00 30.21 C ATOM 1353 CG PHE B 134 3.533 22.520 −27.414 1.00 32.57 C ATOM 1354 CD1 PHE B 134 3.094 23.009 −28.647 1.00 33.22 C ATOM 1355 CE1 PHE B 134 2.312 24.154 −28.704 1.00 32.79 C ATOM 1356 CZ PHE B 134 1.955 24.809 −27.541 1.00 33.90 C ATOM 1357 CE2 PHE B 134 2.401 24.324 −26.305 1.00 32.40 C ATOM 1358 CD2 PHE B 134 3.165 23.197 −26.257 1.00 31.50 C ATOM 1359 C PHE B 134 6.329 22.201 −28.682 1.00 29.84 C ATOM 1360 O PHE B 134 6.534 23.409 −28.792 1.00 30.16 O ATOM 1361 N SER B 135 6.419 21.375 −29.710 1.00 31.15 N ATOM 1362 CA SER B 135 6.679 21.941 −31.053 1.00 32.23 C ATOM 1363 CB SER B 135 7.628 21.052 −31.812 1.00 32.51 C ATOM 1364 OG SER B 135 7.036 19.812 −32.002 1.00 33.57 O ATOM 1365 C SER B 135 5.386 22.073 −31.827 1.00 33.12 C ATOM 1366 O SER B 135 4.420 21.371 −31.537 1.00 31.51 O ATOM 1367 N VAL B 136 5.389 22.959 −32.839 1.00 34.96 N ATOM 1368 CA VAL B 136 4.225 23.143 −33.685 1.00 36.92 C ATOM 1369 CB VAL B 136 3.385 24.440 −33.371 1.00 37.96 C ATOM 1370 CG1 VAL B 136 2.815 24.423 −31.922 1.00 37.33 C ATOM 1371 CG2 VAL B 136 4.185 25.652 −33.544 1.00 38.33 C ATOM 1372 C VAL B 136 4.701 23.143 −35.116 1.00 38.73 C ATOM 1373 O VAL B 136 5.834 23.563 −35.409 1.00 38.26 O ATOM 1374 N ILE B 137 3.882 22.554 −35.969 1.00 40.79 N ATOM 1375 CA ILE B 137 4.031 22.698 −37.411 1.00 44.55 C ATOM 1376 CB ILE B 137 4.633 21.429 −38.099 1.00 44.67 C ATOM 1377 CG1 ILE B 137 3.919 20.174 −37.651 1.00 45.11 C ATOM 1378 CD1 ILE B 137 4.421 18.930 −38.328 1.00 49.18 C ATOM 1379 CG2 ILE B 137 6.109 21.293 −37.822 1.00 47.14 C ATOM 1380 C ILE B 137 2.633 22.973 −37.940 1.00 45.83 C ATOM 1381 O ILE B 137 1.658 22.408 −37.420 1.00 46.23 O ATOM 1382 N PHE B 138 2.539 23.867 −38.932 1.00 48.16 N ATOM 1383 CA PHE B 138 1.279 24.178 −39.629 1.00 50.06 C ATOM 1384 CB PHE B 138 0.792 22.974 −40.474 1.00 51.11 C ATOM 1385 CG PHE B 138 1.852 22.411 −41.398 1.00 53.72 C ATOM 1386 CD1 PHE B 138 2.183 21.054 −41.358 1.00 57.35 C ATOM 1387 CE1 PHE B 138 3.189 20.518 −42.204 1.00 57.68 C ATOM 1388 CZ PHE B 138 3.865 21.353 −43.080 1.00 55.86 C ATOM 1389 CE2 PHE B 138 3.545 22.720 −43.124 1.00 57.45 C ATOM 1390 CD2 PHE B 138 2.543 23.242 −42.286 1.00 55.69 C ATOM 1391 C PHE B 138 0.210 24.607 −38.630 1.00 50.34 C ATOM 1392 O PHE B 138 −0.923 24.093 −38.663 1.00 50.82 O ATOM 1393 N ASP B 139 0.598 25.525 −37.741 1.00 50.41 N ATOM 1394 CA ASP B 139 −0.252 26.037 −36.637 1.00 50.56 C ATOM 1395 CB ASP B 139 −1.150 27.178 −37.125 1.00 52.14 C ATOM 1396 CG ASP B 139 −0.371 28.481 −37.289 1.00 54.55 C ATOM 1397 OD1 ASP B 139 0.301 28.897 −36.307 1.00 57.23 O ATOM 1398 OD2 ASP B 139 −0.409 29.066 −38.398 0.50 56.46 O ATOM 1399 C ASP B 139 −1.004 25.031 −35.770 1.00 49.51 C ATOM 1400 O ASP B 139 −2.110 25.289 −35.243 1.00 49.37 O ATOM 1401 N ARG B 140 −0.355 23.891 −35.580 1.00 47.68 N ATOM 1402 CA ARG B 140 −0.920 22.771 −34.875 1.00 46.64 C ATOM 1403 CB ARG B 140 −1.361 21.736 −35.917 1.00 47.18 C ATOM 1404 CG ARG B 140 −1.906 20.430 −35.365 1.00 50.69 C ATOM 1405 CD ARG B 140 −1.832 19.264 −36.415 1.00 52.62 C ATOM 1406 NE ARG B 140 −0.462 19.002 −36.903 1.00 62.39 N ATOM 1407 CZ ARG B 140 0.398 18.184 −36.289 1.00 65.34 C ATOM 1408 NH1 ARG B 140 0.013 17.558 −35.174 1.00 65.52 N ATOM 1409 NH2 ARG B 140 1.629 17.979 −36.783 1.00 64.58 N ATOM 1410 C ARG B 140 0.174 22.207 −33.955 1.00 43.25 C ATOM 1411 O ARG B 140 1.338 22.141 −34.342 1.00 41.78 O ATOM 1412 N LEU B 141 −0.196 21.798 −32.742 1.00 40.18 N ATOM 1413 CA LEU B 141 0.762 21.133 −31.854 1.00 38.38 C ATOM 1414 CB LEU B 141 0.160 20.825 −30.457 1.00 37.77 C ATOM 1415 CG LEU B 141 1.045 20.010 −29.474 1.00 36.52 C ATOM 1416 CD1 LEU B 141 0.754 20.416 −28.016 1.00 35.80 C ATOM 1417 CD2 LEU B 141 0.821 18.523 −29.680 1.00 30.24 C ATOM 1418 C LEU B 141 1.214 19.859 −32.553 1.00 38.09 C ATOM 1419 O LEU B 141 0.386 19.077 −33.023 1.00 37.31 O ATOM 1420 N GLU B 142 2.535 19.671 −32.607 1.00 37.00 N ATOM 1421 CA GLU B 142 3.161 18.538 −33.253 1.00 36.10 C ATOM 1422 CB GLU B 142 4.385 19.046 −34.050 1.00 36.59 C ATOM 1423 CG GLU B 142 5.078 17.967 −34.887 1.00 38.15 C ATOM 1424 CD GLU B 142 6.464 18.401 −35.444 1.00 40.42 C ATOM 1425 OE1 GLU B 142 6.918 17.751 −36.404 1.00 44.80 O ATOM 1426 OE2 GLU B 142 7.121 19.345 −34.931 1.00 44.67 O ATOM 1427 C GLU B 142 3.586 17.478 −32.219 1.00 33.59 C ATOM 1428 O GLU B 142 3.102 16.346 −32.228 1.00 32.76 O ATOM 1429 N THR B 143 4.496 17.869 −31.332 1.00 32.21 N ATOM 1430 CA THR B 143 5.113 16.979 −30.334 1.00 30.26 C ATOM 1431 CB THR B 143 6.590 16.671 −30.699 1.00 30.51 C ATOM 1432 OG1 THR B 143 6.584 15.914 −31.919 1.00 33.87 O ATOM 1433 CG2 THR B 143 7.249 15.807 −29.661 1.00 27.91 C ATOM 1434 C THR B 143 5.091 17.688 −28.988 1.00 28.93 C ATOM 1435 O THR B 143 5.617 18.800 −28.852 1.00 30.12 O ATOM 1436 N LEU B 144 4.487 17.032 −28.002 1.00 27.73 N ATOM 1437 CA LEU B 144 4.567 17.508 −26.616 1.00 26.43 C ATOM 1438 CB LEU B 144 3.431 16.875 −25.801 1.00 26.11 C ATOM 1439 CG LEU B 144 3.403 17.233 −24.313 1.00 24.22 C ATOM 1440 CD1 LEU B 144 3.063 18.671 −24.183 1.00 22.62 C ATOM 1441 CD2 LEU B 144 2.368 16.369 −23.592 1.00 25.40 C ATOM 1442 C LEU B 144 5.925 17.128 −26.008 1.00 26.12 C ATOM 1443 O LEU B 144 6.324 15.957 −26.032 1.00 26.26 O ATOM 1444 N ILE B 145 6.594 18.101 −25.407 1.00 26.39 N ATOM 1445 CA ILE B 145 7.767 17.789 −24.574 1.00 27.56 C ATOM 1446 CB ILE B 145 8.807 18.976 −24.557 1.00 27.90 C ATOM 1447 CG1 ILE B 145 9.241 19.389 −25.990 1.00 31.80 C ATOM 1448 CD1 ILE B 145 9.501 18.216 −26.807 1.00 32.94 C ATOM 1449 CG2 ILE B 145 10.021 18.674 −23.598 1.00 27.03 C ATOM 1450 C ILE B 145 7.278 17.493 −23.132 1.00 26.46 C ATOM 1451 O ILE B 145 7.527 16.432 −22.576 1.00 25.81 O ATOM 1452 N LEU B 146 6.530 18.428 −22.568 1.00 26.06 N ATOM 1453 CA LEU B 146 6.041 18.267 −21.202 1.00 26.05 C ATOM 1454 CB LEU B 146 7.173 18.571 −20.208 1.00 24.89 C ATOM 1455 CG LEU B 146 6.931 18.388 −18.678 1.00 26.17 C ATOM 1456 CD1 LEU B 146 6.582 16.951 −18.314 1.00 25.01 C ATOM 1457 CD2 LEU B 146 8.135 18.936 −17.871 1.00 27.73 C ATOM 1458 C LEU B 146 4.890 19.191 −20.970 1.00 24.78 C ATOM 1459 O LEU B 146 4.935 20.345 −21.394 1.00 26.29 O ATOM 1460 N LEU B 147 3.863 18.723 −20.243 1.00 24.66 N ATOM 1461 CA LEU B 147 2.797 19.643 −19.856 1.00 23.39 C ATOM 1462 CB LEU B 147 1.441 19.193 −20.441 1.00 23.05 C ATOM 1463 CG LEU B 147 0.225 20.095 −20.123 1.00 24.92 C ATOM 1464 CD1 LEU B 147 −0.772 19.974 −21.269 1.00 24.09 C ATOM 1465 CD2 LEU B 147 −0.444 19.655 −18.790 1.00 25.78 C ATOM 1466 C LEU B 147 2.752 19.524 −18.346 1.00 23.23 C ATOM 1467 O LEU B 147 2.810 18.426 −17.860 1.00 23.78 O ATOM 1468 N ARG B 148 2.610 20.634 −17.638 1.00 24.18 N ATOM 1469 CA ARG B 148 2.443 20.592 −16.171 1.00 25.22 C ATOM 1470 CB ARG B 148 3.744 20.991 −15.459 1.00 23.74 C ATOM 1471 CG ARG B 148 4.731 19.806 −15.393 1.00 24.24 C ATOM 1472 CD ARG B 148 6.127 20.136 −14.793 1.00 24.73 C ATOM 1473 NE ARG B 148 6.742 18.845 −14.478 1.00 26.57 N ATOM 1474 CZ ARG B 148 7.951 18.685 −13.915 1.00 27.32 C ATOM 1475 NH1 ARG B 148 8.675 19.731 −13.582 1.00 27.44 N ATOM 1476 NH2 ARG B 148 8.397 17.473 −13.660 1.00 26.04 N ATOM 1477 C ARG B 148 1.327 21.521 −15.719 1.00 25.27 C ATOM 1478 O ARG B 148 1.089 22.525 −16.348 1.00 26.12 O ATOM 1479 N ALA B 149 0.732 21.216 −14.560 1.00 27.06 N ATOM 1480 CA ALA B 149 −0.365 22.016 −14.035 1.00 26.93 C ATOM 1481 CB ALA B 149 −1.557 21.094 −13.669 1.00 25.27 C ATOM 1482 C ALA B 149 0.140 22.794 −12.817 1.00 27.42 C ATOM 1483 O ALA B 149 0.668 22.201 −11.875 1.00 26.74 O ATOM 1484 N PHE B 150 −0.011 24.108 −12.845 1.00 28.46 N ATOM 1485 CA PHE B 150 0.541 24.969 −11.779 1.00 31.48 C ATOM 1486 CB PHE B 150 1.476 26.039 −12.378 1.00 30.90 C ATOM 1487 CG PHE B 150 2.683 25.461 −13.023 1.00 31.68 C ATOM 1488 CD1 PHE B 150 2.642 25.053 −14.369 1.00 31.92 C ATOM 1489 CE1 PHE B 150 3.777 24.515 −14.992 1.00 31.87 C ATOM 1490 CZ PHE B 150 4.963 24.346 −14.254 1.00 31.46 C ATOM 1491 CE2 PHE B 150 4.996 24.724 −12.907 1.00 35.16 C ATOM 1492 CD2 PHE B 150 3.864 25.283 −12.294 1.00 32.53 C ATOM 1493 C PHE B 150 −0.523 25.681 −10.979 1.00 32.52 C ATOM 1494 O PHE B 150 −1.468 26.207 −11.536 1.00 33.40 O ATOM 1495 N THR B 151 −0.344 25.709 −9.671 1.00 34.98 N ATOM 1496 CA THR B 151 −1.181 26.568 −8.824 1.00 36.44 C ATOM 1497 CB THR B 151 −1.101 26.201 −7.334 1.00 34.71 C ATOM 1498 OG1 THR B 151 0.205 26.513 −6.846 1.00 34.94 O ATOM 1499 CG2 THR B 151 −1.306 24.732 −7.167 1.00 35.77 C ATOM 1500 C THR B 151 −0.693 27.978 −8.994 1.00 38.85 C ATOM 1501 O THR B 151 0.368 28.212 −9.580 1.00 38.32 O ATOM 1502 N GLU B 152 −1.473 28.927 −8.484 1.00 42.00 N ATOM 1503 CA GLU B 152 −1.139 30.341 −8.597 1.00 44.30 C ATOM 1504 CB GLU B 152 −2.230 31.168 −7.951 1.00 45.82 C ATOM 1505 CG GLU B 152 −3.314 31.579 −8.878 1.00 48.98 C ATOM 1506 CD GLU B 152 −4.434 32.252 −8.130 1.00 51.85 C ATOM 1507 OE1 GLU B 152 −4.303 32.390 −6.903 1.00 52.93 O ATOM 1508 OE2 GLU B 152 −5.445 32.619 −8.752 1.00 54.82 O ATOM 1509 C GLU B 152 0.186 30.680 −7.952 1.00 44.72 C ATOM 1510 O GLU B 152 0.841 31.641 −8.347 1.00 45.93 O ATOM 1511 N GLU B 153 0.567 29.881 −6.961 1.00 45.12 N ATOM 1512 CA GLU B 153 1.817 30.034 −6.242 1.00 45.17 C ATOM 1513 CB GLU B 153 1.669 29.415 −4.855 1.00 46.29 C ATOM 1514 CG GLU B 153 0.191 29.411 −4.346 1.00 51.61 C ATOM 1515 CD GLU B 153 −0.230 30.758 −3.760 1.00 58.99 C ATOM 1516 OE1 GLU B 153 0.679 31.558 −3.403 1.00 61.45 O ATOM 1517 OE2 GLU B 153 −1.462 31.023 −3.653 1.00 61.26 O ATOM 1518 C GLU B 153 2.979 29.367 −6.992 1.00 44.04 C ATOM 1519 O GLU B 153 4.143 29.417 −6.535 1.00 43.59 O ATOM 1520 N GLY B 154 2.675 28.728 −8.131 1.00 41.32 N ATOM 1521 CA GLY B 154 3.724 28.130 −8.934 1.00 37.57 C ATOM 1522 C GLY B 154 4.036 26.702 −8.539 1.00 36.03 C ATOM 1523 O GLY B 154 5.054 26.151 −8.942 1.00 35.84 O ATOM 1524 N ALA B 155 3.182 26.072 −7.740 1.00 33.82 N ATOM 1525 CA ALA B 155 3.465 24.653 −7.375 1.00 32.57 C ATOM 1526 CB ALA B 155 2.925 24.332 −6.013 1.00 32.09 C ATOM 1527 C ALA B 155 2.865 23.701 −8.439 1.00 31.21 C ATOM 1528 O ALA B 155 1.803 24.000 −8.987 1.00 32.00 O ATOM 1529 N ILE B 156 3.544 22.579 −8.704 1.00 30.83 N ATOM 1530 CA ILE B 156 3.093 21.593 −9.732 1.00 29.85 C ATOM 1531 CB ILE B 156 4.257 20.837 −10.408 1.00 29.30 C ATOM 1532 CG1 ILE B 156 5.185 21.822 −11.123 1.00 30.27 C ATOM 1533 CD1 ILE B 156 6.673 21.342 −11.257 1.00 24.87 C ATOM 1534 CG2 ILE B 156 3.732 19.766 −11.402 1.00 30.34 C ATOM 1535 C ILE B 156 2.168 20.588 −9.094 1.00 29.67 C ATOM 1536 O ILE B 156 2.477 20.002 −8.031 1.00 28.50 O ATOM 1537 N VAL B 157 0.999 20.401 −9.710 1.00 28.52 N ATOM 1538 CA VAL B 157 0.035 19.457 −9.155 1.00 29.03 C ATOM 1539 CB VAL B 157 −1.210 20.203 −8.605 1.00 28.67 C ATOM 1540 CG1 VAL B 157 −0.805 21.289 −7.551 1.00 29.30 C ATOM 1541 CG2 VAL B 157 −2.015 20.844 −9.723 1.00 28.06 C ATOM 1542 C VAL B 157 −0.395 18.326 −10.108 1.00 28.97 C ATOM 1543 O VAL B 157 −1.082 17.409 −9.684 1.00 29.30 O ATOM 1544 N GLY B 158 0.037 18.405 −11.383 1.00 28.12 N ATOM 1545 CA GLY B 158 −0.251 17.387 −12.380 1.00 27.35 C ATOM 1546 C GLY B 158 0.715 17.552 −13.554 1.00 26.84 C ATOM 1547 O GLY B 158 1.297 18.625 −13.730 1.00 25.99 O ATOM 1548 N GLU B 159 0.931 16.466 −14.290 1.00 27.11 N ATOM 1549 CA GLU B 159 1.705 16.564 −15.543 1.00 28.08 C ATOM 1550 CB GLU B 159 3.218 16.605 −15.275 1.00 27.46 C ATOM 1551 CG GLU B 159 3.852 15.305 −15.222 1.00 30.14 C ATOM 1552 CD GLU B 159 5.361 15.328 −14.806 1.00 30.39 C ATOM 1553 OE1 GLU B 159 5.908 14.231 −14.822 1.00 33.34 O ATOM 1554 OE2 GLU B 159 5.948 16.375 −14.425 1.00 32.04 O ATOM 1555 C GLU B 159 1.361 15.466 −16.559 1.00 27.20 C ATOM 1556 O GLU B 159 0.757 14.462 −16.226 1.00 27.15 O ATOM 1557 N ILE B 160 1.694 15.741 −17.823 1.00 27.13 N ATOM 1558 CA ILE B 160 1.587 14.755 −18.883 1.00 27.82 C ATOM 1559 CB ILE B 160 0.478 15.135 −19.891 1.00 28.16 C ATOM 1560 CG1 ILE B 160 −0.874 15.160 −19.168 1.00 26.78 C ATOM 1561 CD1 ILE B 160 −1.939 15.991 −19.916 1.00 27.37 C ATOM 1562 CG2 ILE B 160 0.390 14.107 −21.028 1.00 26.30 C ATOM 1563 C ILE B 160 2.983 14.739 −19.516 1.00 27.85 C ATOM 1564 O ILE B 160 3.518 15.785 −19.859 1.00 26.40 O ATOM 1565 N SER B 161 3.589 13.569 −19.559 1.00 28.39 N ATOM 1566 CA SER B 161 4.891 13.446 −20.194 1.00 30.42 C ATOM 1567 CB SER B 161 6.019 13.335 −19.158 1.00 29.53 C ATOM 1568 OG SER B 161 5.705 12.327 −18.230 1.00 36.43 O ATOM 1569 C SER B 161 4.891 12.216 −21.092 1.00 30.22 C ATOM 1570 O SER B 161 4.212 11.225 −20.815 1.00 29.26 O ATOM 1571 N PRO B 162 5.653 12.292 −22.198 1.00 31.73 N ATOM 1572 CA PRO B 162 5.830 11.168 −23.108 1.00 33.40 C ATOM 1573 CB PRO B 162 6.620 11.787 −24.278 1.00 33.86 C ATOM 1574 CG PRO B 162 6.244 13.258 −24.215 1.00 34.21 C ATOM 1575 CD PRO B 162 6.298 13.505 −22.706 1.00 31.95 C ATOM 1576 C PRO B 162 6.604 10.061 −22.459 1.00 34.81 C ATOM 1577 O PRO B 162 7.528 10.343 −21.712 1.00 35.86 O ATOM 1578 N LEU B 163 6.202 8.819 −22.718 1.00 36.44 N ATOM 1579 CA LEU B 163 6.904 7.630 −22.250 1.00 40.34 C ATOM 1580 CB LEU B 163 5.974 6.431 −22.203 1.00 40.13 C ATOM 1581 CG LEU B 163 4.712 6.559 −21.340 1.00 42.63 C ATOM 1582 CD1 LEU B 163 3.831 5.395 −21.657 1.00 43.88 C ATOM 1583 CD2 LEU B 163 5.133 6.493 −19.879 1.00 46.62 C ATOM 1584 C LEU B 163 8.064 7.304 −23.202 1.00 42.84 C ATOM 1585 O LEU B 163 7.864 7.201 −24.420 1.00 42.13 O ATOM 1586 N PRO B 164 9.269 7.100 −22.634 1.00 45.85 N ATOM 1587 CA PRO B 164 10.548 6.943 −23.375 1.00 47.72 C ATOM 1588 CB PRO B 164 11.519 6.449 −22.297 1.00 47.76 C ATOM 1589 CG PRO B 164 10.921 6.900 −21.004 1.00 48.29 C ATOM 1590 CD PRO B 164 9.429 6.889 −21.184 1.00 45.64 C ATOM 1591 C PRO B 164 10.428 5.855 −24.422 1.00 49.11 C ATOM 1592 O PRO B 164 10.863 6.022 −25.593 1.00 50.40 O ATOM 1593 N SER B 165 9.806 4.760 −23.985 1.00 50.00 N ATOM 1594 CA SER B 165 9.705 3.526 −24.738 1.00 50.56 C ATOM 1595 CB SER B 165 9.385 2.399 −23.779 1.00 50.90 C ATOM 1596 OG SER B 165 8.001 2.416 −23.479 1.00 51.74 O ATOM 1597 C SER B 165 8.651 3.547 −25.847 1.00 50.55 C ATOM 1598 O SER B 165 8.291 2.493 −26.384 1.00 51.11 O ATOM 1599 N PHE B 166 8.129 4.720 −26.188 1.00 49.55 N ATOM 1600 CA PHE B 166 7.297 4.812 −27.372 1.00 48.18 C ATOM 1601 CB PHE B 166 5.913 5.364 −27.074 1.00 48.72 C ATOM 1602 CG PHE B 166 4.950 4.328 −26.515 1.00 50.30 C ATOM 1603 CD1 PHE B 166 3.954 3.777 −27.318 1.00 52.19 C ATOM 1604 CE1 PHE B 166 3.045 2.834 −26.811 1.00 53.48 C ATOM 1605 CZ PHE B 166 3.139 2.431 −25.480 1.00 52.84 C ATOM 1606 CE2 PHE B 166 4.123 2.993 −24.657 1.00 51.29 C ATOM 1607 CD2 PHE B 166 5.020 3.928 −25.178 1.00 51.96 C ATOM 1608 C PHE B 166 8.029 5.623 −28.425 1.00 47.26 C ATOM 1609 O PHE B 166 8.808 6.516 −28.089 1.00 46.10 O ATOM 1610 N PRO B 167 7.814 5.284 −29.715 1.00 46.43 N ATOM 1611 CA PRO B 167 8.561 6.016 −30.748 1.00 45.41 C ATOM 1612 CB PRO B 167 8.412 5.128 −31.984 1.00 45.90 C ATOM 1613 CG PRO B 167 7.006 4.463 −31.803 1.00 46.91 C ATOM 1614 CD PRO B 167 6.894 4.265 −30.275 1.00 45.94 C ATOM 1615 C PRO B 167 7.970 7.416 −30.995 1.00 44.77 C ATOM 1616 O PRO B 167 8.647 8.278 −31.586 1.00 45.20 O ATOM 1617 N GLY B 168 6.729 7.654 −30.545 1.00 42.28 N ATOM 1618 CA GLY B 168 6.100 8.961 −30.762 1.00 38.80 C ATOM 1619 C GLY B 168 4.652 9.017 −30.289 1.00 36.63 C ATOM 1620 O GLY B 168 4.144 8.066 −29.741 1.00 35.45 O ATOM 1621 N HIS B 169 3.998 10.148 −30.497 1.00 35.02 N ATOM 1622 CA HIS B 169 2.574 10.257 −30.146 1.00 34.10 C ATOM 1623 CB HIS B 169 2.430 10.713 −28.678 1.00 32.49 C ATOM 1624 CG HIS B 169 3.112 12.018 −28.401 1.00 30.56 C ATOM 1625 ND1 HIS B 169 4.370 12.092 −27.835 1.00 28.47 N ATOM 1626 CE1 HIS B 169 4.745 13.365 −27.779 1.00 27.07 C ATOM 1627 NE2 HIS B 169 3.758 14.116 −28.244 1.00 26.23 N ATOM 1628 CD2 HIS B 169 2.735 13.298 −28.656 1.00 26.61 C ATOM 1629 C HIS B 169 1.995 11.315 −31.050 1.00 33.97 C ATOM 1630 O HIS B 169 2.737 12.034 −31.732 1.00 34.14 O ATOM 1631 N THR B 170 0.672 11.472 −31.016 1.00 33.87 N ATOM 1632 CA THR B 170 0.032 12.498 −31.835 1.00 34.49 C ATOM 1633 CB THR B 170 −0.951 11.856 −32.841 1.00 35.29 C ATOM 1634 OG1 THR B 170 −2.138 11.488 −32.134 1.00 38.23 O ATOM 1635 CG2 THR B 170 −0.340 10.570 −33.492 1.00 34.81 C ATOM 1636 C THR B 170 −0.744 13.511 −30.985 1.00 33.67 C ATOM 1637 O THR B 170 −0.985 13.293 −29.780 1.00 32.49 O ATOM 1638 N ILE B 171 −1.123 14.609 −31.616 1.00 32.84 N ATOM 1639 CA ILE B 171 −2.019 15.577 −30.986 1.00 33.37 C ATOM 1640 CB ILE B 171 −2.458 16.719 −31.968 1.00 33.99 C ATOM 1641 CG1 ILE B 171 −3.157 17.840 −31.181 1.00 33.44 C ATOM 1642 CD1 ILE B 171 −3.493 19.085 −31.943 1.00 32.95 C ATOM 1643 CG2 ILE B 171 −3.320 16.164 −33.168 1.00 34.46 C ATOM 1644 C ILE B 171 −3.248 14.895 −30.379 1.00 32.88 C ATOM 1645 O ILE B 171 −3.825 15.377 −29.383 1.00 32.45 O ATOM 1646 N GLU B 172 −3.673 13.775 −30.957 1.00 32.23 N ATOM 1647 CA GLU B 172 −4.881 13.160 −30.431 1.00 32.31 C ATOM 1648 CB GLU B 172 −5.553 12.253 −31.434 1.00 33.12 C ATOM 1649 CG GLU B 172 −5.931 12.970 −32.772 1.00 38.08 C ATOM 1650 CD GLU B 172 −7.034 14.096 −32.699 1.00 42.24 C ATOM 1651 OE1 GLU B 172 −7.962 14.120 −31.828 1.00 38.52 O ATOM 1652 OE2 GLU B 172 −6.976 14.957 −33.605 1.00 44.85 O ATOM 1653 C GLU B 172 −4.575 12.439 −29.117 1.00 31.00 C ATOM 1654 O GLU B 172 −5.427 12.354 −28.221 1.00 29.39 O ATOM 1655 N ASP B 173 −3.364 11.925 −28.994 1.00 29.29 N ATOM 1656 CA ASP B 173 −2.957 11.312 −27.728 1.00 28.81 C ATOM 1657 CB ASP B 173 −1.597 10.654 −27.827 1.00 28.63 C ATOM 1658 CG ASP B 173 −1.591 9.462 −28.738 1.00 30.62 C ATOM 1659 OD1 ASP B 173 −2.461 8.581 −28.601 1.00 29.41 O ATOM 1660 OD2 ASP B 173 −0.660 9.403 −29.549 1.00 33.78 O ATOM 1661 C ASP B 173 −2.880 12.394 −26.684 1.00 27.22 C ATOM 1662 O ASP B 173 −3.223 12.156 −25.524 1.00 29.09 O ATOM 1663 N VAL B 174 −2.390 13.553 −27.090 1.00 26.94 N ATOM 1664 CA VAL B 174 −2.212 14.683 −26.195 1.00 27.05 C ATOM 1665 CB VAL B 174 −1.431 15.823 −26.851 1.00 27.03 C ATOM 1666 CG1 VAL B 174 −1.453 17.050 −25.954 1.00 27.31 C ATOM 1667 CG2 VAL B 174 0.046 15.419 −27.117 1.00 28.19 C ATOM 1668 C VAL B 174 −3.594 15.143 −25.715 1.00 27.12 C ATOM 1669 O VAL B 174 −3.845 15.343 −24.519 1.00 24.96 O ATOM 1670 N LYS B 175 −4.523 15.267 −26.650 1.00 25.83 N ATOM 1671 CA LYS B 175 −5.874 15.649 −26.236 1.00 26.01 C ATOM 1672 CB LYS B 175 −6.749 15.904 −27.458 1.00 26.17 C ATOM 1673 CG LYS B 175 −6.739 17.324 −27.834 1.00 30.35 C ATOM 1674 CD LYS B 175 −6.102 17.480 −29.128 1.00 38.18 C ATOM 1675 CE LYS B 175 −7.142 17.623 −30.145 1.00 37.08 C ATOM 1676 NZ LYS B 175 −7.550 19.051 −30.104 1.00 42.61 N ATOM 1677 C LYS B 175 −6.542 14.661 −25.292 1.00 25.19 C ATOM 1678 O LYS B 175 −7.220 15.074 −24.345 1.00 26.66 O ATOM 1679 N ASN B 176 −6.414 13.358 −25.543 1.00 23.95 N ATOM 1680 CA ASN B 176 −6.974 12.363 −24.636 1.00 23.14 C ATOM 1681 CB ASN B 176 −6.557 10.938 −25.058 1.00 24.94 C ATOM 1682 CG ASN B 176 −7.206 10.470 −26.375 1.00 26.18 C ATOM 1683 OD1 ASN B 176 −8.233 11.005 −26.802 1.00 29.88 O ATOM 1684 ND2 ASN B 176 −6.606 9.452 −26.994 1.00 29.47 N ATOM 1685 C ASN B 176 −6.446 12.572 −23.184 1.00 23.69 C ATOM 1686 O ASN B 176 −7.234 12.592 −22.206 1.00 22.87 O ATOM 1687 N ALA B 177 −5.119 12.682 −23.064 1.00 22.91 N ATOM 1688 CA ALA B 177 −4.442 12.879 −21.767 1.00 23.94 C ATOM 1689 CB ALA B 177 −2.902 12.772 −21.924 1.00 25.51 C ATOM 1690 C ALA B 177 −4.806 14.179 −21.085 1.00 22.98 C ATOM 1691 O ALA B 177 −4.986 14.189 −19.863 1.00 23.61 O ATOM 1692 N ILE B 178 −4.923 15.267 −21.832 1.00 23.01 N ATOM 1693 CA ILE B 178 −5.391 16.554 −21.279 1.00 24.94 C ATOM 1694 CB ILE B 178 −5.277 17.726 −22.315 1.00 23.97 C ATOM 1695 CG1 ILE B 178 −3.783 18.066 −22.574 1.00 25.98 C ATOM 1696 CD1 ILE B 178 −3.585 19.202 −23.573 1.00 27.04 C ATOM 1697 CG2 ILE B 178 −5.957 18.997 −21.792 1.00 24.69 C ATOM 1698 C ILE B 178 −6.823 16.495 −20.696 1.00 25.65 C ATOM 1699 O ILE B 178 −7.076 16.967 −19.583 1.00 26.20 O ATOM 1700 N GLY B 179 −7.741 15.872 −21.421 1.00 24.86 N ATOM 1701 CA GLY B 179 −9.067 15.626 −20.868 1.00 25.64 C ATOM 1702 C GLY B 179 −9.022 14.827 −19.572 1.00 26.53 C ATOM 1703 O GLY B 179 −9.759 15.131 −18.648 1.00 27.05 O ATOM 1704 N VAL B 180 −8.181 13.778 −19.488 1.00 27.64 N ATOM 1705 CA VAL B 180 −8.096 12.989 −18.230 1.00 26.49 C ATOM 1706 CB VAL B 180 −7.242 11.709 −18.330 1.00 27.34 C ATOM 1707 CG1 VAL B 180 −6.987 11.099 −16.920 1.00 27.00 C ATOM 1708 CG2 VAL B 180 −7.918 10.674 −19.251 1.00 26.03 C ATOM 1709 C VAL B 180 −7.571 13.854 −17.088 1.00 26.25 C ATOM 1710 O VAL B 180 −8.148 13.836 −15.964 1.00 26.42 O ATOM 1711 N LEU B 181 −6.511 14.607 −17.353 1.00 25.79 N ATOM 1712 CA LEU B 181 −5.949 15.522 −16.345 1.00 26.04 C ATOM 1713 CB LEU B 181 −4.587 16.119 −16.807 1.00 26.20 C ATOM 1714 CG LEU B 181 −3.936 17.200 −15.923 1.00 26.41 C ATOM 1715 CD1 LEU B 181 −3.517 16.667 −14.581 1.00 22.34 C ATOM 1716 CD2 LEU B 181 −2.717 17.769 −16.620 1.00 24.16 C ATOM 1717 C LEU B 181 −6.890 16.637 −15.881 1.00 26.68 C ATOM 1718 O LEU B 181 −7.083 16.841 −14.654 1.00 26.04 O ATOM 1719 N ILE B 182 −7.471 17.363 −16.835 1.00 26.09 N ATOM 1720 CA ILE B 182 −8.388 18.436 −16.532 1.00 25.74 C ATOM 1721 CB ILE B 182 −8.861 19.141 −17.805 1.00 26.51 C ATOM 1722 CG1 ILE B 182 −7.723 19.973 −18.396 1.00 24.82 C ATOM 1723 CD1 ILE B 182 −8.143 20.834 −19.674 1.00 25.81 C ATOM 1724 CG2 ILE B 182 −10.124 20.002 −17.515 1.00 27.97 C ATOM 1725 C ILE B 182 −9.608 17.916 −15.775 1.00 26.63 C ATOM 1726 O ILE B 182 −10.110 18.623 −14.867 1.00 26.56 O ATOM 1727 N GLY B 183 −10.084 16.717 −16.143 1.00 25.84 N ATOM 1728 CA GLY B 183 −11.280 16.150 −15.538 1.00 26.48 C ATOM 1729 C GLY B 183 −10.999 15.788 −14.062 1.00 26.93 C ATOM 1730 O GLY B 183 −11.881 15.926 −13.212 1.00 25.70 O ATOM 1731 N GLY B 184 −9.780 15.311 −13.765 1.00 24.71 N ATOM 1732 CA GLY B 184 −9.412 14.978 −12.383 1.00 27.81 C ATOM 1733 C GLY B 184 −9.317 16.235 −11.536 1.00 27.95 C ATOM 1734 O GLY B 184 −9.831 16.263 −10.411 1.00 29.12 O ATOM 1735 N LEU B 185 −8.698 17.278 −12.075 1.00 27.43 N ATOM 1736 CA LEU B 185 −8.556 18.574 −11.373 1.00 26.86 C ATOM 1737 CB LEU B 185 −7.718 19.529 −12.199 1.00 26.76 C ATOM 1738 CG LEU B 185 −6.203 19.174 −12.300 1.00 25.88 C ATOM 1739 CD1 LEU B 185 −5.629 20.023 −13.351 1.00 24.14 C ATOM 1740 CD2 LEU B 185 −5.470 19.340 −10.922 1.00 24.41 C ATOM 1741 C LEU B 185 −9.938 19.230 −11.118 1.00 28.13 C ATOM 1742 O LEU B 185 −10.205 19.698 −10.025 1.00 27.27 O ATOM 1743 N GLU B 186 −10.779 19.302 −12.148 1.00 26.45 N ATOM 1744 CA GLU B 186 −12.176 19.722 −12.017 1.00 28.86 C ATOM 1745 CB GLU B 186 −12.913 19.596 −13.378 1.00 28.42 C ATOM 1746 CG GLU B 186 −12.605 20.641 −14.405 1.00 31.60 C ATOM 1747 CD GLU B 186 −13.303 20.308 −15.787 1.00 33.01 C ATOM 1748 OE1 GLU B 186 −13.747 19.131 −16.049 1.00 34.53 O ATOM 1749 OE2 GLU B 186 −13.393 21.253 −16.571 1.00 35.62 O ATOM 1750 C GLU B 186 −12.918 18.895 −10.986 1.00 28.14 C ATOM 1751 O GLU B 186 −13.594 19.470 −10.152 1.00 29.83 O ATOM 1752 N TRP B 187 −12.839 17.557 −11.049 1.00 27.79 N ATOM 1753 CA TRP B 187 −13.520 16.713 −10.106 1.00 29.99 C ATOM 1754 CB TRP B 187 −13.187 15.237 −10.335 1.00 30.68 C ATOM 1755 CG TRP B 187 −13.585 14.307 −9.227 1.00 34.71 C ATOM 1756 CD1 TRP B 187 −12.794 13.848 −8.167 1.00 35.56 C ATOM 1757 NE1 TRP B 187 −13.496 12.989 −7.373 1.00 36.67 N ATOM 1758 CE2 TRP B 187 −14.761 12.866 −7.899 1.00 38.56 C ATOM 1759 CD2 TRP B 187 −14.847 13.686 −9.060 1.00 35.87 C ATOM 1760 CE3 TRP B 187 −16.049 13.746 −9.774 1.00 34.89 C ATOM 1761 CZ3 TRP B 187 −17.098 13.013 −9.333 1.00 37.19 C ATOM 1762 CH2 TRP B 187 −16.998 12.205 −8.162 1.00 37.23 C ATOM 1763 CZ2 TRP B 187 −15.835 12.128 −7.435 1.00 38.41 C ATOM 1764 C TRP B 187 −13.187 17.105 −8.646 1.00 29.34 C ATOM 1765 O TRP B 187 −14.051 16.999 −7.782 1.00 26.13 O ATOM 1766 N ASN B 188 −11.933 17.528 −8.418 1.00 29.25 N ATOM 1767 CA ASN B 188 −11.426 18.015 −7.112 1.00 30.10 C ATOM 1768 CB ASN B 188 −9.922 17.678 −6.960 1.00 30.98 C ATOM 1769 CG ASN B 188 −9.691 16.346 −6.270 1.00 28.83 C ATOM 1770 OD1 ASN B 188 −10.634 15.706 −5.865 1.00 30.25 O ATOM 1771 ND2 ASN B 188 −8.427 15.909 −6.166 1.00 27.24 N ATOM 1772 C ASN B 188 −11.645 19.483 −6.856 1.00 30.32 C ATOM 1773 O ASN B 188 −10.987 20.074 −6.005 1.00 31.38 O ATOM 1774 N ASP B 189 −12.578 20.083 −7.576 1.00 31.64 N ATOM 1775 CA ASP B 189 −12.989 21.492 −7.404 1.00 31.66 C ATOM 1776 CB ASP B 189 −13.739 21.693 −6.056 1.00 33.12 C ATOM 1777 CG ASP B 189 −15.040 20.898 −6.016 1.00 37.29 C ATOM 1778 OD1 ASP B 189 −15.825 21.100 −6.970 1.00 38.57 O ATOM 1779 OD2 ASP B 189 −15.261 20.060 −5.084 1.00 40.54 O ATOM 1780 C ASP B 189 −11.916 22.524 −7.602 1.00 32.43 C ATOM 1781 O ASP B 189 −11.978 23.619 −7.028 1.00 30.55 O ATOM 1782 N ASN B 190 −10.930 22.197 −8.443 1.00 30.63 N ATOM 1783 CA ASN B 190 −10.001 23.204 −8.912 1.00 30.98 C ATOM 1784 CB ASN B 190 −8.642 22.559 −9.244 1.00 29.41 C ATOM 1785 CG ASN B 190 −8.039 21.837 −8.058 1.00 27.80 C ATOM 1786 OD1 ASN B 190 −7.559 22.467 −7.100 1.00 28.21 O ATOM 1787 ND2 ASN B 190 −8.069 20.507 −8.096 1.00 24.72 N ATOM 1788 C ASN B 190 −10.590 23.894 −10.133 1.00 31.62 C ATOM 1789 O ASN B 190 −11.320 23.270 −10.893 1.00 31.86 O ATOM 1790 N THR B 191 −10.304 25.184 −10.298 1.00 32.87 N ATOM 1791 CA THR B 191 −10.634 25.916 −11.509 1.00 34.75 C ATOM 1792 CB THR B 191 −10.945 27.380 −11.169 1.00 35.55 C ATOM 1793 OG1 THR B 191 −12.062 27.415 −10.261 1.00 37.47 O ATOM 1794 CG2 THR B 191 −11.328 28.148 −12.411 1.00 37.42 C ATOM 1795 C THR B 191 −9.437 25.837 −12.451 1.00 34.83 C ATOM 1796 O THR B 191 −8.304 26.214 −12.070 1.00 35.55 O ATOM 1797 N VAL B 192 −9.681 25.329 −13.661 1.00 34.58 N ATOM 1798 CA VAL B 192 −8.604 25.019 −14.605 1.00 34.33 C ATOM 1799 CB VAL B 192 −8.616 23.526 −15.076 1.00 33.53 C ATOM 1800 CG1 VAL B 192 −7.387 23.231 −16.021 1.00 34.55 C ATOM 1801 CG2 VAL B 192 −8.565 22.595 −13.908 1.00 31.05 C ATOM 1802 C VAL B 192 −8.607 25.959 −15.788 1.00 35.32 C ATOM 1803 O VAL B 192 −9.593 26.041 −16.515 1.00 35.56 O ATOM 1804 N ARG B 193 −7.495 26.665 −15.987 1.00 35.84 N ATOM 1805 CA ARG B 193 −7.252 27.415 −17.216 1.00 37.58 C ATOM 1806 CB ARG B 193 −6.868 28.876 −16.900 1.00 37.82 C ATOM 1807 CG ARG B 193 −8.073 29.733 −16.543 1.00 42.79 C ATOM 1808 CD ARG B 193 −7.707 31.011 −15.825 1.00 50.50 C ATOM 1809 NE ARG B 193 −8.639 31.231 −14.712 1.00 55.68 N ATOM 1810 CZ ARG B 193 −8.545 30.633 −13.517 1.00 58.91 C ATOM 1811 NH1 ARG B 193 −7.546 29.763 −13.241 1.00 59.58 N ATOM 1812 NH2 ARG B 193 −9.454 30.908 −12.589 1.00 59.65 N ATOM 1813 C ARG B 193 −6.111 26.775 −18.010 1.00 37.54 C ATOM 1814 O ARG B 193 −5.287 26.058 −17.449 1.00 36.53 O ATOM 1815 N VAL B 194 −6.055 27.093 −19.306 1.00 37.96 N ATOM 1816 CA VAL B 194 −5.076 26.501 −20.232 1.00 37.55 C ATOM 1817 CB VAL B 194 −5.834 25.611 −21.268 1.00 38.83 C ATOM 1818 CG1 VAL B 194 −5.025 25.322 −22.493 1.00 40.07 C ATOM 1819 CG2 VAL B 194 −6.213 24.302 −20.615 1.00 35.70 C ATOM 1820 C VAL B 194 −4.301 27.662 −20.840 1.00 37.68 C ATOM 1821 O VAL B 194 −4.886 28.739 −21.085 1.00 36.58 O ATOM 1822 N SER B 195 −2.984 27.496 −21.020 1.00 36.31 N ATOM 1823 CA SER B 195 −2.171 28.555 −21.584 1.00 35.49 C ATOM 1824 CB SER B 195 −0.710 28.091 −21.710 1.00 35.57 C ATOM 1825 OG SER B 195 −0.564 27.142 −22.752 1.00 33.21 O ATOM 1826 C SER B 195 −2.770 28.982 −22.950 1.00 36.06 C ATOM 1827 O SER B 195 −3.429 28.171 −23.634 1.00 34.56 O ATOM 1828 N LYS B 196 −2.597 30.252 −23.306 1.00 36.20 N ATOM 1829 CA LYS B 196 −3.116 30.760 −24.576 1.00 37.88 C ATOM 1830 CB LYS B 196 −2.919 32.264 −24.713 1.00 38.69 C ATOM 1831 CG LYS B 196 −3.804 33.084 −23.759 1.00 43.56 C ATOM 1832 CD LYS B 196 −3.659 34.583 −24.100 1.00 49.67 C ATOM 1833 CE LYS B 196 −4.059 35.504 −22.919 1.00 52.45 C ATOM 1834 NZ LYS B 196 −2.985 35.632 −21.851 1.00 53.35 N ATOM 1835 C LYS B 196 −2.448 30.060 −25.745 1.00 37.09 C ATOM 1836 O LYS B 196 −3.068 29.898 −26.784 1.00 37.20 O ATOM 1837 N THR B 197 −1.189 29.652 −25.576 1.00 36.42 N ATOM 1838 CA THR B 197 −0.530 28.848 −26.612 1.00 36.69 C ATOM 1839 CB THR B 197 0.992 28.707 −26.426 1.00 36.21 C ATOM 1840 OG1 THR B 197 1.260 28.069 −25.162 1.00 38.36 O ATOM 1841 CG2 THR B 197 1.678 30.046 −26.531 1.00 38.13 C ATOM 1842 C THR B 197 −1.122 27.451 −26.718 1.00 35.35 C ATOM 1843 O THR B 197 −1.297 26.953 −27.793 1.00 35.92 O ATOM 1844 N LEU B 198 −1.418 26.809 −25.601 1.00 36.53 N ATOM 1845 CA LEU B 198 −2.068 25.516 −25.657 1.00 36.92 C ATOM 1846 CB LEU B 198 −2.180 24.876 −24.275 1.00 36.99 C ATOM 1847 CG LEU B 198 −1.098 23.952 −23.729 1.00 33.23 C ATOM 1848 CD1 LEU B 198 −1.449 23.661 −22.274 1.00 33.04 C ATOM 1849 CD2 LEU B 198 −1.072 22.672 −24.603 1.00 29.08 C ATOM 1850 C LEU B 198 −3.467 25.655 −26.256 1.00 39.11 C ATOM 1851 O LEU B 198 −3.850 24.850 −27.092 1.00 38.44 O ATOM 1852 N GLN B 199 −4.252 26.646 −25.830 1.00 41.80 N ATOM 1853 CA GLN B 199 −5.572 26.806 −26.478 1.00 45.46 C ATOM 1854 CB GLN B 199 −6.537 27.763 −25.752 1.00 45.75 C ATOM 1855 CG GLN B 199 −6.008 29.085 −25.299 1.00 49.36 C ATOM 1856 CD GLN B 199 −6.963 29.806 −24.295 1.00 50.29 C ATOM 1857 OE1 GLN B 199 −7.702 29.163 −23.540 1.00 54.54 O ATOM 1858 NE2 GLN B 199 −6.935 31.148 −24.303 1.00 55.26 N ATOM 1859 C GLN B 199 −5.467 27.120 −27.970 1.00 45.02 C ATOM 1860 O GLN B 199 −6.285 26.660 −28.731 1.00 45.85 O ATOM 1861 N ARG B 200 −4.444 27.854 −28.388 1.00 45.93 N ATOM 1862 CA ARG B 200 −4.258 28.142 −29.827 1.00 47.16 C ATOM 1863 CB ARG B 200 −3.270 29.269 −30.062 1.00 47.37 C ATOM 1864 CG ARG B 200 −2.927 29.415 −31.545 1.00 50.46 C ATOM 1865 CD ARG B 200 −2.055 30.607 −31.841 1.00 54.16 C ATOM 1866 NE ARG B 200 −1.831 30.736 −33.284 1.00 58.36 N ATOM 1867 CZ ARG B 200 −0.821 31.406 −33.853 1.00 60.38 C ATOM 1868 NH1 ARG B 200 0.099 32.036 −33.117 1.00 59.70 N ATOM 1869 NH2 ARG B 200 −0.728 31.438 −35.178 1.00 61.24 N ATOM 1870 C ARG B 200 −3.823 26.940 −30.663 1.00 47.23 C ATOM 1871 O ARG B 200 −4.319 26.733 −31.775 1.00 47.03 O ATOM 1872 N PHE B 201 −2.886 26.162 −30.134 1.00 47.51 N ATOM 1873 CA PHE B 201 −2.210 25.130 −30.932 1.00 47.97 C ATOM 1874 CB PHE B 201 −0.697 25.178 −30.715 1.00 46.65 C ATOM 1875 CG PHE B 201 −0.060 26.428 −31.243 1.00 46.30 C ATOM 1876 CD1 PHE B 201 −0.158 26.752 −32.596 1.00 46.65 C ATOM 1877 CE1 PHE B 201 0.426 27.888 −33.096 1.00 44.92 C ATOM 1878 CZ PHE B 201 1.120 28.730 −32.244 1.00 48.15 C ATOM 1879 CE2 PHE B 201 1.217 28.419 −30.878 1.00 46.43 C ATOM 1880 CD2 PHE B 201 0.632 27.280 −30.399 1.00 44.50 C ATOM 1881 C PHE B 201 −2.753 23.736 −30.726 1.00 48.74 C ATOM 1882 O PHE B 201 −2.597 22.864 −31.593 1.00 48.64 O ATOM 1883 N ALA B 202 −3.370 23.508 −29.576 1.00 50.44 N ATOM 1884 CA ALA B 202 −4.033 22.247 −29.341 1.00 53.42 C ATOM 1885 CB ALA B 202 −3.728 21.709 −27.948 1.00 52.66 C ATOM 1886 C ALA B 202 −5.543 22.370 −29.606 1.00 54.73 C ATOM 1887 O ALA B 202 −6.238 21.374 −29.502 1.00 56.24 O ATOM 1888 N TRP B 203 −6.011 23.586 −29.956 1.00 56.29 N ATOM 1889 CA TRP B 203 −7.395 23.933 −30.455 1.00 56.94 C ATOM 1890 CB TRP B 203 −8.380 24.142 −29.301 1.00 58.23 C ATOM 1891 CG TRP B 203 −8.552 22.939 −28.504 1.00 59.56 C ATOM 1892 CD1 TRP B 203 −9.345 21.864 −28.804 1.00 61.53 C ATOM 1893 NE1 TRP B 203 −9.230 20.906 −27.822 1.00 62.77 N ATOM 1894 CE2 TRP B 203 −8.340 21.347 −26.873 1.00 62.01 C ATOM 1895 CD2 TRP B 203 −7.901 22.632 −27.269 1.00 61.50 C ATOM 1896 CE3 TRP B 203 −6.983 23.310 −26.460 1.00 62.77 C ATOM 1897 CZ3 TRP B 203 −6.547 22.698 −25.292 1.00 61.79 C ATOM 1898 CH2 TRP B 203 −7.013 21.418 −24.918 1.00 61.03 C ATOM 1899 CZ2 TRP B 203 −7.898 20.730 −25.690 1.00 60.64 C ATOM 1900 C TRP B 203 −7.437 25.187 −31.366 1.00 57.77 C ATOM 1901 O TRP B 203 −8.201 26.147 −31.186 1.00 57.76 O ATOM 1902 OXT TRP B 203 −6.692 25.319 −32.339 1.00 58.42 O ATOM 1903 N HIS D 56 34.592 2.339 9.216 1.00 64.66 N ATOM 1904 CA HIS D 56 34.345 2.715 10.649 1.00 64.55 C ATOM 1905 CB HIS D 56 35.029 1.705 11.625 1.00 65.47 C ATOM 1906 CG HIS D 56 36.531 1.764 11.637 1.00 68.06 C ATOM 1907 ND1 HIS D 56 37.317 1.022 10.777 1.00 71.84 N ATOM 1908 CE1 HIS D 56 38.593 1.276 11.018 1.00 72.28 C ATOM 1909 NE2 HIS D 56 38.664 2.154 12.006 1.00 70.72 N ATOM 1910 CD2 HIS D 56 37.390 2.469 12.415 1.00 69.56 C ATOM 1911 C HIS D 56 34.649 4.212 10.979 1.00 63.35 C ATOM 1912 O HIS D 56 35.235 4.560 12.024 1.00 63.93 O ATOM 1913 N HIS D 57 34.212 5.104 10.095 1.00 61.01 N ATOM 1914 CA HIS D 57 34.497 6.533 10.244 1.00 58.95 C ATOM 1915 CB HIS D 57 35.769 6.906 9.444 1.00 59.82 C ATOM 1916 CG HIS D 57 36.783 5.797 9.346 1.00 62.98 C ATOM 1917 ND1 HIS D 57 36.602 4.683 8.545 1.00 66.61 N ATOM 1918 CE1 HIS D 57 37.641 3.872 8.672 1.00 67.08 C ATOM 1919 NE2 HIS D 57 38.490 4.417 9.528 1.00 67.51 N ATOM 1920 CD2 HIS D 57 37.979 5.622 9.961 1.00 66.43 C ATOM 1921 C HIS D 57 33.300 7.267 9.654 1.00 55.91 C ATOM 1922 O HIS D 57 32.887 6.931 8.536 1.00 56.18 O ATOM 1923 N HIS D 58 32.694 8.230 10.355 1.00 51.42 N ATOM 1924 CA HIS D 58 31.740 9.014 9.589 1.00 47.26 C ATOM 1925 CB HIS D 58 30.404 9.340 10.238 1.00 48.71 C ATOM 1926 CG HIS D 58 29.369 9.596 9.188 1.00 54.11 C ATOM 1927 ND1 HIS D 58 28.703 10.793 9.049 1.00 58.72 N ATOM 1928 CE1 HIS D 58 27.920 10.740 7.977 1.00 61.41 C ATOM 1929 NE2 HIS D 58 28.103 9.573 7.379 1.00 60.54 N ATOM 1930 CD2 HIS D 58 29.009 8.842 8.112 1.00 59.27 C ATOM 1931 C HIS D 58 32.286 10.247 8.894 1.00 42.65 C ATOM 1932 O HIS D 58 33.093 10.973 9.453 1.00 40.85 O ATOM 1933 N HIS D 59 31.787 10.482 7.680 1.00 37.62 N ATOM 1934 CA HIS D 59 32.120 11.671 6.915 1.00 33.38 C ATOM 1935 CB HIS D 59 31.913 11.451 5.408 1.00 31.80 C ATOM 1936 CG HIS D 59 32.889 10.495 4.815 1.00 30.00 C ATOM 1937 ND1 HIS D 59 34.093 10.904 4.271 1.00 26.51 N ATOM 1938 CE1 HIS D 59 34.761 9.837 3.865 1.00 28.12 C ATOM 1939 NE2 HIS D 59 34.015 8.765 4.067 1.00 27.17 N ATOM 1940 CD2 HIS D 59 32.845 9.148 4.679 1.00 28.48 C ATOM 1941 C HIS D 59 31.362 12.894 7.336 1.00 32.02 C ATOM 1942 O HIS D 59 31.849 13.970 7.117 1.00 32.51 O ATOM 1943 N MET D 60 30.150 12.765 7.885 1.00 31.80 N ATOM 1944 CA MET D 60 29.369 13.977 8.243 1.00 31.40 C ATOM 1945 CB MET D 60 27.889 13.902 7.828 1.00 32.22 C ATOM 1946 CG MET D 60 27.617 13.875 6.267 1.00 37.88 C ATOM 1947 SD MET D 60 27.808 15.376 5.183 1.00 44.72 S ATOM 1948 CE MET D 60 26.475 16.498 5.654 1.00 45.45 C ATOM 1949 C MET D 60 29.501 14.277 9.760 1.00 29.90 C ATOM 1950 O MET D 60 29.577 13.361 10.575 1.00 28.64 O ATOM 1951 N SER D 61 29.535 15.557 10.109 1.00 30.29 N ATOM 1952 CA SER D 61 29.588 15.983 11.499 1.00 30.76 C ATOM 1953 CB SER D 61 29.925 17.460 11.570 1.00 30.74 C ATOM 1954 OG SER D 61 28.848 18.250 11.070 1.00 29.96 O ATOM 1955 C SER D 61 28.253 15.750 12.221 1.00 32.49 C ATOM 1956 O SER D 61 28.206 15.601 13.460 1.00 32.22 O ATOM 1957 N GLY D 62 27.173 15.744 11.452 1.00 33.25 N ATOM 1958 CA GLY D 62 25.831 15.442 11.967 1.00 34.91 C ATOM 1959 C GLY D 62 24.939 15.316 10.728 1.00 37.02 C ATOM 1960 O GLY D 62 25.415 15.463 9.602 1.00 36.12 O ATOM 1961 N GLU D 63 23.649 15.056 10.903 1.00 38.27 N ATOM 1962 CA GLU D 63 22.778 15.047 9.723 1.00 41.05 C ATOM 1963 CB GLU D 63 22.745 13.647 9.064 1.00 41.25 C ATOM 1964 CG GLU D 63 21.929 12.590 9.806 1.00 44.88 C ATOM 1965 CD GLU D 63 22.092 11.175 9.212 1.00 45.68 C ATOM 1966 OE1 GLU D 63 21.509 10.883 8.130 1.00 50.03 O ATOM 1967 OE2 GLU D 63 22.789 10.347 9.848 1.00 51.89 O ATOM 1968 C GLU D 63 21.359 15.560 10.053 1.00 40.41 C ATOM 1969 O GLU D 63 20.917 15.481 11.203 1.00 39.58 O ATOM 1970 N LYS D 64 20.675 16.079 9.030 1.00 39.97 N ATOM 1971 CA LYS D 64 19.253 16.453 9.124 1.00 39.55 C ATOM 1972 CB LYS D 64 18.855 17.312 7.933 1.00 38.27 C ATOM 1973 CG LYS D 64 19.498 18.676 7.978 1.00 37.25 C ATOM 1974 CD LYS D 64 19.352 19.392 6.699 1.00 37.42 C ATOM 1975 CE LYS D 64 19.582 20.874 6.890 1.00 40.00 C ATOM 1976 NZ LYS D 64 19.659 21.591 5.597 1.00 41.12 N ATOM 1977 C LYS D 64 18.447 15.173 9.226 1.00 39.27 C ATOM 1978 O LYS D 64 18.598 14.260 8.428 1.00 40.43 O ATOM 1979 N THR D 65 17.612 15.062 10.241 1.00 40.07 N ATOM 1980 CA THR D 65 17.000 13.756 10.492 1.00 40.21 C ATOM 1981 CB THR D 65 17.075 13.371 11.988 1.00 40.76 C ATOM 1982 OG1 THR D 65 16.660 14.502 12.769 1.00 42.99 O ATOM 1983 CG2 THR D 65 18.532 12.999 12.379 1.00 42.94 C ATOM 1984 C THR D 65 15.543 13.715 10.026 1.00 38.61 C ATOM 1985 O THR D 65 14.950 12.653 9.998 1.00 38.55 O ATOM 1986 N VAL D 66 14.976 14.875 9.685 1.00 37.32 N ATOM 1987 CA VAL D 66 13.577 14.945 9.213 1.00 36.16 C ATOM 1988 CB VAL D 66 12.658 15.607 10.304 1.00 37.17 C ATOM 1989 CG1 VAL D 66 11.174 15.588 9.875 1.00 36.22 C ATOM 1990 CG2 VAL D 66 12.797 14.868 11.625 1.00 37.85 C ATOM 1991 C VAL D 66 13.414 15.723 7.913 1.00 34.38 C ATOM 1992 O VAL D 66 13.926 16.848 7.791 1.00 33.99 O ATOM 1993 N VAL D 67 12.646 15.159 6.969 1.00 34.25 N ATOM 1994 CA VAL D 67 12.330 15.843 5.687 1.00 33.06 C ATOM 1995 CB VAL D 67 11.704 14.865 4.636 1.00 33.93 C ATOM 1996 CG1 VAL D 67 11.168 15.648 3.370 1.00 30.51 C ATOM 1997 CG2 VAL D 67 12.691 13.730 4.262 1.00 34.10 C ATOM 1998 C VAL D 67 11.411 17.069 5.921 1.00 32.76 C ATOM 1999 O VAL D 67 10.519 17.011 6.756 1.00 33.03 O ATOM 2000 N CYS D 68 11.676 18.179 5.236 1.00 32.16 N ATOM 2001 CA CYS D 68 10.907 19.397 5.407 1.00 32.44 C ATOM 2002 CB CYS D 68 11.597 20.575 4.774 1.00 31.82 C ATOM 2003 SG CYS D 68 10.774 22.098 5.030 1.00 33.61 S ATOM 2004 C CYS D 68 9.550 19.203 4.723 1.00 32.88 C ATOM 2005 O CYS D 68 9.476 19.154 3.491 1.00 30.62 O ATOM 2006 N LYS D 69 8.484 19.090 5.519 1.00 33.15 N ATOM 2007 CA LYS D 69 7.172 18.858 4.910 1.00 34.88 C ATOM 2008 CB LYS D 69 6.157 18.270 5.917 1.00 35.34 C ATOM 2009 CG LYS D 69 5.811 19.205 7.044 1.00 36.65 C ATOM 2010 CD LYS D 69 4.712 18.618 7.967 1.00 37.03 C ATOM 2011 CE LYS D 69 3.257 18.968 7.480 1.00 37.27 C ATOM 2012 NZ LYS D 69 2.907 20.446 7.579 1.00 36.89 N ATOM 2013 C LYS D 69 6.676 20.095 4.180 1.00 35.15 C ATOM 2014 O LYS D 69 5.946 19.975 3.181 1.00 35.27 O ATOM 2015 N HIS D 70 7.104 21.288 4.605 1.00 37.08 N ATOM 2016 CA HIS D 70 6.813 22.498 3.813 1.00 38.20 C ATOM 2017 CB HIS D 70 7.195 23.768 4.561 1.00 39.21 C ATOM 2018 CG HIS D 70 6.402 23.956 5.819 1.00 43.73 C ATOM 2019 ND1 HIS D 70 6.986 24.109 7.059 1.00 46.35 N ATOM 2020 CE1 HIS D 70 6.045 24.214 7.979 1.00 47.53 C ATOM 2021 NE2 HIS D 70 4.869 24.094 7.387 1.00 49.18 N ATOM 2022 CD2 HIS D 70 5.063 23.940 6.035 1.00 46.48 C ATOM 2023 C HIS D 70 7.467 22.438 2.441 1.00 38.73 C ATOM 2024 O HIS D 70 6.829 22.759 1.422 1.00 39.48 O ATOM 2025 N TRP D 71 8.725 21.994 2.397 1.00 38.01 N ATOM 2026 CA TRP D 71 9.446 21.887 1.121 1.00 36.93 C ATOM 2027 CB TRP D 71 10.920 21.482 1.360 1.00 36.60 C ATOM 2028 CG TRP D 71 11.596 21.051 0.116 1.00 35.32 C ATOM 2029 CD1 TRP D 71 12.129 21.868 −0.845 1.00 36.20 C ATOM 2030 NE1 TRP D 71 12.666 21.117 −1.863 1.00 33.00 N ATOM 2031 CE2 TRP D 71 12.492 19.786 −1.575 1.00 33.99 C ATOM 2032 CD2 TRP D 71 11.801 19.706 −0.337 1.00 33.26 C ATOM 2033 CE3 TRP D 71 11.486 18.448 0.185 1.00 29.61 C ATOM 2034 CZ3 TRP D 71 11.830 17.336 −0.535 1.00 34.23 C ATOM 2035 CH2 TRP D 71 12.498 17.450 −1.790 1.00 34.83 C ATOM 2036 CZ2 TRP D 71 12.820 18.668 −2.319 1.00 32.77 C ATOM 2037 C TRP D 71 8.754 20.885 0.194 1.00 37.16 C ATOM 2038 O TRP D 71 8.694 21.086 −1.021 1.00 37.02 O ATOM 2039 N LEU D 72 8.255 19.790 0.744 1.00 37.29 N ATOM 2040 CA LEU D 72 7.503 18.834 −0.072 1.00 38.20 C ATOM 2041 CB LEU D 72 6.952 17.721 0.795 1.00 37.67 C ATOM 2042 CG LEU D 72 7.960 16.753 1.405 1.00 38.01 C ATOM 2043 CD1 LEU D 72 7.214 15.930 2.418 1.00 36.10 C ATOM 2044 CD2 LEU D 72 8.554 15.878 0.336 1.00 37.04 C ATOM 2045 C LEU D 72 6.381 19.501 −0.894 1.00 38.76 C ATOM 2046 O LEU D 72 6.122 19.104 −2.037 1.00 38.00 O ATOM 2047 N ARG D 73 5.789 20.555 −0.332 1.00 39.92 N ATOM 2048 CA ARG D 73 4.608 21.205 −0.903 1.00 41.93 C ATOM 2049 CB ARG D 73 3.477 21.262 0.139 1.00 41.43 C ATOM 2050 CG ARG D 73 3.054 19.908 0.710 1.00 41.64 C ATOM 2051 CD ARG D 73 1.665 20.001 1.435 1.00 42.77 C ATOM 2052 NE ARG D 73 0.577 20.306 0.489 1.00 41.40 N ATOM 2053 CZ ARG D 73 −0.128 21.435 0.432 1.00 41.05 C ATOM 2054 NH1 ARG D 73 0.061 22.426 1.297 1.00 38.28 N ATOM 2055 NH2 ARG D 73 −1.048 21.575 −0.533 1.00 40.79 N ATOM 2056 C ARG D 73 4.926 22.597 −1.457 1.00 43.33 C ATOM 2057 O ARG D 73 4.018 23.377 −1.768 1.00 44.11 O ATOM 2058 N GLY D 74 6.222 22.914 −1.564 1.00 44.01 N ATOM 2059 CA GLY D 74 6.686 24.181 −2.145 1.00 45.02 C ATOM 2060 C GLY D 74 6.470 25.382 −1.248 1.00 45.92 C ATOM 2061 O GLY D 74 6.309 26.515 −1.713 1.00 46.72 O ATOM 2062 N LEU D 75 6.445 25.149 0.051 1.00 46.34 N ATOM 2063 CA LEU D 75 6.107 26.222 0.997 1.00 47.13 C ATOM 2064 CB LEU D 75 4.934 25.777 1.885 1.00 46.90 C ATOM 2065 CG LEU D 75 3.568 25.669 1.231 1.00 46.99 C ATOM 2066 CD1 LEU D 75 2.730 24.757 2.056 1.00 48.19 C ATOM 2067 CD2 LEU D 75 2.944 27.049 1.136 1.00 47.54 C ATOM 2068 C LEU D 75 7.309 26.631 1.869 1.00 47.52 C ATOM 2069 O LEU D 75 7.141 27.245 2.939 1.00 48.30 O ATOM 2070 N CYS D 76 8.509 26.251 1.423 1.00 47.15 N ATOM 2071 CA CYS D 76 9.741 26.554 2.151 1.00 47.29 C ATOM 2072 CB CYS D 76 10.341 25.307 2.803 1.00 46.82 C ATOM 2073 SG CYS D 76 11.782 25.664 3.833 1.00 44.67 S ATOM 2074 C CYS D 76 10.736 27.187 1.201 1.00 47.45 C ATOM 2075 O CYS D 76 11.029 26.650 0.125 1.00 47.30 O ATOM 2076 N LYS D 77 11.231 28.342 1.639 1.00 48.56 N ATOM 2077 CA LYS D 77 12.129 29.218 0.883 1.00 49.52 C ATOM 2078 CB LYS D 77 11.691 30.695 1.055 1.00 50.19 C ATOM 2079 CG LYS D 77 10.278 31.028 0.538 1.00 53.97 C ATOM 2080 CD LYS D 77 10.225 30.845 −0.981 1.00 58.79 C ATOM 2081 CE LYS D 77 9.050 29.979 −1.397 1.00 62.13 C ATOM 2082 NZ LYS D 77 9.133 29.643 −2.858 1.00 64.34 N ATOM 2083 C LYS D 77 13.584 29.101 1.377 1.00 48.54 C ATOM 2084 O LYS D 77 14.485 29.711 0.788 1.00 48.99 O ATOM 2085 N LYS D 78 13.787 28.351 2.466 1.00 47.21 N ATOM 2086 CA LYS D 78 15.080 28.269 3.165 1.00 46.17 C ATOM 2087 CB LYS D 78 14.865 27.778 4.588 1.00 45.59 C ATOM 2088 CG LYS D 78 14.052 28.736 5.431 1.00 48.72 C ATOM 2089 CD LYS D 78 13.535 28.042 6.657 1.00 51.08 C ATOM 2090 CE LYS D 78 12.626 28.955 7.426 1.00 54.63 C ATOM 2091 NZ LYS D 78 12.237 28.258 8.680 1.00 57.29 N ATOM 2092 C LYS D 78 16.216 27.465 2.488 1.00 45.04 C ATOM 2093 O LYS D 78 17.366 27.532 2.929 1.00 45.07 O ATOM 2094 N GLY D 79 15.912 26.718 1.432 1.00 43.75 N ATOM 2095 CA GLY D 79 16.935 25.956 0.712 1.00 42.63 C ATOM 2096 C GLY D 79 17.814 25.108 1.629 1.00 41.82 C ATOM 2097 O GLY D 79 17.323 24.490 2.582 1.00 41.57 O ATOM 2098 N ASP D 80 19.118 25.104 1.346 1.00 41.32 N ATOM 2099 CA ASP D 80 20.137 24.381 2.150 1.00 41.34 C ATOM 2100 CB ASP D 80 21.551 24.566 1.548 1.00 40.65 C ATOM 2101 CG ASP D 80 21.723 23.844 0.223 1.00 41.10 C ATOM 2102 OD1 ASP D 80 20.833 23.048 −0.171 1.00 41.81 O ATOM 2103 OD2 ASP D 80 22.763 24.061 −0.440 1.00 41.86 O ATOM 2104 C ASP D 80 20.153 24.779 3.609 1.00 40.66 C ATOM 2105 O ASP D 80 20.533 23.985 4.474 1.00 40.51 O ATOM 2106 N GLN D 81 19.678 25.988 3.874 1.00 40.84 N ATOM 2107 CA GLN D 81 19.728 26.572 5.205 1.00 40.62 C ATOM 2108 CB GLN D 81 19.909 28.096 5.119 1.00 40.77 C ATOM 2109 CG GLN D 81 21.305 28.536 4.655 1.00 41.97 C ATOM 2110 CD GLN D 81 21.538 28.288 3.171 1.00 43.96 C ATOM 2111 OE1 GLN D 81 20.627 28.463 2.370 1.00 44.29 O ATOM 2112 NE2 GLN D 81 22.752 27.878 2.797 1.00 40.50 N ATOM 2113 C GLN D 81 18.514 26.200 6.071 1.00 40.22 C ATOM 2114 O GLN D 81 18.448 26.615 7.231 1.00 39.54 O ATOM 2115 N CYS D 82 17.575 25.410 5.526 1.00 39.25 N ATOM 2116 CA CYS D 82 16.459 24.923 6.329 1.00 38.42 C ATOM 2117 CB CYS D 82 15.385 24.223 5.486 1.00 38.37 C ATOM 2118 SG CYS D 82 13.883 23.896 6.491 1.00 38.87 S ATOM 2119 C CYS D 82 16.962 23.975 7.411 1.00 38.75 C ATOM 2120 O CYS D 82 17.970 23.296 7.235 1.00 38.23 O ATOM 2121 N GLU D 83 16.260 23.945 8.534 1.00 38.22 N ATOM 2122 CA GLU D 83 16.586 23.050 9.622 1.00 38.64 C ATOM 2123 CB GLU D 83 15.717 23.407 10.845 1.00 38.85 C ATOM 2124 CG GLU D 83 15.738 22.391 11.960 1.00 39.99 C ATOM 2125 CD GLU D 83 14.765 22.732 13.111 1.00 43.45 C ATOM 2126 OE1 GLU D 83 14.146 23.834 13.100 1.00 49.61 O ATOM 2127 OE2 GLU D 83 14.624 21.882 14.025 1.00 47.89 O ATOM 2128 C GLU D 83 16.364 21.615 9.174 1.00 36.61 C ATOM 2129 O GLU D 83 16.969 20.663 9.694 1.00 36.20 O ATOM 2130 N PHE D 84 15.448 21.458 8.218 1.00 35.98 N ATOM 2131 CA PHE D 84 14.988 20.138 7.797 1.00 33.86 C ATOM 2132 CB PHE D 84 13.445 20.073 7.860 1.00 34.81 C ATOM 2133 CG PHE D 84 12.908 20.343 9.227 1.00 34.72 C ATOM 2134 CD1 PHE D 84 12.327 21.562 9.522 1.00 37.93 C ATOM 2135 CE1 PHE D 84 11.841 21.806 10.805 1.00 39.57 C ATOM 2136 CZ PHE D 84 11.981 20.835 11.803 1.00 37.48 C ATOM 2137 CE2 PHE D 84 12.557 19.631 11.533 1.00 39.44 C ATOM 2138 CD2 PHE D 84 13.043 19.389 10.238 1.00 37.62 C ATOM 2139 C PHE D 84 15.488 19.841 6.394 1.00 32.86 C ATOM 2140 O PHE D 84 15.867 20.728 5.679 1.00 31.87 O ATOM 2141 N LEU D 85 15.452 18.576 6.012 1.00 32.17 N ATOM 2142 CA LEU D 85 16.090 18.146 4.793 1.00 32.87 C ATOM 2143 CB LEU D 85 16.309 16.646 4.887 1.00 32.14 C ATOM 2144 CG LEU D 85 16.987 15.995 3.686 1.00 32.65 C ATOM 2145 CD1 LEU D 85 18.475 16.518 3.562 1.00 30.51 C ATOM 2146 CD2 LEU D 85 16.905 14.484 3.898 1.00 32.51 C ATOM 2147 C LEU D 85 15.234 18.444 3.563 1.00 34.15 C ATOM 2148 O LEU D 85 14.022 18.140 3.554 1.00 33.04 O ATOM 2149 N HIS D 86 15.865 19.006 2.527 1.00 33.66 N ATOM 2150 CA HIS D 86 15.177 19.238 1.282 1.00 34.81 C ATOM 2151 CB HIS D 86 15.456 20.639 0.786 1.00 34.31 C ATOM 2152 CG HIS D 86 14.760 21.691 1.587 1.00 33.56 C ATOM 2153 ND1 HIS D 86 14.431 22.914 1.062 1.00 35.34 N ATOM 2154 CE1 HIS D 86 13.867 23.653 1.998 1.00 35.36 C ATOM 2155 NE2 HIS D 86 13.761 22.928 3.092 1.00 34.33 N ATOM 2156 CD2 HIS D 86 14.323 21.700 2.869 1.00 32.93 C ATOM 2157 C HIS D 86 15.424 18.223 0.195 1.00 35.48 C ATOM 2158 O HIS D 86 15.701 18.615 −0.934 1.00 36.99 O ATOM 2159 N GLU D 87 15.339 16.938 0.533 1.00 36.60 N ATOM 2160 CA GLU D 87 15.300 15.870 −0.461 1.00 38.04 C ATOM 2161 CB GLU D 87 16.656 15.148 −0.598 1.00 38.88 C ATOM 2162 CG GLU D 87 17.818 16.031 −1.075 1.00 41.12 C ATOM 2163 CD GLU D 87 17.624 16.634 −2.476 1.00 45.48 C ATOM 2164 OE1 GLU D 87 16.697 16.215 −3.226 1.00 41.76 O ATOM 2165 OE2 GLU D 87 18.399 17.568 −2.803 1.00 45.80 O ATOM 2166 C GLU D 87 14.230 14.862 −0.082 1.00 38.87 C ATOM 2167 O GLU D 87 13.856 14.750 1.096 1.00 37.77 O ATOM 2168 N TYR D 88 13.722 14.118 −1.058 1.00 40.40 N ATOM 2169 CA TYR D 88 12.747 13.090 −0.695 1.00 42.60 C ATOM 2170 CB TYR D 88 11.639 12.789 −1.767 1.00 43.58 C ATOM 2171 CG TYR D 88 10.558 11.877 −1.139 1.00 46.74 C ATOM 2172 CD1 TYR D 88 9.714 12.348 −0.109 1.00 47.35 C ATOM 2173 CE1 TYR D 88 8.769 11.503 0.523 1.00 49.00 C ATOM 2174 CZ TYR D 88 8.663 10.177 0.152 1.00 47.77 C ATOM 2175 OH TYR D 88 7.779 9.314 0.784 1.00 47.83 O ATOM 2176 CE2 TYR D 88 9.506 9.679 −0.843 1.00 51.26 C ATOM 2177 CD2 TYR D 88 10.460 10.530 −1.482 1.00 49.05 C ATOM 2178 C TYR D 88 13.410 11.825 −0.149 1.00 42.69 C ATOM 2179 O TYR D 88 13.821 10.941 −0.900 1.00 43.66 O ATOM 2180 N ASP D 89 13.461 11.710 1.169 1.00 42.43 N ATOM 2181 CA ASP D 89 13.906 10.477 1.777 1.00 42.60 C ATOM 2182 CB ASP D 89 15.119 10.778 2.648 1.00 42.36 C ATOM 2183 CG ASP D 89 15.771 9.540 3.182 1.00 42.78 C ATOM 2184 OD1 ASP D 89 15.168 8.442 3.116 1.00 42.68 O ATOM 2185 OD2 ASP D 89 16.914 9.667 3.670 1.00 44.94 O ATOM 2186 C ASP D 89 12.776 9.836 2.595 1.00 43.43 C ATOM 2187 O ASP D 89 12.476 10.292 3.696 1.00 42.72 O ATOM 2188 N MET D 90 12.179 8.762 2.069 1.00 44.28 N ATOM 2189 CA MET D 90 10.995 8.143 2.686 1.00 47.28 C ATOM 2190 CB MET D 90 10.397 7.019 1.805 1.00 46.57 C ATOM 2191 CG MET D 90 11.272 5.745 1.686 1.00 50.99 C ATOM 2192 SD MET D 90 10.600 4.293 0.770 1.00 55.26 S ATOM 2193 CE MET D 90 10.460 4.964 −0.896 1.00 54.61 C ATOM 2194 C MET D 90 11.283 7.639 4.105 1.00 46.07 C ATOM 2195 O MET D 90 10.355 7.302 4.848 1.00 45.61 O ATOM 2196 N THR D 91 12.570 7.594 4.466 1.00 44.61 N ATOM 2197 CA THR D 91 12.987 7.061 5.747 1.00 43.51 C ATOM 2198 CB THR D 91 14.350 6.254 5.648 1.00 44.59 C ATOM 2199 OG1 THR D 91 15.463 7.160 5.457 1.00 45.89 O ATOM 2200 CG2 THR D 91 14.305 5.201 4.517 1.00 44.25 C ATOM 2201 C THR D 91 13.144 8.164 6.764 1.00 41.77 C ATOM 2202 O THR D 91 13.354 7.894 7.948 1.00 42.02 O ATOM 2203 N LYS D 92 13.073 9.406 6.306 1.00 38.80 N ATOM 2204 CA LYS D 92 13.220 10.539 7.197 1.00 37.66 C ATOM 2205 CB LYS D 92 14.428 11.401 6.773 1.00 37.27 C ATOM 2206 CG LYS D 92 15.767 10.664 6.901 1.00 40.93 C ATOM 2207 CD LYS D 92 16.930 11.547 6.425 1.00 37.83 C ATOM 2208 CE LYS D 92 18.245 10.765 6.528 1.00 45.63 C ATOM 2209 NZ LYS D 92 19.377 11.764 6.464 1.00 44.22 N ATOM 2210 C LYS D 92 11.955 11.412 7.290 1.00 35.80 C ATOM 2211 O LYS D 92 12.035 12.615 7.539 1.00 34.91 O ATOM 2212 N MET D 93 10.792 10.805 7.099 1.00 34.90 N ATOM 2213 CA MET D 93 9.547 11.588 7.032 1.00 33.48 C ATOM 2214 CB MET D 93 8.496 10.843 6.180 1.00 33.76 C ATOM 2215 CG MET D 93 8.850 10.843 4.652 1.00 29.06 C ATOM 2216 SD MET D 93 8.662 12.469 3.962 1.00 28.76 S ATOM 2217 CE MET D 93 6.963 12.472 3.449 1.00 36.37 C ATOM 2218 C MET D 93 9.058 11.939 8.444 1.00 33.59 C ATOM 2219 O MET D 93 9.258 11.123 9.349 1.00 32.16 O ATOM 2220 N PRO D 94 8.462 13.153 8.632 1.00 33.50 N ATOM 2221 CA PRO D 94 7.834 13.556 9.940 1.00 34.10 C ATOM 2222 CB PRO D 94 7.201 14.957 9.670 1.00 32.63 C ATOM 2223 CG PRO D 94 7.882 15.485 8.457 1.00 37.71 C ATOM 2224 CD PRO D 94 8.380 14.248 7.607 1.00 35.59 C ATOM 2225 C PRO D 94 6.729 12.581 10.396 1.00 33.49 C ATOM 2226 O PRO D 94 6.261 11.740 9.592 1.00 32.95 O ATOM 2227 N GLU D 95 6.306 12.700 11.664 1.00 31.40 N ATOM 2228 CA GLU D 95 5.262 11.838 12.153 1.00 30.11 C ATOM 2229 CB GLU D 95 5.248 11.771 13.704 1.00 31.59 C ATOM 2230 CG GLU D 95 4.077 10.906 14.222 1.00 31.29 C ATOM 2231 CD GLU D 95 4.067 10.647 15.747 1.00 35.15 C ATOM 2232 OE1 GLU D 95 3.312 9.736 16.195 1.00 42.96 O ATOM 2233 OE2 GLU D 95 4.774 11.367 16.469 1.00 42.80 O ATOM 2234 C GLU D 95 3.932 12.424 11.620 1.00 27.97 C ATOM 2235 O GLU D 95 3.754 13.630 11.549 1.00 26.66 O ATOM 2236 N CYS D 96 3.012 11.552 11.271 1.00 27.21 N ATOM 2237 CA CYS D 96 1.677 11.980 10.816 1.00 26.91 C ATOM 2238 CB CYS D 96 0.972 10.808 10.196 1.00 25.79 C ATOM 2239 SG CYS D 96 −0.756 11.121 9.525 1.00 25.47 S ATOM 2240 C CYS D 96 0.833 12.538 11.964 1.00 27.38 C ATOM 2241 O CYS D 96 0.514 11.837 12.909 1.00 27.92 O ATOM 2242 N TYR D 97 0.452 13.801 11.856 1.00 27.76 N ATOM 2243 CA TYR D 97 −0.365 14.433 12.897 1.00 27.92 C ATOM 2244 CB TYR D 97 −0.652 15.878 12.528 1.00 28.47 C ATOM 2245 CG TYR D 97 −1.354 16.646 13.643 1.00 29.52 C ATOM 2246 CD1 TYR D 97 −0.612 17.386 14.560 1.00 30.25 C ATOM 2247 CE1 TYR D 97 −1.252 18.093 15.628 1.00 32.82 C ATOM 2248 CZ TYR D 97 −2.655 18.015 15.752 1.00 30.54 C ATOM 2249 OH TYR D 97 −3.281 18.703 16.791 1.00 30.45 O ATOM 2250 CE2 TYR D 97 −3.416 17.260 14.837 1.00 29.38 C ATOM 2251 CD2 TYR D 97 −2.766 16.571 13.800 1.00 29.06 C ATOM 2252 C TYR D 97 −1.658 13.672 13.141 1.00 28.09 C ATOM 2253 O TYR D 97 −2.045 13.435 14.298 1.00 27.25 O ATOM 2254 N PHE D 98 −2.318 13.251 12.054 1.00 28.03 N ATOM 2255 CA PHE D 98 −3.631 12.613 12.195 1.00 26.18 C ATOM 2256 CB PHE D 98 −4.407 12.608 10.863 1.00 27.78 C ATOM 2257 CG PHE D 98 −4.754 14.003 10.412 1.00 25.25 C ATOM 2258 CD1 PHE D 98 −5.815 14.669 10.990 1.00 25.95 C ATOM 2259 CE1 PHE D 98 −6.092 15.991 10.625 1.00 25.50 C ATOM 2260 CZ PHE D 98 −5.302 16.649 9.701 1.00 28.69 C ATOM 2261 CE2 PHE D 98 −4.223 16.002 9.144 1.00 31.29 C ATOM 2262 CD2 PHE D 98 −3.963 14.666 9.492 1.00 27.25 C ATOM 2263 C PHE D 98 −3.515 11.238 12.812 1.00 28.26 C ATOM 2264 O PHE D 98 −4.313 10.893 13.689 1.00 26.63 O ATOM 2265 N TYR D 99 −2.538 10.431 12.375 1.00 28.21 N ATOM 2266 CA TYR D 99 −2.406 9.132 13.024 1.00 30.03 C ATOM 2267 CB TYR D 99 −1.371 8.282 12.328 1.00 29.69 C ATOM 2268 CG TYR D 99 −1.522 6.820 12.659 1.00 31.63 C ATOM 2269 CD1 TYR D 99 −2.409 6.015 11.954 1.00 31.51 C ATOM 2270 CE1 TYR D 99 −2.547 4.671 12.258 1.00 31.48 C ATOM 2271 CZ TYR D 99 −1.802 4.118 13.295 1.00 34.31 C ATOM 2272 OH TYR D 99 −1.944 2.761 13.594 1.00 35.60 O ATOM 2273 CE2 TYR D 99 −0.911 4.897 14.014 1.00 34.34 C ATOM 2274 CD2 TYR D 99 −0.772 6.239 13.706 1.00 33.06 C ATOM 2275 C TYR D 99 −2.050 9.285 14.524 1.00 30.74 C ATOM 2276 O TYR D 99 −2.528 8.521 15.362 1.00 31.10 O ATOM 2277 N SER D 100 −1.252 10.292 14.843 1.00 31.22 N ATOM 2278 CA SER D 100 −0.808 10.499 16.231 1.00 33.97 C ATOM 2279 CB SER D 100 0.374 11.452 16.281 1.00 33.74 C ATOM 2280 OG SER D 100 0.531 11.965 17.613 1.00 40.80 O ATOM 2281 C SER D 100 −1.937 11.009 17.142 1.00 33.35 C ATOM 2282 O SER D 100 −2.116 10.476 18.259 1.00 34.24 O ATOM 2283 N LYS D 101 −2.669 12.036 16.694 1.00 32.17 N ATOM 2284 CA LYS D 101 −3.748 12.598 17.513 1.00 32.18 C ATOM 2285 CB LYS D 101 −4.019 14.090 17.233 1.00 31.57 C ATOM 2286 CG LYS D 101 −2.787 14.947 17.229 1.00 35.32 C ATOM 2287 CD LYS D 101 −2.122 15.074 18.568 1.00 41.14 C ATOM 2288 CE LYS D 101 −0.778 15.787 18.385 1.00 45.47 C ATOM 2289 NZ LYS D 101 0.071 15.692 19.614 1.00 49.42 N ATOM 2290 C LYS D 101 −5.043 11.822 17.475 1.00 32.87 C ATOM 2291 O LYS D 101 −5.813 11.880 18.448 1.00 32.25 O ATOM 2292 N PHE D 102 −5.303 11.104 16.366 1.00 32.74 N ATOM 2293 CA PHE D 102 −6.603 10.506 16.130 1.00 31.60 C ATOM 2294 CB PHE D 102 −7.279 11.089 14.871 1.00 31.91 C ATOM 2295 CG PHE D 102 −7.714 12.529 15.022 1.00 29.94 C ATOM 2296 CD1 PHE D 102 −9.004 12.848 15.414 1.00 29.78 C ATOM 2297 CE1 PHE D 102 −9.402 14.211 15.537 1.00 24.97 C ATOM 2298 CZ PHE D 102 −8.488 15.235 15.305 1.00 30.76 C ATOM 2299 CE2 PHE D 102 −7.204 14.894 14.901 1.00 31.66 C ATOM 2300 CD2 PHE D 102 −6.840 13.566 14.763 1.00 29.03 C ATOM 2301 C PHE D 102 −6.491 9.005 16.040 1.00 32.14 C ATOM 2302 O PHE D 102 −7.504 8.304 16.084 1.00 32.25 O ATOM 2303 N GLY D 103 −5.275 8.480 15.911 1.00 31.31 N ATOM 2304 CA GLY D 103 −5.174 7.038 15.785 1.00 31.79 C ATOM 2305 C GLY D 103 −5.567 6.419 14.444 1.00 31.97 C ATOM 2306 O GLY D 103 −5.626 5.206 14.333 1.00 32.46 O ATOM 2307 N GLU D 104 −5.772 7.254 13.424 1.00 31.27 N ATOM 2308 CA GLU D 104 −6.165 6.798 12.103 1.00 32.35 C ATOM 2309 CB GLU D 104 −7.700 6.597 12.055 1.00 31.98 C ATOM 2310 CG GLU D 104 −8.414 7.801 12.597 1.00 37.23 C ATOM 2311 CD GLU D 104 −9.943 7.678 12.652 1.00 39.72 C ATOM 2312 OE1 GLU D 104 −10.592 8.690 13.160 1.00 49.09 O ATOM 2313 OE2 GLU D 104 −10.461 6.616 12.183 1.00 47.00 O ATOM 2314 C GLU D 104 −5.777 7.887 11.094 1.00 28.30 C ATOM 2315 O GLU D 104 −5.610 9.058 11.457 1.00 27.32 O ATOM 2316 N CYS D 105 −5.711 7.505 9.823 1.00 26.03 N ATOM 2317 CA CYS D 105 −5.317 8.438 8.770 1.00 24.64 C ATOM 2318 CB CYS D 105 −3.794 8.380 8.639 1.00 24.89 C ATOM 2319 SG CYS D 105 −3.126 9.266 7.198 1.00 24.05 S ATOM 2320 C CYS D 105 −5.989 7.928 7.501 1.00 25.33 C ATOM 2321 O CYS D 105 −6.010 6.721 7.249 1.00 24.40 O ATOM 2322 N SER D 106 −6.619 8.836 6.741 1.00 25.56 N ATOM 2323 CA SER D 106 −7.389 8.422 5.548 1.00 26.47 C ATOM 2324 CB SER D 106 −8.516 9.453 5.249 1.00 26.24 C ATOM 2325 OG SER D 106 −9.360 9.627 6.387 1.00 28.23 O ATOM 2326 C SER D 106 −6.556 8.272 4.293 1.00 25.71 C ATOM 2327 O SER D 106 −7.097 7.880 3.284 1.00 25.71 O ATOM 2328 N ASN D 107 −5.249 8.580 4.324 1.00 26.46 N ATOM 2329 CA ASN D 107 −4.446 8.453 3.098 1.00 25.74 C ATOM 2330 CB ASN D 107 −3.369 9.531 3.066 1.00 26.14 C ATOM 2331 CG ASN D 107 −2.628 9.608 1.732 1.00 26.49 C ATOM 2332 OD1 ASN D 107 −2.882 8.825 0.829 1.00 26.10 O ATOM 2333 ND2 ASN D 107 −1.747 10.610 1.599 1.00 25.07 N ATOM 2334 C ASN D 107 −3.799 7.076 2.986 1.00 26.04 C ATOM 2335 O ASN D 107 −2.829 6.795 3.679 1.00 24.98 O ATOM 2336 N LYS D 108 −4.287 6.235 2.078 1.00 26.11 N ATOM 2337 CA LYS D 108 −3.702 4.897 1.874 1.00 27.13 C ATOM 2338 CB LYS D 108 −4.374 4.196 0.702 1.00 27.98 C ATOM 2339 CG LYS D 108 −5.821 3.823 0.946 1.00 28.66 C ATOM 2340 CD LYS D 108 −6.383 2.992 −0.222 1.00 28.13 C ATOM 2341 CE LYS D 108 −7.909 3.041 −0.137 1.00 29.83 C ATOM 2342 NZ LYS D 108 −8.548 2.711 −1.468 1.00 33.21 N ATOM 2343 C LYS D 108 −2.236 5.019 1.559 1.00 28.60 C ATOM 2344 O LYS D 108 −1.474 4.091 1.797 1.00 28.74 O ATOM 2345 N GLU D 109 −1.833 6.181 1.040 1.00 28.07 N ATOM 2346 CA GLU D 109 −0.454 6.365 0.587 1.00 29.49 C ATOM 2347 CB GLU D 109 −0.418 6.922 −0.872 1.00 29.49 C ATOM 2348 CG GLU D 109 −0.531 5.937 −2.016 1.00 33.84 C ATOM 2349 CD GLU D 109 −1.877 5.272 −2.118 1.00 38.05 C ATOM 2350 OE1 GLU D 109 −2.892 5.951 −2.409 1.00 37.86 O ATOM 2351 OE2 GLU D 109 −1.903 4.025 −1.918 1.00 43.82 O ATOM 2352 C GLU D 109 0.234 7.360 1.531 1.00 27.85 C ATOM 2353 O GLU D 109 1.170 8.038 1.126 1.00 27.90 O ATOM 2354 N CYS D 110 −0.224 7.468 2.794 1.00 27.24 N ATOM 2355 CA CYS D 110 0.349 8.464 3.668 1.00 26.45 C ATOM 2356 CB CYS D 110 −0.217 8.424 5.110 1.00 26.19 C ATOM 2357 SG CYS D 110 0.473 9.819 6.015 1.00 26.60 S ATOM 2358 C CYS D 110 1.861 8.236 3.757 1.00 26.83 C ATOM 2359 O CYS D 110 2.306 7.136 4.093 1.00 27.21 O ATOM 2360 N PRO D 111 2.644 9.264 3.464 1.00 28.24 N ATOM 2361 CA PRO D 111 4.100 9.026 3.588 1.00 29.52 C ATOM 2362 CB PRO D 111 4.693 9.997 2.571 1.00 29.24 C ATOM 2363 CG PRO D 111 3.697 11.231 2.593 1.00 29.52 C ATOM 2364 CD PRO D 111 2.314 10.617 2.940 1.00 28.03 C ATOM 2365 C PRO D 111 4.652 9.291 5.006 1.00 30.98 C ATOM 2366 O PRO D 111 5.844 9.085 5.254 1.00 30.98 O ATOM 2367 N PHE D 112 3.804 9.736 5.928 1.00 30.89 N ATOM 2368 CA PHE D 112 4.269 10.140 7.250 1.00 31.40 C ATOM 2369 CB PHE D 112 3.488 11.400 7.720 1.00 30.20 C ATOM 2370 CG PHE D 112 3.666 12.592 6.808 1.00 31.21 C ATOM 2371 CD1 PHE D 112 4.830 13.347 6.840 1.00 29.10 C ATOM 2372 CE1 PHE D 112 4.997 14.422 5.991 1.00 29.55 C ATOM 2373 CZ PHE D 112 3.956 14.776 5.080 1.00 30.53 C ATOM 2374 CE2 PHE D 112 2.787 14.019 5.060 1.00 29.65 C ATOM 2375 CD2 PHE D 112 2.657 12.959 5.902 1.00 29.41 C ATOM 2376 C PHE D 112 4.207 8.961 8.248 1.00 32.22 C ATOM 2377 O PHE D 112 3.457 7.988 8.060 1.00 31.82 O ATOM 2378 N LEU D 113 5.006 9.029 9.317 1.00 32.63 N ATOM 2379 CA LEU D 113 5.022 7.932 10.298 1.00 33.39 C ATOM 2380 CB LEU D 113 6.094 8.155 11.371 1.00 33.96 C ATOM 2381 CG LEU D 113 7.531 8.394 10.944 1.00 36.30 C ATOM 2382 CD1 LEU D 113 8.354 8.768 12.166 1.00 38.73 C ATOM 2383 CD2 LEU D 113 8.092 7.138 10.288 1.00 40.51 C ATOM 2384 C LEU D 113 3.682 7.730 11.012 1.00 33.17 C ATOM 2385 O LEU D 113 3.125 8.664 11.575 1.00 32.95 O ATOM 2386 N HIS D 114 3.226 6.489 11.016 1.00 33.23 N ATOM 2387 CA HIS D 114 2.100 6.069 11.799 1.00 35.48 C ATOM 2388 CB HIS D 114 1.117 5.267 10.947 1.00 34.35 C ATOM 2389 CG HIS D 114 0.415 6.058 9.871 1.00 30.91 C ATOM 2390 ND1 HIS D 114 −0.475 5.460 9.007 1.00 30.62 N ATOM 2391 CE1 HIS D 114 −0.961 6.359 8.166 1.00 29.38 C ATOM 2392 NE2 HIS D 114 −0.466 7.543 8.486 1.00 21.78 N ATOM 2393 CD2 HIS D 114 0.420 7.374 9.546 1.00 25.39 C ATOM 2394 C HIS D 114 2.577 5.228 13.001 1.00 37.49 C ATOM 2395 O HIS D 114 2.769 4.011 12.893 1.00 38.30 O ATOM 2396 N ILE D 115 2.744 5.897 14.124 1.00 40.28 N ATOM 2397 CA ILE D 115 3.278 5.292 15.358 1.00 44.28 C ATOM 2398 CB ILE D 115 4.306 6.217 16.026 1.00 43.85 C ATOM 2399 CG1 ILE D 115 5.492 6.454 15.092 1.00 43.41 C ATOM 2400 CD1 ILE D 115 6.188 7.704 15.411 1.00 43.55 C ATOM 2401 CG2 ILE D 115 4.798 5.626 17.367 1.00 45.91 C ATOM 2402 C ILE D 115 2.145 5.013 16.347 1.00 46.74 C ATOM 2403 O ILE D 115 1.410 5.930 16.739 1.00 45.72 O ATOM 2404 N ASP D 116 2.009 3.739 16.714 1.00 50.52 N ATOM 2405 CA ASP D 116 0.967 3.299 17.636 1.00 54.53 C ATOM 2406 CB ASP D 116 0.748 1.815 17.497 1.00 54.79 C ATOM 2407 CG ASP D 116 −0.004 1.487 16.252 1.00 57.65 C ATOM 2408 OD1 ASP D 116 −0.920 2.284 15.908 1.00 58.31 O ATOM 2409 OD2 ASP D 116 0.332 0.459 15.605 1.00 60.82 O ATOM 2410 C ASP D 116 1.257 3.653 19.082 1.00 57.26 C ATOM 2411 O ASP D 116 2.430 3.687 19.507 1.00 57.07 O ATOM 2412 N PRO D 117 0.187 3.944 19.844 1.00 59.98 N ATOM 2413 CA PRO D 117 0.354 4.429 21.206 1.00 62.24 C ATOM 2414 CB PRO D 117 −1.063 4.434 21.747 1.00 62.12 C ATOM 2415 CG PRO D 117 −1.913 4.600 20.533 1.00 61.61 C ATOM 2416 CD PRO D 117 −1.233 3.827 19.468 1.00 60.37 C ATOM 2417 C PRO D 117 1.253 3.461 21.965 1.00 64.67 C ATOM 2418 O PRO D 117 1.000 2.237 21.993 1.00 64.83 O ATOM 2419 N GLU D 118 2.326 4.029 22.514 1.00 67.27 N ATOM 2420 CA GLU D 118 3.477 3.280 23.006 1.00 69.59 C ATOM 2421 CB GLU D 118 4.684 4.230 23.201 1.00 70.33 C ATOM 2422 CG GLU D 118 5.298 4.836 21.899 1.00 73.39 C ATOM 2423 CD GLU D 118 4.568 6.103 21.334 1.00 76.34 C ATOM 2424 OE1 GLU D 118 5.246 7.142 21.133 1.00 78.16 O ATOM 2425 OE2 GLU D 118 3.342 6.068 21.065 1.00 76.31 O ATOM 2426 C GLU D 118 3.091 2.594 24.317 1.00 70.03 C ATOM 2427 O GLU D 118 2.772 1.396 24.331 1.00 70.42 O ATOM 2428 OXT GLU D 118 3.057 3.230 25.381 1.00 70.37 O ATOM 2429 ZN ZN D 502 −0.941 9.474 7.886 1.00 26.96 ZN ATOM 2430 ZN ZN D 501 12.470 23.684 4.582 1.00 38.67 ZN ATOM 2431 N HIS E 58 −45.599 5.932 −6.806 1.00 42.25 N ATOM 2432 CA HIS E 58 −44.990 6.748 −5.741 1.00 41.89 C ATOM 2433 CB HIS E 58 −43.463 6.785 −5.831 1.00 44.50 C ATOM 2434 CG HIS E 58 −42.795 6.886 −4.479 1.00 50.77 C ATOM 2435 ND1 HIS E 58 −43.456 7.346 −3.347 1.00 54.95 N ATOM 2436 CE1 HIS E 58 −42.629 7.341 −2.319 1.00 56.42 C ATOM 2437 NE2 HIS E 58 −41.448 6.908 −2.737 1.00 57.08 N ATOM 2438 CD2 HIS E 58 −41.527 6.607 −4.081 1.00 54.69 C ATOM 2439 C HIS E 58 −45.544 8.155 −5.678 1.00 39.42 C ATOM 2440 O HIS E 58 −46.314 8.545 −6.529 1.00 39.21 O ATOM 2441 N HIS E 59 −45.137 8.891 −4.639 1.00 36.77 N ATOM 2442 CA HIS E 59 −45.638 10.226 −4.323 1.00 34.79 C ATOM 2443 CB HIS E 59 −45.422 10.533 −2.828 1.00 34.59 C ATOM 2444 CG HIS E 59 −46.395 9.818 −1.940 1.00 33.03 C ATOM 2445 ND1 HIS E 59 −47.619 10.358 −1.596 1.00 32.36 N ATOM 2446 CE1 HIS E 59 −48.284 9.494 −0.853 1.00 31.07 C ATOM 2447 NE2 HIS E 59 −47.546 8.412 −0.712 1.00 33.32 N ATOM 2448 CD2 HIS E 59 −46.366 8.577 −1.404 1.00 33.19 C ATOM 2449 C HIS E 59 −45.044 11.294 −5.192 1.00 33.88 C ATOM 2450 O HIS E 59 −45.621 12.347 −5.359 1.00 34.21 O ATOM 2451 N MET E 60 −43.868 11.030 −5.751 1.00 33.64 N ATOM 2452 CA MET E 60 −43.150 12.064 −6.456 1.00 32.83 C ATOM 2453 CB MET E 60 −41.660 12.062 −6.014 1.00 33.04 C ATOM 2454 CG MET E 60 −41.453 12.437 −4.513 1.00 31.91 C ATOM 2455 SD MET E 60 −41.776 14.194 −4.217 1.00 32.73 S ATOM 2456 CE MET E 60 −40.473 15.014 −5.195 1.00 37.28 C ATOM 2457 C MET E 60 −43.287 11.794 −7.946 1.00 32.82 C ATOM 2458 O MET E 60 −43.281 10.640 −8.378 1.00 31.69 O ATOM 2459 N SER E 61 −43.409 12.856 −8.720 1.00 34.88 N ATOM 2460 CA SER E 61 −43.525 12.717 −10.180 1.00 36.77 C ATOM 2461 CB SER E 61 −43.851 14.048 −10.771 1.00 36.98 C ATOM 2462 OG SER E 61 −42.777 14.923 −10.515 1.00 36.64 O ATOM 2463 C SER E 61 −42.240 12.186 −10.826 1.00 38.65 C ATOM 2464 O SER E 61 −42.276 11.508 −11.861 1.00 38.84 O ATOM 2465 N GLY E 62 −41.109 12.548 −10.238 1.00 38.90 N ATOM 2466 CA GLY E 62 −39.821 11.937 −10.565 1.00 42.02 C ATOM 2467 C GLY E 62 −38.915 12.104 −9.370 1.00 42.64 C ATOM 2468 O GLY E 62 −39.227 12.872 −8.468 1.00 42.24 O ATOM 2469 N GLU E 63 −37.796 11.393 −9.347 1.00 45.02 N ATOM 2470 CA GLU E 63 −36.847 11.545 −8.225 1.00 47.21 C ATOM 2471 CB GLU E 63 −36.811 10.301 −7.315 1.00 47.94 C ATOM 2472 CG GLU E 63 −36.103 9.079 −7.946 1.00 50.89 C ATOM 2473 CD GLU E 63 −35.983 7.892 −7.000 1.00 52.10 C ATOM 2474 OE1 GLU E 63 −36.013 8.100 −5.750 1.00 59.78 O ATOM 2475 OE2 GLU E 63 −35.856 6.753 −7.508 1.00 58.02 O ATOM 2476 C GLU E 63 −35.450 11.851 −8.749 1.00 46.14 C ATOM 2477 O GLU E 63 −35.088 11.464 −9.878 1.00 46.17 O ATOM 2478 N LYS E 64 −34.683 12.571 −7.939 1.00 44.27 N ATOM 2479 CA LYS E 64 −33.270 12.750 −8.212 1.00 42.93 C ATOM 2480 CB LYS E 64 −32.739 13.869 −7.367 1.00 41.82 C ATOM 2481 CG LYS E 64 −33.343 15.218 −7.693 1.00 41.03 C ATOM 2482 CD LYS E 64 −33.057 16.133 −6.512 1.00 41.77 C ATOM 2483 CE LYS E 64 −33.368 17.576 −6.788 1.00 41.00 C ATOM 2484 NZ LYS E 64 −32.771 18.415 −5.702 1.00 40.32 N ATOM 2485 C LYS E 64 −32.560 11.436 −7.918 1.00 42.50 C ATOM 2486 O LYS E 64 −33.026 10.610 −7.135 1.00 44.38 O ATOM 2487 N THR E 65 −31.441 11.193 −8.562 1.00 42.38 N ATOM 2488 CA THR E 65 −30.831 9.888 −8.402 1.00 41.77 C ATOM 2489 CB THR E 65 −30.720 9.186 −9.760 1.00 42.28 C ATOM 2490 OG1 THR E 65 −30.159 10.128 −10.693 1.00 41.94 O ATOM 2491 CG2 THR E 65 −32.135 8.713 −10.241 1.00 45.27 C ATOM 2492 C THR E 65 −29.423 9.995 −7.862 1.00 40.59 C ATOM 2493 O THR E 65 −28.849 8.977 −7.475 1.00 40.78 O ATOM 2494 N VAL E 66 −28.842 11.193 −7.905 1.00 38.83 N ATOM 2495 CA VAL E 66 −27.426 11.331 −7.492 1.00 37.55 C ATOM 2496 CB VAL E 66 −26.459 11.437 −8.729 1.00 38.38 C ATOM 2497 CG1 VAL E 66 −25.006 11.254 −8.300 1.00 37.81 C ATOM 2498 CG2 VAL E 66 −26.794 10.360 −9.780 1.00 38.40 C ATOM 2499 C VAL E 66 −27.227 12.484 −6.511 1.00 35.67 C ATOM 2500 O VAL E 66 −27.741 13.564 −6.731 1.00 35.07 O ATOM 2501 N VAL E 67 −26.471 12.247 −5.427 1.00 35.49 N ATOM 2502 CA VAL E 67 −26.180 13.321 −4.440 1.00 33.32 C ATOM 2503 CB VAL E 67 −25.455 12.741 −3.186 1.00 34.57 C ATOM 2504 CG1 VAL E 67 −25.038 13.845 −2.204 1.00 32.91 C ATOM 2505 CG2 VAL E 67 −26.283 11.653 −2.507 1.00 34.32 C ATOM 2506 C VAL E 67 −25.326 14.407 −5.084 1.00 33.24 C ATOM 2507 O VAL E 67 −24.399 14.102 −5.828 1.00 33.82 O ATOM 2508 N CYS E 68 −25.604 15.669 −4.811 1.00 31.69 N ATOM 2509 CA CYS E 68 −24.799 16.744 −5.313 1.00 31.28 C ATOM 2510 CB CYS E 68 −25.538 18.035 −5.075 1.00 29.96 C ATOM 2511 SG CYS E 68 −24.739 19.465 −5.730 1.00 33.39 S ATOM 2512 C CYS E 68 −23.381 16.862 −4.647 1.00 31.68 C ATOM 2513 O CYS E 68 −23.271 17.214 −3.467 1.00 28.47 O ATOM 2514 N LYS E 69 −22.325 16.598 −5.431 1.00 31.61 N ATOM 2515 CA LYS E 69 −20.908 16.763 −5.017 1.00 32.83 C ATOM 2516 CB LYS E 69 −20.027 16.837 −6.279 1.00 33.94 C ATOM 2517 CG LYS E 69 −19.380 15.596 −6.682 1.00 36.27 C ATOM 2518 CD LYS E 69 −18.340 15.955 −7.751 1.00 36.61 C ATOM 2519 CE LYS E 69 −16.997 16.551 −7.151 1.00 35.02 C ATOM 2520 NZ LYS E 69 −16.668 17.768 −7.999 1.00 34.32 N ATOM 2521 C LYS E 69 −20.618 18.068 −4.349 1.00 32.43 C ATOM 2522 O LYS E 69 −19.978 18.119 −3.327 1.00 33.76 O ATOM 2523 N HIS E 70 −20.993 19.132 −5.029 1.00 32.65 N ATOM 2524 CA HIS E 70 −20.764 20.507 −4.616 1.00 34.13 C ATOM 2525 CB HIS E 70 −21.208 21.475 −5.716 1.00 35.61 C ATOM 2526 CG HIS E 70 −20.401 21.362 −6.974 1.00 41.83 C ATOM 2527 ND1 HIS E 70 −20.975 21.215 −8.219 1.00 44.87 N ATOM 2528 CE1 HIS E 70 −20.021 21.107 −9.131 1.00 46.74 C ATOM 2529 NE2 HIS E 70 −18.850 21.169 −8.521 1.00 46.66 N ATOM 2530 CD2 HIS E 70 −19.057 21.348 −7.173 1.00 45.07 C ATOM 2531 C HIS E 70 −21.499 20.875 −3.375 1.00 33.85 C ATOM 2532 O HIS E 70 −20.965 21.612 −2.540 1.00 32.81 O ATOM 2533 N TRP E 71 −22.735 20.382 −3.234 1.00 32.72 N ATOM 2534 CA TRP E 71 −23.473 20.633 −1.999 1.00 31.55 C ATOM 2535 CB TRP E 71 −24.898 20.093 −2.128 1.00 31.78 C ATOM 2536 CG TRP E 71 −25.618 20.081 −0.863 1.00 30.88 C ATOM 2537 CD1 TRP E 71 −26.208 21.145 −0.255 1.00 32.24 C ATOM 2538 NE1 TRP E 71 −26.752 20.766 0.939 1.00 30.42 N ATOM 2539 CE2 TRP E 71 −26.545 19.423 1.119 1.00 31.60 C ATOM 2540 CD2 TRP E 71 −25.810 18.959 0.001 1.00 31.97 C ATOM 2541 CE3 TRP E 71 −25.453 17.599 −0.064 1.00 29.83 C ATOM 2542 CZ3 TRP E 71 −25.828 16.755 0.982 1.00 31.73 C ATOM 2543 CH2 TRP E 71 −26.576 17.246 2.082 1.00 31.68 C ATOM 2544 CZ2 TRP E 71 −26.932 18.579 2.164 1.00 33.50 C ATOM 2545 C TRP E 71 −22.779 19.988 −0.793 1.00 31.55 C ATOM 2546 O TRP E 71 −22.696 20.588 0.273 1.00 31.49 O ATOM 2547 N LEU E 72 −22.324 18.753 −0.940 1.00 31.49 N ATOM 2548 CA LEU E 72 −21.521 18.104 0.095 1.00 33.29 C ATOM 2549 CB LEU E 72 −20.882 16.817 −0.408 1.00 32.05 C ATOM 2550 CG LEU E 72 −21.709 15.628 −0.834 1.00 33.40 C ATOM 2551 CD1 LEU E 72 −20.740 14.576 −1.311 1.00 33.05 C ATOM 2552 CD2 LEU E 72 −22.533 15.074 0.324 1.00 34.38 C ATOM 2553 C LEU E 72 −20.421 18.995 0.666 1.00 35.07 C ATOM 2554 O LEU E 72 −20.179 18.977 1.889 1.00 34.12 O ATOM 2555 N ARG E 73 −19.811 19.800 −0.211 1.00 36.81 N ATOM 2556 CA ARG E 73 −18.657 20.617 0.109 1.00 40.54 C ATOM 2557 CB ARG E 73 −17.582 20.487 −0.995 1.00 40.08 C ATOM 2558 CG ARG E 73 −17.188 19.023 −1.253 1.00 38.53 C ATOM 2559 CD ARG E 73 −15.766 18.806 −1.829 1.00 42.91 C ATOM 2560 NE ARG E 73 −14.721 19.373 −0.957 1.00 44.71 N ATOM 2561 CZ ARG E 73 −13.988 20.441 −1.248 1.00 41.53 C ATOM 2562 NH1 ARG E 73 −14.110 21.056 −2.418 1.00 38.99 N ATOM 2563 NH2 ARG E 73 −13.095 20.874 −0.366 1.00 39.88 N ATOM 2564 C ARG E 73 −19.038 22.074 0.384 1.00 42.77 C ATOM 2565 O ARG E 73 −18.175 22.881 0.710 1.00 44.16 O ATOM 2566 N GLY E 74 −20.336 22.386 0.298 1.00 44.23 N ATOM 2567 CA GLY E 74 −20.858 23.741 0.583 1.00 46.05 C ATOM 2568 C GLY E 74 −20.728 24.678 −0.610 1.00 46.86 C ATOM 2569 O GLY E 74 −20.793 25.910 −0.460 1.00 48.02 O ATOM 2570 N LEU E 75 −20.532 24.104 −1.791 1.00 47.48 N ATOM 2571 CA LEU E 75 −20.302 24.871 −3.020 1.00 48.84 C ATOM 2572 CB LEU E 75 −19.129 24.266 −3.816 1.00 49.51 C ATOM 2573 CG LEU E 75 −17.738 24.086 −3.189 1.00 50.58 C ATOM 2574 CD1 LEU E 75 −16.902 23.169 −4.073 1.00 50.57 C ATOM 2575 CD2 LEU E 75 −17.066 25.434 −2.994 1.00 50.81 C ATOM 2576 C LEU E 75 −21.498 24.943 −3.983 1.00 49.52 C ATOM 2577 O LEU E 75 −21.321 25.345 −5.153 1.00 50.54 O ATOM 2578 N CYS E 76 −22.682 24.497 −3.561 1.00 48.50 N ATOM 2579 CA CYS E 76 −23.841 24.558 −4.460 1.00 49.32 C ATOM 2580 CB CYS E 76 −24.746 23.332 −4.338 1.00 49.22 C ATOM 2581 SG CYS E 76 −25.966 23.095 −5.719 1.00 45.68 S ATOM 2582 C CYS E 76 −24.616 25.803 −4.123 1.00 50.25 C ATOM 2583 O CYS E 76 −24.951 26.040 −2.956 1.00 50.15 O ATOM 2584 N LYS E 77 −24.885 26.608 −5.145 1.00 51.41 N ATOM 2585 CA LYS E 77 −25.629 27.849 −4.945 1.00 52.98 C ATOM 2586 CB LYS E 77 −24.868 29.022 −5.590 1.00 54.17 C ATOM 2587 CG LYS E 77 −23.520 29.356 −4.910 1.00 55.63 C ATOM 2588 CD LYS E 77 −23.643 29.529 −3.369 1.00 59.35 C ATOM 2589 CE LYS E 77 −22.265 29.528 −2.689 1.00 60.06 C ATOM 2590 NZ LYS E 77 −22.296 28.836 −1.352 1.00 63.41 N ATOM 2591 C LYS E 77 −27.092 27.775 −5.458 1.00 52.74 C ATOM 2592 O LYS E 77 −27.834 28.756 −5.373 1.00 53.10 O ATOM 2593 N LYS E 78 −27.478 26.606 −5.971 1.00 52.29 N ATOM 2594 CA LYS E 78 −28.781 26.376 −6.618 1.00 51.59 C ATOM 2595 CB LYS E 78 −28.629 25.314 −7.701 1.00 51.61 C ATOM 2596 CG LYS E 78 −27.597 25.644 −8.736 1.00 55.37 C ATOM 2597 CD LYS E 78 −27.595 24.600 −9.828 1.00 60.45 C ATOM 2598 CE LYS E 78 −26.265 24.629 −10.576 1.00 64.73 C ATOM 2599 NZ LYS E 78 −26.241 23.689 −11.766 1.00 67.80 N ATOM 2600 C LYS E 78 −29.925 25.946 −5.695 1.00 50.45 C ATOM 2601 O LYS E 78 −31.070 25.859 −6.152 1.00 50.69 O ATOM 2602 N GLY E 79 −29.622 25.633 −4.431 1.00 48.61 N ATOM 2603 CA GLY E 79 −30.626 25.169 −3.467 1.00 46.20 C ATOM 2604 C GLY E 79 −31.582 24.117 −4.026 1.00 45.27 C ATOM 2605 O GLY E 79 −31.149 23.109 −4.600 1.00 42.86 O ATOM 2606 N ASP E 80 −32.889 24.387 −3.878 1.00 45.12 N ATOM 2607 CA ASP E 80 −33.971 23.474 −4.336 1.00 44.97 C ATOM 2608 CB ASP E 80 −35.331 23.877 −3.733 1.00 45.06 C ATOM 2609 CG ASP E 80 −35.385 23.621 −2.241 1.00 45.92 C ATOM 2610 OD1 ASP E 80 −34.552 22.805 −1.797 1.00 50.22 O ATOM 2611 OD2 ASP E 80 −36.209 24.215 −1.505 1.00 43.28 O ATOM 2612 C ASP E 80 −34.055 23.260 −5.850 1.00 45.13 C ATOM 2613 O ASP E 80 −34.584 22.247 −6.298 1.00 44.46 O ATOM 2614 N GLN E 81 −33.486 24.186 −6.620 1.00 45.80 N ATOM 2615 CA GLN E 81 −33.488 24.107 −8.089 1.00 46.94 C ATOM 2616 CB GLN E 81 −33.388 25.513 −8.722 1.00 47.91 C ATOM 2617 CG GLN E 81 −34.653 26.382 −8.648 1.00 49.80 C ATOM 2618 CD GLN E 81 −35.031 26.756 −7.225 1.00 52.50 C ATOM 2619 OE1 GLN E 81 −34.201 27.259 −6.450 1.00 56.42 O ATOM 2620 NE2 GLN E 81 −36.271 26.508 −6.866 1.00 53.27 N ATOM 2621 C GLN E 81 −32.354 23.226 −8.628 1.00 46.85 C ATOM 2622 O GLN E 81 −32.232 23.038 −9.840 1.00 47.31 O ATOM 2623 N CYS E 82 −31.532 22.660 −7.741 1.00 46.00 N ATOM 2624 CA CYS E 82 −30.473 21.759 −8.197 1.00 44.71 C ATOM 2625 CB CYS E 82 −29.479 21.471 −7.058 1.00 44.58 C ATOM 2626 SG CYS E 82 −28.029 20.574 −7.678 1.00 44.34 S ATOM 2627 C CYS E 82 −31.048 20.446 −8.726 1.00 44.24 C ATOM 2628 O CYS E 82 −32.071 19.975 −8.225 1.00 44.60 O ATOM 2629 N GLU E 83 −30.404 19.860 −9.739 1.00 43.02 N ATOM 2630 CA GLU E 83 −30.808 18.571 −10.321 1.00 42.89 C ATOM 2631 CB GLU E 83 −30.223 18.471 −11.729 1.00 43.36 C ATOM 2632 CG GLU E 83 −29.088 19.514 −11.963 1.00 47.27 C ATOM 2633 CD GLU E 83 −28.176 19.165 −13.153 1.00 48.75 C ATOM 2634 OE1 GLU E 83 −27.193 19.932 −13.395 1.00 55.39 O ATOM 2635 OE2 GLU E 83 −28.415 18.114 −13.830 1.00 55.23 O ATOM 2636 C GLU E 83 −30.335 17.384 −9.494 1.00 39.93 C ATOM 2637 O GLU E 83 −30.741 16.215 −9.687 1.00 39.21 O ATOM 2638 N PHE E 84 −29.430 17.670 −8.570 1.00 37.89 N ATOM 2639 CA PHE E 84 −28.891 16.613 −7.756 1.00 35.71 C ATOM 2640 CB PHE E 84 −27.343 16.609 −7.806 1.00 35.62 C ATOM 2641 CG PHE E 84 −26.766 16.461 −9.205 1.00 36.55 C ATOM 2642 CD1 PHE E 84 −26.238 17.561 −9.868 1.00 35.78 C ATOM 2643 CE1 PHE E 84 −25.683 17.440 −11.182 1.00 38.26 C ATOM 2644 CZ PHE E 84 −25.649 16.207 −11.803 1.00 38.82 C ATOM 2645 CE2 PHE E 84 −26.161 15.078 −11.147 1.00 42.35 C ATOM 2646 CD2 PHE E 84 −26.716 15.210 −9.829 1.00 39.76 C ATOM 2647 C PHE E 84 −29.455 16.778 −6.320 1.00 34.41 C ATOM 2648 O PHE E 84 −29.864 17.860 −5.913 1.00 33.89 O ATOM 2649 N LEU E 85 −29.455 15.676 −5.603 1.00 33.01 N ATOM 2650 CA LEU E 85 −29.962 15.539 −4.242 1.00 34.42 C ATOM 2651 CB LEU E 85 −29.888 14.039 −3.909 1.00 34.42 C ATOM 2652 CG LEU E 85 −30.854 12.999 −3.361 1.00 38.28 C ATOM 2653 CD1 LEU E 85 −32.315 13.248 −3.771 1.00 39.00 C ATOM 2654 CD2 LEU E 85 −30.402 11.593 −3.836 1.00 34.69 C ATOM 2655 C LEU E 85 −29.122 16.367 −3.237 1.00 34.30 C ATOM 2656 O LEU E 85 −27.880 16.259 −3.198 1.00 33.65 O ATOM 2657 N HIS E 86 −29.786 17.193 −2.434 1.00 33.63 N ATOM 2658 CA HIS E 86 −29.142 17.847 −1.317 1.00 33.34 C ATOM 2659 CB HIS E 86 −29.541 19.304 −1.260 1.00 32.70 C ATOM 2660 CG HIS E 86 −28.884 20.172 −2.295 1.00 31.14 C ATOM 2661 ND1 HIS E 86 −28.827 21.541 −2.162 1.00 30.21 N ATOM 2662 CE1 HIS E 86 −28.204 22.066 −3.195 1.00 31.04 C ATOM 2663 NE2 HIS E 86 −27.817 21.077 −3.983 1.00 27.66 N ATOM 2664 CD2 HIS E 86 −28.236 19.883 −3.447 1.00 28.50 C ATOM 2665 C HIS E 86 −29.508 17.096 −0.031 1.00 34.46 C ATOM 2666 O HIS E 86 −30.227 17.602 0.834 1.00 34.31 O ATOM 2667 N GLU E 87 −29.018 15.860 0.059 1.00 35.41 N ATOM 2668 CA GLU E 87 −29.192 15.005 1.212 1.00 37.64 C ATOM 2669 CB GLU E 87 −30.511 14.229 1.121 1.00 37.29 C ATOM 2670 CG GLU E 87 −30.694 13.235 2.264 1.00 38.59 C ATOM 2671 CD GLU E 87 −31.891 12.280 2.135 1.00 38.23 C ATOM 2672 OE1 GLU E 87 −32.573 12.259 1.077 1.00 35.85 O ATOM 2673 OE2 GLU E 87 −32.117 11.536 3.137 1.00 41.22 O ATOM 2674 C GLU E 87 −28.040 13.999 1.175 1.00 39.03 C ATOM 2675 O GLU E 87 −27.698 13.479 0.100 1.00 38.12 O ATOM 2676 N TYR E 88 −27.453 13.683 2.329 1.00 40.99 N ATOM 2677 CA TYR E 88 −26.438 12.647 2.306 1.00 43.56 C ATOM 2678 CB TYR E 88 −25.405 12.692 3.460 1.00 44.72 C ATOM 2679 CG TYR E 88 −24.238 11.718 3.169 1.00 47.61 C ATOM 2680 CD1 TYR E 88 −23.255 12.023 2.216 1.00 49.16 C ATOM 2681 CE1 TYR E 88 −22.220 11.110 1.913 1.00 48.23 C ATOM 2682 CZ TYR E 88 −22.190 9.907 2.524 1.00 44.96 C ATOM 2683 OH TYR E 88 −21.205 9.042 2.249 1.00 49.62 O ATOM 2684 CE2 TYR E 88 −23.132 9.561 3.470 1.00 49.06 C ATOM 2685 CD2 TYR E 88 −24.161 10.464 3.790 1.00 48.49 C ATOM 2686 C TYR E 88 −27.123 11.341 2.243 1.00 44.32 C ATOM 2687 O TYR E 88 −27.732 10.920 3.203 1.00 45.92 O ATOM 2688 N ASP E 89 −27.039 10.698 1.093 1.00 45.86 N ATOM 2689 CA ASP E 89 −27.430 9.313 0.980 1.00 47.31 C ATOM 2690 CB ASP E 89 −28.644 9.171 0.048 1.00 46.75 C ATOM 2691 CG ASP E 89 −29.146 7.733 −0.071 1.00 47.59 C ATOM 2692 OD1 ASP E 89 −28.410 6.765 0.237 1.00 46.06 O ATOM 2693 OD2 ASP E 89 −30.306 7.566 −0.503 1.00 50.29 O ATOM 2694 C ASP E 89 −26.221 8.580 0.428 1.00 48.29 C ATOM 2695 O ASP E 89 −25.901 8.717 −0.747 1.00 47.55 O ATOM 2696 N MET E 90 −25.566 7.805 1.295 1.00 50.53 N ATOM 2697 CA MET E 90 −24.346 7.060 0.956 1.00 53.26 C ATOM 2698 CB MET E 90 −23.756 6.309 2.188 1.00 53.27 C ATOM 2699 CG MET E 90 −24.552 5.053 2.647 1.00 56.70 C ATOM 2700 SD MET E 90 −24.136 4.344 4.281 1.00 58.92 S ATOM 2701 CE MET E 90 −22.763 3.255 3.864 1.00 60.49 C ATOM 2702 C MET E 90 −24.551 6.100 −0.214 1.00 52.16 C ATOM 2703 O MET E 90 −23.581 5.736 −0.879 1.00 52.83 O ATOM 2704 N THR E 91 −25.810 5.715 −0.474 1.00 51.03 N ATOM 2705 CA THR E 91 −26.135 4.762 −1.551 1.00 49.35 C ATOM 2706 CB THR E 91 −27.402 3.887 −1.243 1.00 49.74 C ATOM 2707 OG1 THR E 91 −28.539 4.732 −1.018 1.00 49.46 O ATOM 2708 CG2 THR E 91 −27.172 3.001 −0.031 1.00 50.99 C ATOM 2709 C THR E 91 −26.377 5.443 −2.873 1.00 47.57 C ATOM 2710 O THR E 91 −26.556 4.765 −3.900 1.00 47.97 O ATOM 2711 N LYS E 92 −26.410 6.773 −2.870 1.00 44.84 N ATOM 2712 CA LYS E 92 −26.694 7.493 −4.110 1.00 42.64 C ATOM 2713 CB LYS E 92 −28.060 8.202 −4.052 1.00 42.47 C ATOM 2714 CG LYS E 92 −29.239 7.224 −4.140 1.00 43.53 C ATOM 2715 CD LYS E 92 −30.550 7.958 −4.021 1.00 46.74 C ATOM 2716 CE LYS E 92 −31.751 7.118 −4.485 1.00 49.77 C ATOM 2717 NZ LYS E 92 −32.896 8.037 −4.867 1.00 50.02 N ATOM 2718 C LYS E 92 −25.573 8.457 −4.501 1.00 40.10 C ATOM 2719 O LYS E 92 −25.796 9.458 −5.136 1.00 38.93 O ATOM 2720 N MET E 93 −24.349 8.133 −4.122 1.00 39.27 N ATOM 2721 CA MET E 93 −23.235 9.034 −4.437 1.00 36.91 C ATOM 2722 CB MET E 93 −22.119 8.773 −3.412 1.00 37.41 C ATOM 2723 CG MET E 93 −22.479 9.291 −1.964 1.00 31.53 C ATOM 2724 SD MET E 93 −22.304 11.036 −1.841 1.00 28.70 S ATOM 2725 CE MET E 93 −20.484 11.169 −1.694 1.00 34.53 C ATOM 2726 C MET E 93 −22.765 8.825 −5.899 1.00 37.37 C ATOM 2727 O MET E 93 −22.918 7.710 −6.447 1.00 36.91 O ATOM 2728 N PRO E 94 −22.165 9.857 −6.536 1.00 36.94 N ATOM 2729 CA PRO E 94 −21.564 9.531 −7.838 1.00 37.19 C ATOM 2730 CB PRO E 94 −21.254 10.895 −8.461 1.00 36.24 C ATOM 2731 CG PRO E 94 −20.950 11.736 −7.389 1.00 38.23 C ATOM 2732 CD PRO E 94 −21.988 11.296 −6.224 1.00 39.37 C ATOM 2733 C PRO E 94 −20.320 8.631 −7.811 1.00 36.57 C ATOM 2734 O PRO E 94 −19.810 8.256 −6.737 1.00 35.69 O ATOM 2735 N GLU E 95 −19.914 8.226 −9.014 1.00 35.80 N ATOM 2736 CA GLU E 95 −18.753 7.391 −9.223 1.00 35.27 C ATOM 2737 CB GLU E 95 −18.713 6.907 −10.675 1.00 35.38 C ATOM 2738 CG GLU E 95 −17.861 5.669 −10.825 1.00 38.08 C ATOM 2739 CD GLU E 95 −17.766 5.134 −12.274 1.00 40.77 C ATOM 2740 OE1 GLU E 95 −18.593 5.507 −13.149 1.00 46.42 O ATOM 2741 OE2 GLU E 95 −16.839 4.316 −12.507 1.00 46.20 O ATOM 2742 C GLU E 95 −17.498 8.196 −8.913 1.00 31.36 C ATOM 2743 O GLU E 95 −17.424 9.384 −9.207 1.00 31.21 O ATOM 2744 N CYS E 96 −16.527 7.556 −8.294 1.00 29.43 N ATOM 2745 CA CYS E 96 −15.284 8.265 −7.889 1.00 28.13 C ATOM 2746 CB CYS E 96 −14.508 7.365 −6.971 1.00 27.21 C ATOM 2747 SG CYS E 96 −12.849 7.953 −6.549 1.00 27.50 S ATOM 2748 C CYS E 96 −14.508 8.471 −9.175 1.00 27.70 C ATOM 2749 O CYS E 96 −14.232 7.501 −9.836 1.00 27.84 O ATOM 2750 N TYR E 97 −14.181 9.703 −9.531 1.00 26.25 N ATOM 2751 CA TYR E 97 −13.414 9.932 −10.745 1.00 27.57 C ATOM 2752 CB TYR E 97 −13.183 11.447 −10.963 1.00 27.83 C ATOM 2753 CG TYR E 97 −12.434 11.765 −12.280 1.00 27.33 C ATOM 2754 CD1 TYR E 97 −13.144 11.989 −13.471 1.00 27.83 C ATOM 2755 CE1 TYR E 97 −12.478 12.267 −14.677 1.00 27.62 C ATOM 2756 CZ TYR E 97 −11.082 12.321 −14.685 1.00 28.27 C ATOM 2757 OH TYR E 97 −10.432 12.605 −15.880 1.00 25.71 O ATOM 2758 CE2 TYR E 97 −10.354 12.103 −13.511 1.00 24.85 C ATOM 2759 CD2 TYR E 97 −11.038 11.817 −12.316 1.00 26.24 C ATOM 2760 C TYR E 97 −12.073 9.203 −10.758 1.00 28.02 C ATOM 2761 O TYR E 97 −11.659 8.599 −11.805 1.00 27.69 O ATOM 2762 N PHE E 98 −11.400 9.205 −9.593 1.00 28.03 N ATOM 2763 CA PHE E 98 −10.056 8.574 −9.539 1.00 28.74 C ATOM 2764 CB PHE E 98 −9.209 9.067 −8.348 1.00 27.42 C ATOM 2765 CG PHE E 98 −8.924 10.529 −8.429 1.00 27.64 C ATOM 2766 CD1 PHE E 98 −7.877 11.006 −9.197 1.00 23.70 C ATOM 2767 CE1 PHE E 98 −7.658 12.398 −9.317 1.00 26.52 C ATOM 2768 CZ PHE E 98 −8.497 13.304 −8.674 1.00 28.09 C ATOM 2769 CE2 PHE E 98 −9.562 12.831 −7.920 1.00 28.78 C ATOM 2770 CD2 PHE E 98 −9.789 11.454 −7.817 1.00 28.89 C ATOM 2771 C PHE E 98 −10.123 7.079 −9.657 1.00 29.39 C ATOM 2772 O PHE E 98 −9.326 6.464 −10.377 1.00 29.21 O ATOM 2773 N TYR E 99 −11.082 6.463 −8.980 1.00 30.20 N ATOM 2774 CA TYR E 99 −11.204 5.035 −9.147 1.00 31.46 C ATOM 2775 CB TYR E 99 −12.314 4.476 −8.289 1.00 32.90 C ATOM 2776 CG TYR E 99 −12.154 3.001 −8.112 1.00 35.08 C ATOM 2777 CD1 TYR E 99 −11.241 2.484 −7.198 1.00 34.37 C ATOM 2778 CE1 TYR E 99 −11.089 1.106 −7.057 1.00 36.08 C ATOM 2779 CZ TYR E 99 −11.825 0.251 −7.867 1.00 36.77 C ATOM 2780 OH TYR E 99 −11.700 −1.119 −7.754 1.00 39.62 O ATOM 2781 CE2 TYR E 99 −12.712 0.738 −8.781 1.00 38.21 C ATOM 2782 CD2 TYR E 99 −12.871 2.107 −8.916 1.00 36.36 C ATOM 2783 C TYR E 99 −11.462 4.646 −10.616 1.00 32.82 C ATOM 2784 O TYR E 99 −10.908 3.659 −11.120 1.00 32.79 O ATOM 2785 N SER E 100 −12.332 5.389 −11.280 1.00 33.86 N ATOM 2786 CA SER E 100 −12.687 5.068 −12.670 1.00 35.38 C ATOM 2787 CB SER E 100 −13.824 5.936 −13.129 1.00 35.98 C ATOM 2788 OG SER E 100 −14.948 5.495 −12.418 1.00 42.18 O ATOM 2789 C SER E 100 −11.552 5.261 −13.634 1.00 34.57 C ATOM 2790 O SER E 100 −11.311 4.382 −14.485 1.00 35.38 O ATOM 2791 N LYS E 101 −10.898 6.419 −13.544 1.00 33.48 N ATOM 2792 CA LYS E 101 −9.846 6.763 −14.475 1.00 33.32 C ATOM 2793 CB LYS E 101 −9.693 8.273 −14.596 1.00 32.76 C ATOM 2794 CG LYS E 101 −10.919 8.921 −15.140 1.00 35.61 C ATOM 2795 CD LYS E 101 −11.059 8.628 −16.629 1.00 39.82 C ATOM 2796 CE LYS E 101 −12.355 9.151 −17.199 1.00 42.68 C ATOM 2797 NZ LYS E 101 −12.484 8.574 −18.576 1.00 42.39 N ATOM 2798 C LYS E 101 −8.497 6.108 −14.191 1.00 33.88 C ATOM 2799 O LYS E 101 −7.759 5.832 −15.139 1.00 33.90 O ATOM 2800 N PHE E 102 −8.181 5.861 −12.912 1.00 32.56 N ATOM 2801 CA PHE E 102 −6.835 5.447 −12.503 1.00 31.86 C ATOM 2802 CB PHE E 102 −6.209 6.431 −11.495 1.00 31.71 C ATOM 2803 CG PHE E 102 −5.911 7.752 −12.070 1.00 29.81 C ATOM 2804 CD1 PHE E 102 −4.669 8.009 −12.648 1.00 30.67 C ATOM 2805 CE1 PHE E 102 −4.383 9.228 −13.206 1.00 31.08 C ATOM 2806 CZ PHE E 102 −5.313 10.210 −13.239 1.00 29.85 C ATOM 2807 CE2 PHE E 102 −6.592 9.960 −12.677 1.00 32.46 C ATOM 2808 CD2 PHE E 102 −6.855 8.741 −12.088 1.00 30.80 C ATOM 2809 C PHE E 102 −6.867 4.069 −11.922 1.00 32.42 C ATOM 2810 O PHE E 102 −5.820 3.478 −11.671 1.00 33.02 O ATOM 2811 N GLY E 103 −8.068 3.525 −11.746 1.00 31.07 N ATOM 2812 CA GLY E 103 −8.200 2.204 −11.153 1.00 31.68 C ATOM 2813 C GLY E 103 −7.805 2.110 −9.684 1.00 31.41 C ATOM 2814 O GLY E 103 −7.611 1.003 −9.152 1.00 31.06 O ATOM 2815 N GLU E 104 −7.663 3.257 −9.019 1.00 29.83 N ATOM 2816 CA GLU E 104 −7.265 3.253 −7.620 1.00 30.89 C ATOM 2817 CB GLU E 104 −5.732 3.019 −7.469 1.00 29.78 C ATOM 2818 CG GLU E 104 −4.916 4.241 −7.780 1.00 33.61 C ATOM 2819 CD GLU E 104 −3.398 4.038 −7.615 1.00 36.14 C ATOM 2820 OE1 GLU E 104 −2.709 3.917 −8.663 1.00 46.90 O ATOM 2821 OE2 GLU E 104 −2.887 3.988 −6.469 1.00 39.91 O ATOM 2822 C GLU E 104 −7.690 4.595 −7.001 1.00 29.61 C ATOM 2823 O GLU E 104 −7.924 5.573 −7.706 1.00 28.68 O ATOM 2824 N CYS E 105 −7.825 4.607 −5.671 1.00 29.11 N ATOM 2825 CA CYS E 105 −8.246 5.809 −4.944 1.00 28.00 C ATOM 2826 CB CYS E 105 −9.773 5.777 −4.754 1.00 28.22 C ATOM 2827 SG CYS E 105 −10.400 7.210 −3.819 1.00 26.77 S ATOM 2828 C CYS E 105 −7.535 5.815 −3.584 1.00 27.95 C ATOM 2829 O CYS E 105 −7.514 4.801 −2.897 1.00 25.98 O ATOM 2830 N SER E 106 −6.951 6.947 −3.213 1.00 27.07 N ATOM 2831 CA SER E 106 −6.105 7.032 −1.999 1.00 27.68 C ATOM 2832 CB SER E 106 −5.147 8.214 −2.106 1.00 28.93 C ATOM 2833 OG SER E 106 −4.158 8.061 −3.082 1.00 32.26 O ATOM 2834 C SER E 106 −6.926 7.262 −0.708 1.00 27.48 C ATOM 2835 O SER E 106 −6.392 7.202 0.389 1.00 25.89 O ATOM 2836 N ASN E 107 −8.224 7.543 −0.847 1.00 27.00 N ATOM 2837 CA ASN E 107 −9.022 7.880 0.340 1.00 27.38 C ATOM 2838 CB ASN E 107 −10.085 8.933 −0.017 1.00 25.51 C ATOM 2839 CG ASN E 107 −10.890 9.409 1.197 1.00 27.22 C ATOM 2840 OD1 ASN E 107 −10.602 9.029 2.353 1.00 25.23 O ATOM 2841 ND2 ASN E 107 −11.888 10.253 0.951 1.00 23.13 N ATOM 2842 C ASN E 107 −9.615 6.620 0.922 1.00 26.72 C ATOM 2843 O ASN E 107 −10.527 6.051 0.323 1.00 27.32 O ATOM 2844 N LYS E 108 −9.112 6.171 2.083 1.00 27.29 N ATOM 2845 CA LYS E 108 −9.675 4.967 2.740 1.00 28.64 C ATOM 2846 CB LYS E 108 −9.005 4.634 4.084 1.00 29.14 C ATOM 2847 CG LYS E 108 −7.538 4.411 4.047 1.00 32.85 C ATOM 2848 CD LYS E 108 −7.002 4.055 5.424 1.00 35.90 C ATOM 2849 CE LYS E 108 −5.512 4.069 5.365 1.00 36.28 C ATOM 2850 NZ LYS E 108 −4.896 4.177 6.709 1.00 38.68 N ATOM 2851 C LYS E 108 −11.169 5.115 3.022 1.00 28.54 C ATOM 2852 O LYS E 108 −11.874 4.132 3.143 1.00 28.63 O ATOM 2853 N GLU E 109 −11.635 6.345 3.166 1.00 28.33 N ATOM 2854 CA GLU E 109 −13.047 6.575 3.462 1.00 29.24 C ATOM 2855 CB GLU E 109 −13.216 7.516 4.691 1.00 30.12 C ATOM 2856 CG GLU E 109 −12.867 6.879 6.081 1.00 35.42 C ATOM 2857 CD GLU E 109 −11.375 6.836 6.374 1.00 39.45 C ATOM 2858 OE1 GLU E 109 −10.711 7.883 6.247 1.00 43.20 O ATOM 2859 OE2 GLU E 109 −10.867 5.756 6.753 1.00 42.90 O ATOM 2860 C GLU E 109 −13.729 7.224 2.273 1.00 26.67 C ATOM 2861 O GLU E 109 −14.689 7.956 2.466 1.00 27.77 O ATOM 2862 N CYS E 110 −13.258 6.987 1.039 1.00 25.08 N ATOM 2863 CA CYS E 110 −13.932 7.567 −0.125 1.00 22.73 C ATOM 2864 CB CYS E 110 −13.376 7.014 −1.473 1.00 22.38 C ATOM 2865 SG CYS E 110 −14.027 7.983 −2.730 1.00 25.05 S ATOM 2866 C CYS E 110 −15.435 7.227 −0.065 1.00 23.60 C ATOM 2867 O CYS E 110 −15.792 6.066 0.033 1.00 22.90 O ATOM 2868 N PRO E 111 −16.302 8.231 −0.103 1.00 25.41 N ATOM 2869 CA PRO E 111 −17.756 7.947 −0.173 1.00 26.31 C ATOM 2870 CB PRO E 111 −18.338 9.189 0.451 1.00 25.57 C ATOM 2871 CG PRO E 111 −17.444 10.247 −0.107 1.00 26.34 C ATOM 2872 CD PRO E 111 −16.056 9.690 −0.017 1.00 24.13 C ATOM 2873 C PRO E 111 −18.303 7.806 −1.607 1.00 28.09 C ATOM 2874 O PRO E 111 −19.532 7.606 −1.781 1.00 29.35 O ATOM 2875 N PHE E 112 −17.433 7.912 −2.620 1.00 27.81 N ATOM 2876 CA PHE E 112 −17.882 7.841 −4.035 1.00 28.90 C ATOM 2877 CB PHE E 112 −17.134 8.827 −4.915 1.00 27.89 C ATOM 2878 CG PHE E 112 −17.352 10.241 −4.519 1.00 29.43 C ATOM 2879 CD1 PHE E 112 −18.534 10.897 −4.864 1.00 29.20 C ATOM 2880 CE1 PHE E 112 −18.766 12.200 −4.465 1.00 31.44 C ATOM 2881 CZ PHE E 112 −17.793 12.893 −3.678 1.00 33.51 C ATOM 2882 CE2 PHE E 112 −16.595 12.222 −3.336 1.00 36.00 C ATOM 2883 CD2 PHE E 112 −16.403 10.905 −3.756 1.00 32.00 C ATOM 2884 C PHE E 112 −17.782 6.434 −4.538 1.00 30.08 C ATOM 2885 O PHE E 112 −17.062 5.634 −3.968 1.00 29.81 O ATOM 2886 N LEU E 113 −18.581 6.077 −5.546 1.00 32.91 N ATOM 2887 CA LEU E 113 −18.669 4.649 −5.892 1.00 35.90 C ATOM 2888 CB LEU E 113 −19.833 4.379 −6.828 1.00 37.47 C ATOM 2889 CG LEU E 113 −21.292 4.429 −6.377 1.00 41.02 C ATOM 2890 CD1 LEU E 113 −21.876 3.209 −7.053 1.00 44.71 C ATOM 2891 CD2 LEU E 113 −21.536 4.386 −4.840 1.00 43.90 C ATOM 2892 C LEU E 113 −17.391 4.132 −6.538 1.00 36.02 C ATOM 2893 O LEU E 113 −16.829 4.764 −7.434 1.00 36.35 O ATOM 2894 N HIS E 114 −16.931 2.977 −6.089 1.00 36.99 N ATOM 2895 CA HIS E 114 −15.750 2.409 −6.678 1.00 37.82 C ATOM 2896 CB HIS E 114 −14.693 2.014 −5.614 1.00 36.44 C ATOM 2897 CG HIS E 114 −13.917 3.183 −5.031 1.00 30.06 C ATOM 2898 ND1 HIS E 114 −12.967 3.009 −4.046 1.00 27.67 N ATOM 2899 CE1 HIS E 114 −12.448 4.177 −3.706 1.00 29.37 C ATOM 2900 NE2 HIS E 114 −12.992 5.119 −4.459 1.00 21.70 N ATOM 2901 CD2 HIS E 114 −13.942 4.521 −5.284 1.00 28.54 C ATOM 2902 C HIS E 114 −16.206 1.255 −7.575 1.00 41.48 C ATOM 2903 O HIS E 114 −16.540 0.141 −7.109 1.00 41.75 O ATOM 2904 N ILE E 115 −16.225 1.542 −8.874 1.00 45.09 N ATOM 2905 CA ILE E 115 −16.770 0.592 −9.829 1.00 48.98 C ATOM 2906 CB ILE E 115 −17.879 1.233 −10.682 1.00 48.73 C ATOM 2907 CG1 ILE E 115 −19.018 1.650 −9.769 1.00 49.30 C ATOM 2908 CD1 ILE E 115 −20.108 2.486 −10.414 1.00 52.31 C ATOM 2909 CG2 ILE E 115 −18.429 0.233 −11.703 1.00 50.04 C ATOM 2910 C ILE E 115 −15.698 −0.097 −10.663 1.00 51.45 C ATOM 2911 O ILE E 115 −14.888 0.552 −11.342 1.00 51.91 O ATOM 2912 N ASP E 116 −15.713 −1.426 −10.604 1.00 55.09 N ATOM 2913 CA ASP E 116 −14.838 −2.269 −11.446 1.00 58.10 C ATOM 2914 CB ASP E 116 −14.477 −3.551 −10.704 1.00 57.84 C ATOM 2915 CG ASP E 116 −13.320 −3.361 −9.748 1.00 59.39 C ATOM 2916 OD1 ASP E 116 −12.283 −2.772 −10.153 1.00 58.51 O ATOM 2917 OD2 ASP E 116 −13.450 −3.816 −8.591 1.00 61.50 O ATOM 2918 C ASP E 116 −15.346 −2.612 −12.862 1.00 59.18 C ATOM 2919 O ASP E 116 −14.564 −2.484 −13.826 1.00 59.43 O ATOM 2920 N PRO E 117 −16.632 −3.068 −12.982 1.00 60.29 N ATOM 2921 CA PRO E 117 −17.292 −3.632 −14.189 1.00 61.09 C ATOM 2922 CB PRO E 117 −18.750 −3.133 −14.046 1.00 61.33 C ATOM 2923 CG PRO E 117 −18.991 −3.196 −12.535 1.00 60.80 C ATOM 2924 CD PRO E 117 −17.592 −3.089 −11.852 1.00 60.62 C ATOM 2925 C PRO E 117 −16.713 −3.318 −15.593 1.00 62.20 C ATOM 2926 O PRO E 117 −16.501 −2.150 −15.971 1.00 62.74 O ATOM 2927 OXT PRO E 117 −16.466 −4.245 −16.386 1.00 62.43 O ATOM 2928 ZN ZN E 502 −12.635 7.037 −4.437 1.00 27.25 ZN ATOM 2929 ZN ZN E 501 −26.608 21.029 −5.804 1.00 39.92 ZN ATOM 2930 OH2 HOH W 1 −17.549 40.654 24.318 1.00 31.56 ATOM 2931 OH2 HOH W 2 17.362 20.052 −2.479 1.00 25.50 ATOM 2932 OH2 HOH W 3 −2.011 29.501 11.491 1.00 30.11 ATOM 2933 OH2 HOH W 4 −1.231 11.877 4.344 1.00 33.10 ATOM 2934 OH2 HOH W 5 −15.837 4.131 −2.007 1.00 34.35 ATOM 2935 OH2 HOH W 6 −18.878 24.607 32.037 1.00 37.33 ATOM 2936 OH2 HOH W 7 −8.008 1.692 −4.434 1.00 36.76 ATOM 2937 OH2 HOH W 8 0.580 21.608 13.618 1.00 37.53 ATOM 2938 OH2 HOH W 9 16.380 17.882 10.672 1.00 37.87 ATOM 2939 OH2 HOH W 10 −22.130 37.815 21.073 1.00 35.89 ATOM 2940 OH2 HOH W 11 4.673 13.758 −32.750 1.00 33.95 ATOM 2941 OH2 HOH W 12 −20.499 24.465 5.437 1.00 28.59 ATOM 2942 OH2 HOH W 13 23.425 25.428 −2.508 1.00 37.38 ATOM 2943 OH2 HOH W 14 −14.983 15.840 −4.699 1.00 46.26 ATOM 2944 OH2 HOH W 15 −10.233 9.257 −27.822 1.00 38.63 ATOM 2945 OH2 HOH W 16 −21.192 34.424 12.062 1.00 37.61 ATOM 2946 OH2 HOH W 17 0.053 26.141 −3.950 1.00 54.93 ATOM 2947 OH2 HOH W 18 −5.394 4.386 9.736 1.00 37.09 ATOM 2948 OH2 HOH W 19 −8.975 14.385 −2.075 1.00 37.40 ATOM 2949 OH2 HOH W 20 −11.483 11.732 −4.064 1.00 48.02 ATOM 2950 OH2 HOH W 21 8.538 14.250 −15.163 1.00 45.77 ATOM 2951 OH2 HOH W 22 −13.507 26.363 33.684 1.00 36.52 ATOM 2952 OH2 HOH W 23 −22.909 39.389 25.431 1.00 51.50 ATOM 2953 OH2 HOH W 24 −6.016 34.962 15.554 1.00 40.08 ATOM 2954 OH2 HOH W 25 −27.799 20.311 13.356 1.00 40.64 ATOM 2955 OH2 HOH W 26 −9.659 40.204 28.277 1.00 50.22 ATOM 2956 OH2 HOH W 27 −22.574 19.101 15.450 1.00 47.34 ATOM 2957 OH2 HOH W 28 −37.126 26.264 −0.600 1.00 39.56 ATOM 2958 OH2 HOH W 29 −9.898 30.112 1.970 1.00 56.19 ATOM 2959 OH2 HOH W 30 14.875 14.573 −3.591 1.00 37.15 ATOM 2960 OH2 HOH W 31 −1.553 2.908 9.016 1.00 47.01 ATOM 2961 OH2 HOH W 32 −21.032 30.547 7.051 1.00 40.04 ATOM 2962 OH2 HOH W 33 −0.209 7.321 −31.105 1.00 38.83 ATOM 2963 OH2 HOH W 34 −9.687 37.554 14.224 1.00 43.90 ATOM 2964 OH2 HOH W 35 −22.793 14.964 −8.325 1.00 50.86 ATOM 2965 OH2 HOH W 36 −8.615 28.359 −20.387 1.00 40.23 ATOM 2966 OH2 HOH W 37 −14.482 27.081 1.103 1.00 48.65 ATOM 2967 OH2 HOH W 38 −21.411 9.115 −11.631 1.00 44.01 ATOM 2968 OH2 HOH W 39 −11.464 1.095 −12.508 1.00 45.05 ATOM 2969 OH2 HOH W 40 −0.402 15.047 −34.444 1.00 41.68 ATOM 2970 OH2 HOH W 41 13.970 29.824 −18.438 1.00 46.66 ATOM 2971 OH2 HOH W 42 0.010 18.179 −1.761 1.00 44.33 ATOM 2972 OH2 HOH W 43 −24.141 42.098 27.887 1.00 62.32 ATOM 2973 OH2 HOH W 44 −28.543 34.801 14.268 1.00 48.79 ATOM 2974 OH2 HOH W 45 −19.052 36.669 14.149 1.00 43.38 ATOM 2975 OH2 HOH W 46 −21.027 5.982 −0.187 1.00 43.29 ATOM 2976 OH2 HOH W 47 −11.461 10.710 26.650 1.00 45.24 ATOM 2977 OH2 HOH W 48 −32.578 9.524 −0.486 1.00 62.86 ATOM 2978 OH2 HOH W 49 −25.755 40.650 29.914 1.00 48.32 ATOM 2979 OH2 HOH W 50 −1.405 33.346 −4.925 1.00 60.35 ATOM 2980 OH2 HOH W 51 −5.133 15.525 3.092 1.00 32.86 ATOM 2981 OH2 HOH W 52 −13.645 18.564 32.922 1.00 50.50 ATOM 2982 OH2 HOH W 53 −12.789 9.521 30.610 1.00 53.37 ATOM 2983 OH2 HOH W 54 −9.573 17.794 28.093 1.00 49.45 ATOM 2984 OH2 HOH W 55 −12.428 24.883 −14.429 1.00 43.17 ATOM 2985 OH2 HOH W 56 −27.927 17.852 13.258 1.00 49.70 ATOM 2986 OH2 HOH W 57 2.388 8.886 18.777 1.00 45.10 ATOM 2987 OH2 HOH W 58 −12.077 0.367 −3.463 1.00 44.30 ATOM 2988 OW0 HOH W 59 1.704 8.508 14.181 1.00 30.60 ATOM 2989 OW0 HOH W 60 −7.056 24.808 −1.087 1.00 33.17 ATOM 2990 OW0 HOH W 61 −12.392 10.737 −1.805 1.00 34.81 ATOM 2991 OW0 HOH W 62 −2.525 5.036 5.866 1.00 36.96 ATOM 2992 OW0 HOH W 63 −12.292 41.162 28.775 1.00 28.15 ATOM 2993 OW0 HOH W 64 −7.563 19.859 7.620 1.00 29.26 ATOM 2994 OW0 HOH W 65 −15.842 2.676 −14.366 1.00 53.47 ATOM 2995 OW0 HOH W 66 −31.515 20.265 −4.155 1.00 35.35 ATOM 2996 OW0 HOH W 67 −3.936 8.455 −26.236 1.00 32.60 ATOM 2997 OW0 HOH W 68 −11.026 3.554 −0.830 1.00 40.04 ATOM 2998 OW0 HOH W 69 −19.858 20.494 4.314 1.00 31.44 ATOM 2999 OW0 HOH W 70 8.620 14.453 −26.618 1.00 35.55 ATOM 3000 OW0 HOH W 71 −2.280 13.892 6.137 1.00 38.09 ATOM 3001 OW0 HOH W 72 4.718 30.472 −24.432 1.00 38.03 ATOM 3002 OW0 HOH W 73 −5.982 20.628 −1.464 1.00 46.93 ATOM 3003 OW0 HOH W 74 3.340 20.902 4.854 1.00 37.94 ATOM 3004 OW0 HOH W 75 18.667 21.796 −0.422 1.00 35.98 ATOM 3005 OW0 HOH W 76 −9.114 7.695 8.920 1.00 46.41 ATOM 3006 OW0 HOH W 77 −2.725 9.410 −24.189 1.00 35.50 ATOM 3007 OW0 HOH W 78 26.980 18.899 12.829 1.00 31.81 ATOM 3008 OW0 HOH W 79 17.646 21.683 3.437 1.00 31.91 ATOM 3009 OW0 HOH W 80 −8.571 17.509 −24.553 1.00 34.33 ATOM 3010 OW0 HOH W 81 −7.652 32.985 8.726 1.00 43.98 ATOM 3011 OW0 HOH W 82 −2.625 5.632 −10.150 1.00 36.97 ATOM 3012 OW0 HOH W 83 −12.028 32.276 7.227 1.00 39.35 ATOM 3013 OW0 HOH W 84 −33.711 27.130 −3.174 1.00 42.56 ATOM 3014 OW0 HOH W 85 −17.611 17.995 17.184 1.00 34.50 ATOM 3015 OW0 HOH W 86 −19.109 18.971 27.592 1.00 35.69 ATOM 3016 OW0 HOH W 87 −21.991 22.413 5.160 1.00 39.27 ATOM 3017 OW0 HOH W 88 13.659 19.242 −8.046 1.00 47.60 ATOM 3018 OW0 HOH W 89 −10.339 18.565 25.687 1.00 42.43 ATOM 3019 OW0 HOH W 90 1.970 26.030 6.048 1.00 40.39 ATOM 3020 OW0 HOH W 91 −8.765 21.673 0.433 1.00 37.72 ATOM 3021 OW0 HOH W 92 −20.850 26.325 2.908 1.00 56.35 ATOM 3022 OW0 HOH W 93 −12.366 9.191 20.494 1.00 34.84 ATOM 3023 OW0 HOH W 94 −9.896 37.447 29.444 1.00 34.76 ATOM 3024 OW0 HOH W 95 −17.552 18.919 −5.164 1.00 41.85 ATOM 3025 OW0 HOH W 96 6.232 22.128 −7.201 1.00 41.21 ATOM 3026 OW0 HOH W 97 −6.797 16.849 0.240 1.00 36.86 ATOM 3027 OW0 HOH W 98 1.161 18.227 −5.047 1.00 57.06 ATOM 3028 OW0 HOH W 99 2.288 6.066 6.745 1.00 37.06 ATOM 3029 OW0 HOH W 100 −29.295 32.635 11.013 1.00 43.96 ATOM 3030 OW0 HOH W 101 −28.464 25.424 7.690 1.00 45.49 ATOM 3031 OW0 HOH W 102 −30.152 13.612 −9.680 1.00 43.80 ATOM 3032 OW0 HOH W 103 −1.599 6.868 17.329 1.00 42.18 ATOM 3033 OW0 HOH W 104 −1.887 24.290 18.531 1.00 44.13 ATOM 3034 OW0 HOH W 105 27.796 19.455 3.634 1.00 48.46 ATOM 3035 OW0 HOH W 106 −8.030 10.167 −31.332 1.00 48.25 ATOM 3036 OW0 HOH W 107 −2.985 30.050 15.427 1.00 49.05 ATOM 3037 OW0 HOH W 108 −1.504 32.061 −21.190 1.00 44.44 ATOM 3038 OW0 HOH W 109 6.204 30.000 −16.933 1.00 42.31 ATOM 3039 OW0 HOH W 110 −4.122 20.605 23.054 1.00 41.35 ATOM 3040 OW0 HOH W 111 −9.885 40.341 21.208 1.00 43.88 ATOM 3041 OW0 HOH W 112 −20.863 15.617 19.646 1.00 52.25 ATOM 3042 OW0 HOH W 113 −27.560 21.675 7.325 1.00 36.97 ATOM 3043 OW0 HOH W 114 −13.970 38.207 15.196 1.00 36.20 ATOM 3044 OW0 HOH W 115 −10.257 8.670 16.396 1.00 44.34 ATOM 3045 OW0 HOH W 116 −26.779 32.379 17.536 1.00 46.46 ATOM 3046 OW0 HOH W 117 14.378 29.066 −14.762 1.00 43.06 ATOM 3047 OW0 HOH W 118 −19.826 37.668 18.886 1.00 43.88 ATOM 3048 OW0 HOH W 119 7.366 26.176 −46.829 1.00 49.36 ATOM 3049 OW0 HOH W 120 −29.626 18.951 11.431 1.00 43.10 ATOM 3050 OW0 HOH W 121 −14.313 21.458 −18.725 1.00 40.54 ATOM 3051 OW0 HOH W 122 −0.759 26.600 1.740 1.00 45.86 ATOM 3052 OW0 HOH W 123 −2.111 2.918 −16.154 1.00 46.67 ATOM 3053 OW0 HOH W 124 3.331 26.748 −37.297 1.00 48.14 ATOM 3054 OW0 HOH W 125 −2.436 28.999 −11.573 1.00 46.74 ATOM 3055 OW0 HOH W 126 10.219 29.479 4.241 1.00 56.66 ATOM 3056 OW0 HOH W 127 8.822 19.046 9.037 1.00 46.32 ATOM 3057 OW0 HOH W 128 −2.874 16.046 4.626 1.00 37.70 ATOM 3058 OW0 HOH W 129 −0.279 3.806 5.506 1.00 52.87 ATOM 3059 OW0 HOH W 130 −32.360 19.413 1.195 1.00 50.24 ATOM 3060 OW0 HOH W 131 −6.511 17.061 −7.831 1.00 39.09 ATOM 3061 OW0 HOH W 132 2.417 23.144 8.408 1.00 44.56 ATOM 3062 OW0 HOH W 133 −16.608 10.384 −12.085 1.00 45.07 ATOM 3063 OW0 HOH W 134 −2.846 29.191 3.912 1.00 46.72 ATOM 3064 OW0 HOH W 135 −17.527 21.749 4.420 1.00 43.90 ATOM 3065 OW0 HOH W 136 −23.992 22.344 21.494 1.00 41.44 ATOM 3066 OW0 HOH W 137 −23.795 27.206 3.547 1.00 54.65 ATOM 3067 OW0 HOH W 138 −29.116 14.677 5.068 1.00 51.65 ATOM 3068 OW0 HOH W 139 9.313 19.837 −4.271 1.00 55.48 ATOM 3069 OW0 HOH W 140 −15.044 19.642 5.067 1.00 42.06 ATOM 3070 OW0 HOH W 141 3.974 1.933 15.902 1.00 52.22 ATOM 3071 OW0 HOH W 142 0.091 17.275 4.399 1.00 49.56 ATOM 3072 OW0 HOH W 143 −25.537 21.936 14.509 1.00 42.90 ATOM 3073 OW0 HOH W 144 −15.697 22.135 2.544 1.00 53.67 ATOM 3074 OW0 HOH W 145 −16.772 39.732 17.788 1.00 46.17 ATOM 3075 OW0 HOH W 146 −22.834 23.263 26.427 1.00 44.02 ATOM 3076 OW0 HOH W 147 −4.433 30.459 1.897 1.00 54.37 ATOM 3077 OW0 HOH W 148 10.805 29.216 −12.444 1.00 46.47 ATOM 3078 OW0 HOH W 149 9.875 15.248 −22.074 1.00 39.59 ATOM 3079 OW0 HOH W 150 19.274 21.111 10.902 1.00 45.24 ATOM 3080 OW0 HOH W 151 −23.788 22.513 −8.738 1.00 50.90 ATOM 3081 OW0 HOH W 152 −18.012 12.403 12.283 1.00 58.78 ATOM 3082 OW0 HOH W 153 −23.602 19.922 19.962 1.00 46.19 ATOM 3083 OW0 HOH W 154 19.294 22.358 13.809 1.00 47.46 ATOM 3084 OW0 HOH W 155 −16.570 11.359 31.299 1.00 48.30 ATOM 3085 OW0 HOH W 156 −10.846 16.772 31.754 1.00 51.00 ATOM 3086 OW0 HOH W 157 −6.781 8.331 −29.531 1.00 48.71 ATOM 3087 OW0 HOH W 158 −25.361 37.429 21.866 1.00 53.58 ATOM 3088 OW0 HOH W 159 −25.833 29.686 21.358 1.00 50.75 ATOM 3089 OW0 HOH W 160 −47.219 5.581 −4.792 1.00 56.63 ATOM 3090 OW0 HOH W 161 6.673 27.621 −10.556 1.00 44.41 ATOM 3091 OW0 HOH W 162 0.676 23.720 14.657 1.00 45.33 ATOM 3092 OW0 HOH W 163 −17.977 1.385 −4.066 1.00 49.80 ATOM 3093 OW0 HOH W 164 6.273 19.800 −5.128 1.00 41.05 ATOM 3094 OW0 HOH W 165 1.774 1.455 12.183 1.00 53.13 ATOM 3095 OW0 HOH W 166 −47.850 5.153 0.253 1.00 54.28 ATOM 3096 OW0 HOH W 167 0.571 0.928 −8.183 1.00 57.03 ATOM 3097 OW0 HOH W 168 −15.657 41.281 19.809 1.00 33.76 ATOM 3098 OW0 HOH W 169 −1.350 19.580 18.894 1.00 48.90 ATOM 3099 OW0 HOH W 170 −22.822 18.718 −8.056 1.00 46.46 ATOM 3100 OW0 HOH W 171 −27.476 27.793 21.291 1.00 44.42 ATOM 3101 OW0 HOH W 172 −13.995 8.378 13.827 1.00 46.07 ATOM 3102 OW0 HOH W 173 1.334 4.996 −4.827 1.00 43.01 ATOM 3103 OW0 HOH W 174 6.478 14.054 −35.398 1.00 65.54 ATOM 3104 OW0 HOH W 175 −12.962 4.523 −16.881 1.00 54.38 ATOM 3105 OW0 HOH W 176 8.991 14.162 −32.740 1.00 48.50 ATOM 3106 OW0 HOH W 177 30.119 7.742 6.505 1.00 52.79 ATOM 3107 OW0 HOH W 178 4.020 0.076 −9.889 1.00 58.79 ATOM 3108 OW0 HOH W 179 1.144 5.559 −8.474 1.00 65.45 ATOM 3109 OW0 HOH W 180 2.468 19.016 −2.946 1.00 58.33 ATOM 3110 OW0 HOH W 181 8.790 31.553 −20.525 1.00 54.64 ATOM 3111 OW0 HOH W 182 −2.088 20.162 20.999 1.00 50.34 ATOM 3112 OW0 HOH W 183 −13.986 18.401 1.898 1.00 42.05 ATOM 3113 OW0 HOH W 184 −12.269 28.571 −31.407 1.00 56.39 ATOM 3114 OW0 HOH W 185 3.689 19.990 −5.623 1.00 51.48 ATOM 3115 OW0 HOH W 186 −17.974 38.675 31.865 1.00 38.99 ATOM 3116 OW0 HOH W 187 −19.158 28.362 36.510 1.00 54.63 ATOM 3117 OW0 HOH W 188 −0.990 2.141 −5.489 1.00 52.92 ATOM 3118 OW0 HOH W 189 −16.508 19.586 −9.105 1.00 39.50 ATOM 3119 OW0 HOH W 190 −8.651 33.293 29.448 1.00 51.21 ATOM 3120 OW0 HOH W 191 −21.074 18.375 −10.228 1.00 59.13 ATOM 3121 OW0 HOH W 192 −6.961 2.168 −15.223 1.00 50.82 END 

What is claimed is:
 1. An antiviral drug comprising an F3 Zn-finger molecule of CPSF30, and variants thereof, adapted for use against influenza A infection in humans, poultry, and other livestock.
 2. An attenuated influenza A virus vaccine comprising eight viral RNA segments, wherein a viral RNA segment eight has a first mutation that causes a substitution of a first amino acid corresponding to an amino acid of SEQ. ID. NO. 1 at a position F103, L105, M106, K110, 1117, 1119, Q121, D125, L144, V180, G183, G184, W187; corresponding positions in other influenza A strains and combinations thereof, wherein the first mutation decreases the CPSF30 binding ability of the NS1A protein.
 3. The vaccine of claim 2, further comprising at least a second mutation corresponding to an amino acid of SEQ ID NO.: 1 at position F103, L105, M106, K110, 1117, 1119, Q121, D125, L144, V180, G183, G184; corresponding positions in other influenza A strains, and combinations thereof.
 4. The vaccine of claim 2, further comprising at least a second mutation corresponding to an amino acid of SEQ. ID. NO. 1 at a position T5, P31, D34, R35, R38, K41, G45, R46, and T49 in a double-strand RNA binding epitope, corresponding positions in other influenza A strains and combinations thereof.
 5. The vaccine of claim 2, further comprising at least a second mutation corresponding to an amino acid of SEQ ID NO.: 1 at position F103, L105, M106, K110, 1117, 1119, Q121, D125, L144, V180, G183, G184; corresponding positions in other influenza A strains and combinations thereof; and at least a third amino acid mutation corresponding to an amino acid of SEQ. ID. NO. 1 at a position T5, P31, D34, R35, R38, K41, G45, R46, and T49 in a double-strand RNA binding epitope, or corresponding positions in other influenza A strains and combinations thereof.
 6. The vaccine of claim 2, wherein the influenza virus is a cold-adapted influenza virus.
 7. The vaccine of claim 2, wherein said vaccine is capable of eliciting an immune response.
 8. The vaccine of claim 2, wherein the influenza virus is selected from the group consisting of a human influenza A virus, a bovine influenza A virus, an equine influenza A virus, a porcine influenza A virus, an avian influenza A virus, an avian H5N1 viral strain.
 9. A pharmaceutical composition comprising a live attenuated influenza A virus vaccine by mutation of specific residues in the CPSF30-binding site, a tetramer interface and combinations thereof, of the NS1A protein, based on the 3D structure of the complex formed between NS1A (85-215) and F2F3 of CPSF30, and a pharmaceutically acceptable carrier or diluent.
 10. The composition of claim 9, wherein the live attenuated influenza A virus vaccine further comprises one or more mutations in the dsRNA-binding epitope of NS1A.
 11. A method of prophylaxis of a disease condition caused by the influenza A virus comprising administering to a subject in need thereof a therapeutically effective amount of a live attenuated influenza A virus vaccine by mutation of specific residues in the CPSF30-binding site, a tetramer interface, and combinations thereof, of the NS1A protein based on the 3D structure of the complex formed between NS1A (85-215) and F2F3.
 12. The method of claim 11, wherein the live attenuated influenza A virus vaccine further comprises one or more mutations in the dsRNA-binding epitope of NS1A. 